![]() | Stephen V Faraone∗Department of Psychiatry and Behavioral Sciences, State University of New York Upstate Medical University, Syracuse, NY 13210 | Departments of Psychiatry and Neuroscience and ... |
Kol currículo para Stephen V Faraone∗
Year | |
---|---|
2022 | Department of Psychiatry and Behavioral Sciences, State University of New York Upstate Medical University, Syracuse, NY 13210 |
2021 | Department of Neuroscience and Physiology, State University of New York Upstate Medical University, Syracuse, New York Clinical and Research Programs in Pediatric Psychopharmacology and Adult ADHD, Massachusetts General Hospital, Boston, Massachusetts, USA |
2020 | K.G. Jebsen Centre for Psychiatric Disorders, Department of Biomedicine, University of Bergen, Bergen, Norway Departments of Psychiatry and of Neuroscience and Physiology, SUNY Upstate Medical Center, Syracuse, NY, USA Department of Psychiatry and of Neuroscience and Physiology, State University of New York (SUNY) Upstate Medical University, Syracuse, NY, United States The full list of authors in the ENIGMA working groups, author affiliations, author disclosures, and acknowledgments are provided in online supplements. |
2019 | Departments of Psychiatry and Neuroscience and Physiology, SUNY Upstate Medical University, New York, USA The Department of Human Genetics, Donders Institute for Brain, Cognition, and Behavior, Radboud University Medical Center, Nijmegen, the Netherlands (Klein, Bralten, Roth Mota, Arias-Vasquez, Franke); University Medical Center Utrecht, UMC Utrecht Brain Center, Department of Psychiatry, Utrecht, the Netherlands (Klein); the Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston (Walters, Neale); Program in Medical and Population Genetics (Walters) and Stanley Center for Psychiatric Research, Broad Institute of Harvard and MIT, Cambridge, Mass (Walters, Neale); the Department of Biomedicine and the Center for Integrative Sequencing, Aarhus University, Aarhus, Denmark (Demontis, Mattheisen, Børglum); the Lundbeck Foundation Initiative for Integrative Psychiatric Research (iPSYCH), Denmark (Demontis, Børglum); the Department of Genetics and the Neuroscience Center, University of North Carolina, Chapel Hill (Stein); the Imaging Genetics Center, USC Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of Medicine, University of Southern California, Los Angeles (Hibar, Thompson); the Department of Epidemiology and the Department of Radiology and Nuclear Medicine, Erasmus Medical Center, Rotterdam, the Netherlands (Adams); the Department of Psychiatry and the Research Institute, Hospital for Sick Children, University of Toronto, Toronto (Schachar); the Department of Child and Adolescent Psychiatry, Institute of Psychiatry, Psychology, and Neuroscience, King's College London (Sonuga-Barke); the Department of Psychiatry, Psychosomatics and Psychotherapy, University of Wuerzburg, Wuerzburg, Germany (Mattheisen); the Department of Clinical Neuroscience, Center for Psychiatric Research, Karolinska Institute, Stockholm (Mattheisen); Stockholm Health Care Services, Stockholm County Council, Stockholm (Mattheisen); the Department of Neurology, Keck School of Medicine, University of Southern California, Los Angeles (Thompson); the Quantitative Genetics Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Medland); the Department of Psychiatry and the Department of Neuroscience and Physiology, SUNY Upstate Medical University, Syracuse, N.Y. (Faraone); the K.G. Jebsen Center for Neuropsychiatric Disorders, University of Bergen, Bergen, Norway (Faraone); and the Department of Psychiatry, Donders Institute for Brain, Cognition, and Behavior, Radboud University Medical Center, Nijmegen, the Netherlands (Roth Mota, Arias-Vasquez, Franke). Department of Psychiatry, Upstate Medical University, Syracuse, New York; Department of Neuroscience and Physiology, Upstate Medical University, Syracuse, New York. SUNY Upstate Medical University, Syracuse, NY |
Stephen V Faraone∗: Influência estatística
Concept | World rank |
---|---|
cbclbp profile | #1 |
persons rels | #1 |
selfreport adhd | #1 |
stimulant treatment risk | #1 |
oih cpt | #1 |
offspring behavioral disinhibition | #1 |
schizophrenia familybased studies | #1 |
genetic risk severity | #1 |
paternal smoking conception | #1 |
adhd fam | #1 |
treatment stimulant | #1 |
schizotaxia subjects | #1 |
140 adhd probands | #1 |
2276tc | #1 |
bipolars unipolar relatives | #1 |
parental children | #1 |
familially | #1 |
matter volumes volumes | #1 |
morbidity adhd | #1 |
disorders comorbid mania | #1 |
shared endophenotypes | #1 |
volumes participants | #1 |
association snap25 | #1 |
p179e06 | #1 |
adhd findings | #1 |
subsets linkage | #1 |
discordant twin study | #1 |
opd add opd | #1 |
fhraff | #1 |
adhdmethodcurves | #1 |
oih pain tolerance | #1 |
9 nhe9 | #1 |
childhood predictors adhd | #1 |
anx relatives | #1 |
bpd anx | #1 |
trypotphan | #1 |
differences medications | #1 |
disorders parents | #1 |
adhd familial disorder | #1 |
temperamental risk factor | #1 |
parental polygenic risk | #1 |
dust addictive drug | #1 |
conduct disorder probands | #1 |
clock genes rorb | #1 |
masir ldx | #1 |
intron8 | #1 |
adhd dat1 gene | #1 |
assess adult adhd | #1 |
desr siblings | #1 |
analysis adhd | #1 |
impactnl | #1 |
adhd adolescent | #1 |
alcohol dependence relatives | #1 |
intellectual delays | #1 |
genetics adhd | #1 |
adhd pattern | #1 |
pdics | #1 |
stimulants childhood | #1 |
psud controls | #1 |
genetic correlation adhd | #1 |
adhd bipolar comorbidity | #1 |
schizophrenia nonpsychotic relatives | #1 |
children antisocial disorders | #1 |
bpi sza | #1 |
10repeats | #1 |
subthreshold adhd | #1 |
risk aggressive symptoms | #1 |
affective psychosis hraff | #1 |
efds bpi disorder | #1 |
endophenotypic construct | #1 |
interobserver agreement measures | #1 |
training raters | #1 |
deficits time | #1 |
educational failure | #1 |
valid diagnosis | #1 |
interaction adhd | #1 |
adhd drug dependence | #1 |
adhd module mwq | #1 |
diagnostic criteria adhd | #1 |
adhd bpi disorder | #1 |
comorbidity major depression | #1 |
adhd desr probands | #1 |
mania pdd subjects | #1 |
psychiatric comorbidity md | #1 |
diagnoses probands | #1 |
male individuals adhd | #1 |
adhd cbcl | #1 |
relatives bpi probands | #1 |
gender familial risk | #1 |
adolescent psychiatric cohort | #1 |
stimulant treatment | #1 |
adhd increased | #1 |
neuroleptic nonresponse | #1 |
adhd volumetric reductions | #1 |
putamen volume alterations | #1 |
multiplex sample | #1 |
model ermph | #1 |
covariates dopamine receptors | #1 |
bpi disorder youth | #1 |
nonreferred subjects | #1 |
adhd vntr | #1 |
adhd symptoms crf | #1 |
late‐onset adhd | #1 |
adhd children bpd | #1 |
treatment masxr | #1 |
rs3916970 | #1 |
pair health | #1 |
criteria☆ | #1 |
timely renewal | #1 |
adhd genetic exome | #1 |
diagnostic efficiency analysis | #1 |
adhd genetic receptors | #1 |
risk disorder | #1 |
adhd girls | #1 |
addh dmi | #1 |
ldx adult adhd | #1 |
efficacy medications | #1 |
2455 controls | #1 |
locus adhd | #1 |
aspd youth | #1 |
familiar disease | #1 |
re‐review | #1 |
cardinal symptom mania | #1 |
expression adhd | #1 |
akt1 snp markers | #1 |
hyperactivity cross | #1 |
hyperactivity cognition | #1 |
anxiety disorders twins | #1 |
treatment moderated | #1 |
inattentive hyperactive | #1 |
anxiety disorders baseline | #1 |
braingenie | #1 |
proband youth bpdsud | #1 |
aggregate cutoff score | #1 |
adhd total score | #1 |
depression adhd child | #1 |
17yearold boys | #1 |
latrophilin 3 gene | #1 |
mania conduct disorder | #1 |
relszs | #1 |
euphoria cardinal symptom | #1 |
adhd adolescent patients | #1 |
relatives diagnoses | #1 |
control probands | #1 |
unfamiliar challenges | #1 |
fm pain tolerance | #1 |
transient financial stress | #1 |
diagnosis bpi disorder | #1 |
disorders hypothesis | #1 |
foursnp | #1 |
adolescence longitudinal analysis | #1 |
methylphenidate efficacy | #1 |
robust familiality | #1 |
rels persons | #1 |
method authors | #1 |
addictive drugs dust | #1 |
adhd bipolar studies | #1 |
dat1 adhd | #1 |
earlyandmoderate | #1 |
adhd income loss | #1 |
bpd parents | #1 |
males overweight obesity | #1 |
adhd aes | #1 |
life adult adhd | #1 |
antisocial disorder relatives | #1 |
association evidence | #1 |
nonreferred samples | #1 |
prescription stimulant nonmedical | #1 |
studies adhd children | #1 |
treating adhd | #1 |
genetic sexual dimorphism | #1 |
adhd adhd cases | #1 |
cacng2 genes schizophrenia | #1 |
psychiatric risk vcfs | #1 |
odd disorders follow | #1 |
association syp | #1 |
229 families | #1 |
lifetime impairment survey | #1 |
bipolar disorder bpprss | #1 |
smd greater severity | #1 |
unexplored void | #1 |
relatives multiplex families | #1 |
prss adhd | #1 |
bpi disorder aspd | #1 |
oros methylphenidate orosmph | #1 |
interviews disease humans | #1 |
adhd highly | #1 |
molecular genetics network | #1 |
executive functioning adults | #1 |
hyperactivity body | #1 |
impact tic disorders | #1 |
siblings control probands | #1 |
dat110 6 | #1 |
controls rels | #1 |
adhd attention | #1 |
adhd familial | #1 |
–rs2272080 | #1 |
adhd desr | #1 |
clinical response orosmph | #1 |
variants aggressive behavior | #1 |
pathways adhd | #1 |
p446e08 | #1 |
motor preference | #1 |
notch4 polymorphisms | #1 |
expected growth children | #1 |
insular lobule | #1 |
school reliability | #1 |
adhd girls adhd | #1 |
children motor competence | #1 |
candidate genes adhd | #1 |
siblings adhd | #1 |
sud bpdsud | #1 |
prodromal overt psychosis | #1 |
referred juveniles | #1 |
odd control | #1 |
regions age | #1 |
diagnostic continuity | #1 |
anxious depressed subscales | #1 |
common genetic risk | #1 |
hyperactivity disorder adults | #1 |
adhd comorbid | #1 |
familial evidence | #1 |
hyperactivity | #1 |
120 normal controls | #1 |
families adhd | #1 |
unipolar relatives bipolars | #1 |
findings adhd | #1 |
clinical features adhd | #1 |
adolescent follow youth | #1 |
twin adoption studies | #1 |
schizophrenia hrscz | #1 |
variance oppositional symptoms | #1 |
bmi mts | #1 |
77e08 | #1 |
ermph clinical response | #1 |
youth informant source | #1 |
d15s1012 | #1 |
illness adolescent | #1 |
cohorts age groups | #1 |
opd add | #1 |
anx bpd | #1 |
postmortem brain identifies | #1 |
ldx growth | #1 |
stimulant treatment profiles | #1 |
asds clinical scales | #1 |
adhd social disability | #1 |
nfspds | #1 |
nhe inhibitors adhd | #1 |
scz palau | #1 |
behavioral disinhibition offspring | #1 |
stress exposure connectivity | #1 |
shlod | #1 |
masxr treatment | #1 |
clinical correlates ocd | #1 |
palauans maps loci | #1 |
comt maoa | #1 |
bpd anx bpd | #1 |
cortical thickness adhd | #1 |
112 80 | #1 |
bpprss | #1 |
bmi ldx | #1 |
htf9c | #1 |
authors adhd | #1 |
add pdics | #1 |
adhd efficacy outcome | #1 |
administration marijuana | #1 |
20183 cases | #1 |
df39 | #1 |
suds crosssectional studies | #1 |
ldx bmi | #1 |
kiaa1292 | #1 |
falconer3 | #1 |
adhd adverse impact | #1 |
add parent report | #1 |
familial disorders adhd | #1 |
elevated rates adhd | #1 |
sud risk offspring | #1 |
disorder boys | #1 |
comt odd | #1 |
desr subjects | #1 |
hyperactivity child | #1 |
ainslbl | #1 |
neuropsychological probes | #1 |
md parents | #1 |
groundskeeper | #1 |
adhd mp | #1 |
21 circadian genes | #1 |
ptsd familial disorders | #1 |
adhd sample model | #1 |
treatment bsd | #1 |
downward extension adolescents | #1 |
convergent functional genomic | #1 |
relatives control | #1 |
masir | #1 |
fsiq comt | #1 |
adhd gender | #1 |
slc9a9 adhd | #1 |
adolescents concurrent adhd | #1 |
children pdag parents | #1 |
cdh13 memory performance | #1 |
impaired sensorimotor timing | #1 |
persistence childhood adhd | #1 |
parental panic depression | #1 |
nonreferred | #1 |
ldx growth delays | #1 |
criteria pdd | #1 |
4‐year follow‐up study | #1 |
female adhd | #1 |
p647e07 | #1 |
relatives default network | #1 |
asthma motor preference | #1 |
aklt01 tova api | #1 |
ptsd siblings | #1 |
adhd higher | #1 |
adhd smoking | #1 |
moderating effects patterns | #1 |
children motor domain | #1 |
adhd dbds | #1 |
stimulants abuse potential | #1 |
adhd female individuals | #1 |
children disorder | #1 |
git1 association adhd | #1 |
onset criterion adhd | #1 |
suds adhd | #1 |
familial moderators | #1 |
gsprs adhd | #1 |
referred samples | #1 |
dat1 untranslated regions | #1 |
dbds adhd | #1 |
shifting sands | #1 |
behavioral inhibition parents | #1 |
adhd adult adhd | #1 |
age1542 | #1 |
scales risk | #1 |
ats siblings | #1 |
increased methylation genes | #1 |
adhd screening | #1 |
maternal inattention anxiety | #1 |
adhd 11 years | #1 |
bipolar disorder switches | #1 |
genes sexdifferentiated effects | #1 |
exposure clinical features | #1 |
risk childhood onset | #1 |
subtype adhd | #1 |
83097 | #1 |
schizophrenia european samples | #1 |
nmu oral | #1 |
depressed children depression | #1 |
association behavioral inhibition | #1 |
bpi disorder children | #1 |
adhd module | #1 |
chi28783 | #1 |
offspring parental md | #1 |
relatives 1 probands | #1 |
new psychometric definition | #1 |
rs3792452 | #1 |
diagnoses adhd | #1 |
rs9610449 | #1 |
risk psud | #1 |
adults diagnosis | #1 |
probands adhd | #1 |
4q3121 | #1 |
normal sexual dimorphisms | #1 |
motor preference disability | #1 |
chi25762 | #1 |
orosmph adult adhd | #1 |
symptoms versus impairment | #1 |
actual motor performance | #1 |
valid psychiatric disorder | #1 |
clinical interview mania | #1 |
adhd asd youth | #1 |
adhd sexes | #1 |
neuropsychological impairments relatives | #1 |
p902e−07 | #1 |
adhd learning | #1 |
adhd risk factors | #1 |
vivo neuroreceptor imaging | #1 |
sexdifferentiated effects traits | #1 |
mania manic features | #1 |
relatives pediatric probands | #1 |
onset distribution | #1 |
adhd population | #1 |
add aff | #1 |
risk anxiety disorders | #1 |
adhd cognition | #1 |
repeat allele | #1 |
adhd scores | #1 |
p97e−03 | #1 |
psychiatric disorders adhd | #1 |
relatives 3 probands | #1 |
bpi disorder adhd | #1 |
fhrscz | #1 |
adolescent patients adhd | #1 |
levels dysfunction | #1 |
autistic traits presence | #1 |
smaller total brain | #1 |
schizophrenia notch4 | #1 |
nfspd | #1 |
consensus combination | #1 |
controls adhd probands | #1 |
nasal nmu nmu | #1 |
ldx masir | #1 |
genetic overlap adhd | #1 |
specific psychopathology children | #1 |
anxiety disorders relatives | #1 |
adhd asthma | #1 |
childhood genetic background | #1 |
context adhd | #1 |
adhd gwas | #1 |
familybased studies association | #1 |
parental suds | #1 |
longitudinal outcome boys | #1 |
stimulant nonmedical | #1 |
social adjustment inventory | #1 |
rs6000200 | #1 |
boys female gender | #1 |
based association study | #1 |
rutters | #1 |
shr iiv | #1 |
rs11133767 | #1 |
adult samples model | #1 |
adhd candidate | #1 |
dependence controls | #1 |
adhd clinical trial | #1 |
youth bpi disorder | #1 |
adhd pdics | #1 |
dsmiv subtypes adhd | #1 |
co‐expression modules | #1 |
morbidity bipolar disorder | #1 |
familial transmission adhd | #1 |
comorbid adult adhd | #1 |
hamiltondepression | #1 |
stimulant treatment alcohol | #1 |
biomarkers adhd | #1 |
medications adhd | #1 |
adhd seconddegree relatives | #1 |
parents sud | #1 |
disability asthma | #1 |
serotonin genetic | #1 |
“forgetfulness | #1 |
adhd psychoactive substance | #1 |
children idiopathic adhd | #1 |
genetic association rorb | #1 |
multi‐stage study | #1 |
brain activity flow | #1 |
clinically diagnosed obesity | #1 |
adhd conclusions | #1 |
offspring parental adhd | #1 |
p0499 | #1 |
pinslbl | #1 |
children mania diagnosis | #1 |
nonreferred sample | #1 |
nonreferred adult | #1 |
or133 | #1 |
individuals adhd | #1 |
adults neurodevelopmental disorder | #1 |
pepple | #1 |
odd disruptive behavior | #1 |
lateandmoderate | #1 |
sud phenotypes | #1 |
comorbid problems | #1 |
criteria 14 children | #1 |
druggable genome disorder | #1 |
abstinence pharmacological treatment | #1 |
pregnancy adhd | #1 |
adhd females | #1 |
pippi longstocking | #1 |
psychopharmacologic | #1 |
probands add | #1 |
followup assessment | #1 |
parental md | #1 |
adhd probands | #1 |
increased adhd symptoms | #1 |
motor preference adhd | #1 |
adhd cigarette smoking | #1 |
adhd somatosensory functioning | #1 |
quantitative analyses treatment | #1 |
youth adhd | #1 |
adhd baseline assessment | #1 |
valid disorder | #1 |
lateonset adhd | #1 |
depressed children adhd | #1 |
hyperactivity child humans | #1 |
distribution child | #1 |
subthreshold adhd subjects | #1 |
gene studies | #1 |
familial links | #1 |
matching fallacy | #1 |
paternal overtransmission | #1 |
expressed emotion children | #1 |
adhd ads | #1 |
dbds adhddbds | #1 |
consensus statement combination | #1 |
asrs scores | #1 |
rs2469758–rs2461489 | #1 |
oral methylphenidate treatment | #1 |
large controlled study | #1 |
efs girls | #1 |
highiq adults | #1 |
onset distributions | #1 |
desipraminestimulants | #1 |
adhd child comorbidity | #1 |
adhd rat | #1 |
cdbpd | #1 |
firstdegree relatives children | #1 |
bpi probands | #1 |
adhd control probands | #1 |
cadhd aadhd | #1 |
nonpsychotic relatives controls | #1 |
adhd psychiatric conditions | #1 |
weaknesses comorbidity | #1 |
adhd risk alleles | #1 |
laboratory driving simulation | #1 |
genes hallucinations states | #1 |
adhd conduct disorder | #1 |
adhd familial risk | #1 |
anxiety disorders siblings | #1 |
adhd neuropsychological impairments | #1 |
asrs‐v11 | #1 |
adhd asm snps | #1 |
disorders aa | #1 |
children ermph | #1 |
depression offspring variables | #1 |
ptsd bpi disorder | #1 |
height ldx | #1 |
adhd degree relatives | #1 |
studies adhd | #1 |
adult adhd diagnosis | #1 |
aadhd cadhd | #1 |
relbps | #1 |
adhd genetic variants | #1 |
marijuana smoking metaanalysis | #1 |
adherence stimulant treatment | #1 |
sample adhd | #1 |
subthreshold pediatric | #1 |
risk female relatives | #1 |
23 candidate genes | #1 |
distal genomic region | #1 |
self‐reported adhd | #1 |
antisocial disorders bpd | #1 |
type adhd | #1 |
symptoms adult | #1 |
adhd iiv | #1 |
loci adhd | #1 |
subjects ldx | #1 |
rtv adhd prs | #1 |
relatives girls | #1 |
vall66 | #1 |
potential endophenotypes adhd | #1 |
aklt01 adhd | #1 |
relatives control probands | #1 |
inattention shr | #1 |
adult persistence | #1 |
sensitive adhd | #1 |
hyperactivity biomarkers aadhd | #1 |
disorder schizotaxia | #1 |
anxiousdepressed | #1 |
siblings adhd probands | #1 |
expected height weight | #1 |
higher adhd | #1 |
disorder meta | #1 |
pdd criteria | #1 |
hyperactivity comorbidity humans | #1 |
adhd children ld | #1 |
suggestive linkage signals | #1 |
adhd baseline | #1 |
adhd sample | #1 |
severe emotional dysregulation | #1 |
anterior insular lobule | #1 |
disorder molecular | #1 |
142 combined subtype | #1 |
pediatric bipolar spectrum | #1 |
persistence disorder | #1 |
smoking schizophrenia families | #1 |
psud relatives | #1 |
adhd african | #1 |
drd4 association | #1 |
parental sud sud | #1 |
infas | #1 |
callingalgorithms | #1 |
31item | #1 |
anxiety disorders findings | #1 |
bpi disorder efds | #1 |
adherence xr | #1 |
15q13 deletions | #1 |
adhd reliability | #1 |
persistence pediatric disorder | #1 |
adverse impact adhd | #1 |
female humans inhibition | #1 |
p20e04 | #1 |
disorder adhd | #1 |
overlapping symptoms | #1 |
pooleddata | #1 |
smd higher rates | #1 |
patients adhdpi | #1 |
adults stimulant sizes | #1 |
racial heterogeneity | #1 |
adhd disorders comorbidity | #1 |
adhd teenage parents | #1 |
type attention | #1 |
hypothesized precursors | #1 |
selfreport adhd symptoms | #1 |
dsm bipolar disorder | #1 |
features adhd | #1 |
adhd alleles | #1 |
persistent adhd symptoms | #1 |
adhdoddcd | #1 |
inattentive subtype adhd | #1 |
association tph2 | #1 |
psud adhd probands | #1 |
relatives adhd status | #1 |
autism symptoms adhd | #1 |
attention deficit | #1 |
week treatment response | #1 |
adhd prss | #1 |
mdd pdag mdd | #1 |
european treatment guideline | #1 |
treatment effects values | #1 |
efds youth | #1 |
disorder follow | #1 |
mr005 | #1 |
etiology adhd | #1 |
symptoms aggregation | #1 |
adhd medications placebo | #1 |
mothers fam | #1 |
age onset criterion | #1 |
rs1051312 | #1 |
lod213 | #1 |
pilot study adhd | #1 |
suds neurocognitive functions | #1 |
adhd haplotype block | #1 |
adults ldx sizes | #1 |
familial vulnerability schizophrenia | #1 |
tass adhd | #1 |
familial subtype | #1 |
adhd candidate genes | #1 |
adhd long term | #1 |
childhoodonset mania | #1 |
bpd relatives | #1 |
ldx size children | #1 |
affective symptoms children | #1 |
risk substance disorders | #1 |
maoa adhd | #1 |
inattention adhd | #1 |
ld addh children | #1 |
neuropsychological testing individuals | #1 |
schizophrenia current knowledge | #1 |
diagnoses valid | #1 |
predictors persistence | #1 |
adhddbds adhd | #1 |
siblings antisocial families | #1 |
adhd probands relatives | #1 |
idir aversion | #1 |
african‐american pedigrees | #1 |
adolescents sud treatment | #1 |
adhdtd | #1 |
nr3c1 stress exposure | #1 |
daily parent rating | #1 |
subthreshold diagnoses valid | #1 |
disorder | #1 |
prevalence attention | #1 |
np functioning chr | #1 |
adhd maoa | #1 |
2327t | #1 |
association psychiatric comorbidity | #1 |
lobe mri measures | #1 |
sodasmph | #1 |
discipline problem | #1 |
new phenotype definition | #1 |
genetic variation nr3c1 | #1 |
compared adhd | #1 |
rs3746544 rs1051312 | #1 |
preschool comorbidity | #1 |
adhd hyperactivity automobile | #1 |
maoa neuropsychological functioning | #1 |
ldx amses | #1 |
adhd alcohol dependence | #1 |
criteria age | #1 |
prospective datasets | #1 |
add antisocial disorders | #1 |
association slc6a3 | #1 |
adhd | #1 |
mania rates | #1 |
17year | #1 |
mwq inattention items | #1 |
subcortical structure volume | #1 |
diagnoses relatives | #1 |
impulsive behavioral aggression | #1 |
elevated risk adhd | #1 |
idir proteins siblings | #1 |
deficits expected growth | #1 |
adhd adhd probands | #1 |
sud remittent adhd | #1 |
deletioncarrier | #1 |
manic symptoms disorder | #1 |
psychiatric comorbidities adhd | #1 |
smoking cessation controls | #1 |
12allele | #1 |
rs7118422 | #1 |
maoa impulsivity | #1 |
efficacy outcome week | #1 |
structural differences children | #1 |
135–526 | #1 |
children teaes | #1 |
motheronly | #1 |
psychopathology reward dysfunction | #1 |
validity diagnosis | #1 |
95 hrr | #1 |
rs9325032 | #1 |
adhd children exposure | #1 |
substantial genetic component | #1 |
adult adhd differences | #1 |
tidqam | #1 |
mitigates stimulant | #1 |
amses amrs | #1 |
2 familial factors | #1 |
association dopamine receptors | #1 |
impulsive subtype | #1 |
ldx expected height | #1 |
prs58502974 | #1 |
pdag mdd mdd | #1 |
deficit hyperactivity | #1 |
schizotypal relatives | #1 |
apol1 schizophrenia | #1 |
proband youth bpd | #1 |
rs1633445 | #1 |
persistence adhd | #1 |
abnormalities adhd | #1 |
nonreferred siblings | #1 |
risk comt gene | #1 |
adhd structural abnormalities | #1 |
tdt analysis | #1 |
risk tourette spectrum | #1 |
low attention | #1 |
growth delays weight | #1 |
mania criteria | #1 |
interaction adhd severity | #1 |
bpd bpd anx | #1 |
rs1040399 | #1 |
adhdrs5 | #1 |
hartsough | #1 |
rs2449340 | #1 |
hyperactivity pdi | #1 |
cyp2d6 hypothesis | #1 |
desr probands siblings | #1 |
association evidence schizophrenia | #1 |
adhd children | #1 |
groups girls | #1 |
druggable genome adhd | #1 |
predictors adhd | #1 |
impulsiveness inattention | #1 |
genes association studies | #1 |
familial risk analyses | #1 |
comt fsiq | #1 |
dsmiiir dsmiv adhd | #1 |
transmission parents | #1 |
bpd firstdegree relatives | #1 |
suds genetic studies | #1 |
schizophrenic probands1portions | #1 |
aud adhd | #1 |
genes adhd | #1 |
2327ct | #1 |
vntr haplotype | #1 |
aadhd hyperactivity biomarkers | #1 |
severe dysregulation | #1 |
linkage wave | #1 |
adhd clinical obesity | #1 |
disorder familial | #1 |
mph adult adhd | #1 |
age groups cohorts | #1 |
adhdtd siblings | #1 |
vcfsadhd adhd | #1 |
hyperactivity disorder scores | #1 |
placebo cgsq | #1 |
patients adhdct | #1 |
adhd antisocial comorbidity | #1 |
odd relatives | #1 |
memory adults | #1 |
suggestive linkage | #1 |
adhdassociated alleles | #1 |
35191 | #1 |
osa genetic heterogeneity | #1 |
female individuals adhd | #1 |
adhd neuropsychological functioning | #1 |
40basepairrepeat | #1 |
pdi hyperactivity | #1 |
relatives alcohol dependence | #1 |
behaviors substances | #1 |
children behavioral | #1 |
dao gene schizophrenia | #1 |
stimulant treatment youth | #1 |
odd familial disorders | #1 |
molecular genetic studies | #1 |
drugplacebo response curve | #1 |
nonreferred siblings probands | #1 |
biased maternal reporting | #1 |
parental bpd | #1 |
adhd comorbid dbds | #1 |
add 73 probands | #1 |
oih fm | #1 |
adhd youth ld | #1 |
comorbid oppositional | #1 |
adhd slc6a3 genotype | #1 |
meaningful anxiety phenotype | #1 |
antisocial disorders risk | #1 |
impulsive symptoms | #1 |
adhd antisocial disorders | #1 |
risk factor psud | #1 |
visual memory deficit | #1 |
disorder relatives | #1 |
neuropsychological functioning boys | #1 |
conduct disorder aspd | #1 |
cognitive endophenotypes adhd | #1 |
snp quantitative phenotype | #1 |
mph controls | #1 |
structured interview pdd | #1 |
structured interview mania | #1 |
adult adhd treatment | #1 |
stable behavioral inhibition | #1 |
ctcata | #1 |
drugplacebo | #1 |
neurocognitive traits | #1 |
future dsm | #1 |
proband child | #1 |
association adhd | #1 |
gsprss | #1 |
copy organization | #1 |
maf⩾1 | #1 |
adhd maternal | #1 |
dopamine d4 gene | #1 |
male adolescents adhdct | #1 |
evidence sud phenotypes | #1 |
comorbid problems adhd | #1 |
fiveminutespeechsample | #1 |
major depression youth | #1 |
versus disability | #1 |
adhd genetic | #1 |
twin adoption | #1 |
taf9bp2 | #1 |
adult samples adhd | #1 |
adhd stronger connectivity | #1 |
trait educational attainment | #1 |
adult adhd | #1 |
adhde | #1 |
drd4 7repeat allele | #1 |
adhd outcome | #1 |
adhd prss adhd | #1 |
familial association adhd | #1 |
studies method | #1 |
aud alcohol disorders | #1 |
concurrent adhd sud | #1 |
daodisc1 | #1 |
risk suds | #1 |
subcortical volumes adhd | #1 |
adhd disorder | #1 |
adolescents genetic risk | #1 |
cbclbp | #1 |
siblings adolescent | #1 |
subjects lateonset adhd | #1 |
slc6a4 gene risk | #1 |
starsadhd | #1 |
slc9a9 disease associations | #1 |
pediatric bpi disorder | #1 |
longitudinal analysis childhood | #1 |
sbrv | #1 |
adhd comorbid odd | #1 |
hyperactivity comorbidity | #1 |
bipolar disorder girls | #1 |
palau scz | #1 |
rates relatives | #1 |
motor problems adhd | #1 |
stimulant treatment adults | #1 |
genomesignificance | #1 |
aff add | #1 |
mania referred children | #1 |
cbclbp profile children | #1 |
oral nmu | #1 |
relatives multiplex | #1 |
rs1799835 | #1 |
prescription stimulant nmu | #1 |
substance disorders relatives | #1 |
adhd druggable genes | #1 |
comorbidity conduct | #1 |
schizophrenia bipolar psychoses | #1 |
stimulant treatment differences | #1 |
adhd gsprs | #1 |
cigarette smoking siblings | #1 |
association maoa | #1 |
vulnerability indicators schizophrenia | #1 |
schizophrenia fhrs | #1 |
desr adults | #1 |
d10s195 | #1 |
genetic correlations schizophrenia | #1 |
symptom burden adults | #1 |
controls adhd children | #1 |
metabias | #1 |
probands clinical status | #1 |
paternal over‐transmission | #1 |
tass adhdrs | #1 |
bpd girls | #1 |
cbcldesr | #1 |
5ht1b receptor gene | #1 |
add relatives | #1 |
adhd concurrent sud | #1 |
cbt intervention adolescents | #1 |
parental sud adhd | #1 |
family‐based association test | #1 |
persistent adhd adults | #1 |
adhdrsivinv | #1 |
rs12843268 | #1 |
drd5 vntr | #1 |
zmynd17 genes | #1 |
bipolar disorder parents | #1 |
2276ct | #1 |
cacng2 gene | #1 |
tomoxetine adult adhd | #1 |
adhd drd4 | #1 |
sexes bpi disorder | #1 |
risk adhd | #1 |
emotional symptoms adhd | #1 |
rs6077690 | #1 |
adhd comorbid disorders | #1 |
mddprss | #1 |
adhd snps | #1 |
individuals attention | #1 |
bpi disorder | #1 |
comorbid psychopathology childhood | #1 |
n122 | #1 |
juvenile antisocial traits | #1 |
parents behavioral disinhibition | #1 |
smoking wm microstructure | #1 |
caregiver strain cgsq | #1 |
5‐generation | #1 |
rare protective allele | #1 |
productivity adhd | #1 |
growth deficits deficits | #1 |
hyperactivity female | #1 |
mtbi adhd | #1 |
norepinephrine transporter gene | #1 |
9r allele | #1 |
hypothesis disorders | #1 |
disorder hyperactivity | #1 |
vcfs manic symptoms | #1 |
nonmental diseases adhd | #1 |
hyperactivity case | #1 |
tova api aklt01 | #1 |
inattentive symptoms adults | #1 |
rs916455 | #1 |
adhd probands adhd | #1 |
inattention items | #1 |
relatives children | #1 |
tic persistence | #1 |
hamshere | #1 |
stimulants height | #1 |
adolescent outcome adhd | #1 |
peer environmental factors | #1 |
asd weaknesses | #1 |
stimulant treatment adhd | #1 |
rs2272080 | #1 |
pharmacogenetics predictors | #1 |
35191 controls | #1 |
neural network correlates | #1 |
neuropsychological performance adhd | #1 |
sbrv adhd | #1 |
adhd diagnosed | #1 |
99item cbs | #1 |
c759t | #1 |
adhd linkage | #1 |
bipolar disorders psud | #1 |
probands rates | #1 |
arch ger psychiatry | #1 |
quantitative phenotype snp | #1 |
genetic studies sud | #1 |
ermph cgsq | #1 |
adhd dsm | #1 |
dysfunctional gene | #1 |
adhd siblings | #1 |
sud adolescence | #1 |
referred parents | #1 |
fspds | #1 |
competitivep | #1 |
hyperactive impulsive | #1 |
higher prevalence girls | #1 |
nonreferred adults | #1 |
onset mania | #1 |
13052159 | #1 |
genetic heterogeneity adhd | #1 |
adhd switches | #1 |
adhd genetic correlation | #1 |
adhd genetic studies | #1 |
boys social disability | #1 |
smoking adhd | #1 |
disorder versus disability | #1 |
adhd mini | #1 |
adhd followup | #1 |
adhd neuroimage study | #1 |
drd2 disrupts | #1 |
schizotaxia negative schizotypy | #1 |
snps quantitative phenotypes | #1 |
suds relatives | #1 |
git1 adhd | #1 |
clinical controls | #1 |
adolescent sud | #1 |
adhd oppositional | #1 |
asrs | #1 |
desr adult probands | #1 |
report adhd | #1 |
psychiatric comorbidity girls | #1 |
adhd euphoria | #1 |
adhd follow | #1 |
network‐level assessment | #1 |
motor preference asthma | #1 |
onset adult subjects | #1 |
rs2469770 | #1 |
adhd psychiatric | #1 |
pediatric bipolari disorder | #1 |
biological schizophrenia stress | #1 |
children growth delays | #1 |
adhd obesity overweight | #1 |
896 cases | #1 |
genotype calling procedures | #1 |
rs552655 | #1 |
non‐adhd children | #1 |
learning disorders adhd | #1 |
bpi disorder sexes | #1 |
parental probands | #1 |
adhd neuropsychological | #1 |
siblings adhd children | #1 |
key conceptual issues | #1 |
anachronisms | #1 |
criteria mania | #1 |
neurocognitive functions suds | #1 |
adhd phenotypes | #1 |
gene interaction comt | #1 |
gene attention | #1 |
adhd studies | #1 |
conduct bipolar disorders | #1 |
adults life | #1 |
disorganized symptom dimensions | #1 |
lifetime impairment | #1 |
dopamine receptor polymorphism | #1 |
teacher report | #1 |
motorendophenotypes | #1 |
high‐risk adolescent offspring | #1 |
iiv hyperactivity behavior | #1 |
adhd predictors | #1 |
stimulant therapy youths | #1 |
adhd adoption studies | #1 |
sob adhd | #1 |
relatives adhd probands | #1 |
drug dependence relatives | #1 |
pdi impulsiveness | #1 |
manic children pdd | #1 |
adhd prs rtv | #1 |
children adolescents cohorts | #1 |
marijuana cocaine crack | #1 |
iiv shr | #1 |
adhd subjects controls | #1 |
familial risk gender | #1 |
rs550818 | #1 |
s034 | #1 |
parents proband youth | #1 |
1 relatives | #1 |
adherence stimulant medication | #1 |
aggressive symptoms risk | #1 |
adhd proband | #1 |
rf025 | #1 |
prsanalyses | #1 |
comorbid odd adhd | #1 |
ldx sizes children | #1 |
european treatment guidelines | #1 |
healthy cortical development | #1 |
bpdsud bpd | #1 |
p81e06 | #1 |
20183 | #1 |
efficacy outcome adhd | #1 |
140 adhd | #1 |
transmission adhd | #1 |
187 children | #1 |
comt maoa interaction | #1 |
alphaglx | #1 |
diagnosis adhd | #1 |
childhood adhd adulthood | #1 |
parental adhd sud | #1 |
adhd smoking risk | #1 |
genetic frontal schizophrenia | #1 |
genetic variants adhd | #1 |
greater risk adhd | #1 |
prs rtv | #1 |
adhd single nucleotide | #1 |
loci asd symptoms | #1 |
studies depressed children | #1 |
adhd community sample | #1 |
deficit | #1 |
increased expression methylation | #1 |
relatives drug dependence | #1 |
risk subsequent substance | #1 |
connectivity executive control | #1 |
bpd hypothesis | #1 |
longacting medications | #1 |
outcome adhd | #1 |
phenotype adhd | #1 |
neurocognitive dysfunctions | #1 |
age stimulant treatment | #1 |
drd2 risk gene | #1 |
haplotypes adhd | #1 |
trait impulsivity adhdct | #1 |
combination scientific data | #1 |
efficacy adderall | #1 |
impulsive drive | #1 |
years adhd | #1 |
adhd african children | #1 |
adhdi prenatal exposure | #1 |
adoption studies | #1 |
bpi relatives | #1 |
fam mothers | #1 |
rs2279805 | #1 |
treatment mts | #1 |
rs11568324 | #1 |
benefit‐risk ratio | #1 |
sob sob association | #1 |
48basepairrepeat | #1 |
onset attention | #1 |
adhd aud | #1 |
bpd probands | #1 |
relation stress exposure | #1 |
adhd methods | #1 |
pain tolerance fm | #1 |
autistic traits youth | #1 |
learning disabilities girls | #1 |
adhd stimulant treatment | #1 |
adults cadhd | #1 |
remission definition | #1 |
adhd adhdtd | #1 |
tass internal consistency | #1 |
adhd context | #1 |
ermph placebo groups | #1 |
allele adhd | #1 |
qelbree | #1 |
concurrent adhd | #1 |
adhddbds | #1 |
thermenos | #1 |
hyperactivity child genome | #1 |
schizophrenia rs1076560t | #1 |
lifetime adhd | #1 |
neurocognitive marker | #1 |
cigarette smoking metaanalysis | #1 |
cgsq ermph | #1 |
treatment stimulants | #1 |
standardized manner | #1 |
notch4 polymorphisms schizophrenia | #1 |
increasing resource demand | #1 |
gene comt | #1 |
paediatric patients adhd | #1 |
relatives bpi | #1 |
illness child comorbidity | #1 |
schizophrenia families smoking | #1 |
chinese outpatient sample | #1 |
ldx sizes adults | #1 |
adolescent attention | #1 |
sp067 | #1 |
adhd specific | #1 |
probands comorbidity | #1 |
gene aggressive behavior | #1 |
adhd background | #1 |
emotional problems pmee | #1 |
p27e05 | #1 |
affs add | #1 |
time qualitative review | #1 |
innovative sms intervention | #1 |
regions lgi | #1 |
h2053 | #1 |
depression symptoms aggregation | #1 |
alcohol disorders offspring | #1 |
adhd valid | #1 |
pdd mania mania | #1 |
placebo ldx treatment | #1 |
ldx sizes | #1 |
scqscore | #1 |
relatives bipolar | #1 |
adults adhd subjects | #1 |
schizophrenia code | #1 |
exposure parental adhd | #1 |
adhd adult disorder | #1 |
adhd brain alterations | #1 |
reproducibility adolescent | #1 |
desr adhd | #1 |
bipolar mdd | #1 |
paediatric adhd | #1 |
pdd pdd subjects | #1 |
4q28 | #1 |
adhd gene | #1 |
parents md | #1 |
cortical networks attention | #1 |
confusability analyses | #1 |
mspi allele | #1 |
patterns psychiatric comorbidity | #1 |
validity adhd | #1 |
hyperactivity child child | #1 |
stimulant misuse | #1 |
adhd mdd prss | #1 |
highiq youths | #1 |
adhd clinical | #1 |
dna methylation adhd | #1 |
paliperidone monotherapy | #1 |
nonverbal social–emotional cues | #1 |
14 children pdd | #1 |
rs1076560t | #1 |
larger samples | #1 |
mania pdd | #1 |
risk factors opd | #1 |
offspring sud parents | #1 |
late onset adhd | #1 |
2064 trios | #1 |
acting medications | #1 |
nplz | #1 |
cbcl clinical scales | #1 |
pharmacological treatment adolescents | #1 |
switches bipolar disorder | #1 |
mp adhd | #1 |
adhd educational deficits | #1 |
volume alterations | #1 |
pdd mania | #1 |
adhd community | #1 |
unique impairments | #1 |
bipolar adhd | #1 |
adhd social class | #1 |
molecular psychiatric genetics | #1 |
metaanalysis controlled study | #1 |
higher pdi | #1 |
slc9a9 | #1 |
hyperactive impulsive symptoms | #1 |
growth outcomes adhd | #1 |
adult probands siblings | #1 |
antisocial families | #1 |
exposure maternal smoking | #1 |
prescription stimulant adults | #1 |
pain tolerance oih | #1 |
adhd responders | #1 |
rf041 | #1 |
hyperactivity biomarkers | #1 |
affective symptoms dbds | #1 |
medications adult adhd | #1 |
psychopathology implications | #1 |
rate symptoms | #1 |
efds functional outcomes | #1 |
relatives add probands | #1 |
relatives greater activation | #1 |
schizotaxia schizophrenia | #1 |
suds nicotine dependence | #1 |
chronic emotional dysregulation | #1 |
teenage parents individuals | #1 |
overweight obesity males | #1 |
adhd personality traits | #1 |
girls learning disabilities | #1 |
unaffected siblings volumes | #1 |
galantamine hydrogen bromide | #1 |
adhd sex | #1 |
adhd functional | #1 |
neuroanatomic predictors | #1 |
girls disorder | #1 |
genetic studies adhd | #1 |
gender adhd | #1 |
youth adhd prss | #1 |
adult persistence adhd | #1 |
rorb bipolar disorder | #1 |
pediatric panic disorder | #1 |
comt intelligence | #1 |
rs7124601 | #1 |
endosomal genes asds | #1 |
association attention | #1 |
adhd prs gwas | #1 |
experts abstinence | #1 |
sud parents | #1 |
fbxo33 | #1 |
predicted clinical response | #1 |
tourettes syndrome adhd | #1 |
children behavioral inhibition | #1 |
items 99item cbs | #1 |
regulation desr | #1 |
adhd depressed children | #1 |
1350t | #1 |
genes disorder | #1 |
asd youth adhd | #1 |
measurement invariance study | #1 |
adulthood genetic architecture | #1 |
intelligence additive effects | #1 |
adhd 5 | #1 |
chronological age age | #1 |
motorendophenotype | #1 |
children bpi disorder | #1 |
sob association adhd | #1 |
adhd treatment treatment | #1 |
adhd oxidative stress | #1 |
anxiety disorders families | #1 |
rs9627183 | #1 |
oral nmu nmu | #1 |
adhd france | #1 |
stimulant nmu | #1 |
adhd children mania | #1 |
model adult samples | #1 |
daonrg1 | #1 |
familial underpinnings | #1 |
relatives wm performance | #1 |
sud adolescent patients | #1 |
rs3027400 | #1 |
stimulants comorbidity | #1 |
51 genes | #1 |
relatives conduct disorder | #1 |
genes etiology | #1 |
sex bpi disorder | #1 |
adhd serotonin | #1 |
elaborative verbal encoding | #1 |
evidence stimulant treatment | #1 |
parental panic disorder | #1 |
ptsd adhd probands | #1 |
inflation personal satisfaction | #1 |
manic symptoms vcfs | #1 |
odd affective symptoms | #1 |
psychiatric conditions adults | #1 |
disorder attention | #1 |
positive peer affiliation | #1 |
adhd antisocial | #1 |
faraone | #1 |
relatives adhd girls | #1 |
risk opioid dependence | #1 |
child psychiatry referrals | #1 |
siblings males | #1 |
adhd maternal smoking | #1 |
adolescent response inhibition | #1 |
mania clinical interview | #1 |
snpssnpsa | #1 |
diagnostic continuity adhd | #1 |
schizotaxia negative symptoms | #1 |
adhd children depression | #1 |
adhd clinical characteristics | #1 |
sud adolescent | #1 |
asrs aisrs | #1 |
adhd highiq youths | #1 |
relatives risk adhd | #1 |
adhd symptom counts | #1 |
nimh genetics initiative | #1 |
drug frequency variables | #1 |
nonmental diseases | #1 |
syp female adhd | #1 |
age 7repeat allele | #1 |
rs41084 | #1 |
adhd efds | #1 |
mr006 | #1 |
mgh studies | #1 |
a409p | #1 |
p44e05 | #1 |
prss psychiatric disorders | #1 |
daorasd2 | #1 |
noninhibited children | #1 |
time reproduction children | #1 |
add opd | #1 |
non‐random error | #1 |
stress adhd severity | #1 |
cases adhd | #1 |
personality traits adults | #1 |
n55374 | #1 |
teachers cbt intervention | #1 |
distinct subtype | #1 |
disorder report | #1 |
18 items impairment | #1 |
effects lisdexamfetamine dimesylate | #1 |
nmu nasal nmu | #1 |
aisrs asrs | #1 |
rs2498799 | #1 |
cortical surface adhd | #1 |
rs1482337–rs2252471 | #1 |
htf9c gene | #1 |
teacher combined | #1 |
adhd susceptibility genes | #1 |
new diagnoses age | #1 |
pdd subjects mania | #1 |
nonaffected siblings children | #1 |
1236a | #1 |
“schizotypes | #1 |
dyscalculia adhd | #1 |
bpd anx relatives | #1 |
mwq adhd module | #1 |
rationaleadhd | #1 |
5q23q31 | #1 |
major depression share | #1 |
adhdfamilies | #1 |
qms adult adhd | #1 |
children general psychopathology | #1 |
n6979 | #1 |
etiology disorder | #1 |
highiq adults adhd | #1 |
dsm5 adult adhd | #1 |
comparison subjects participants | #1 |
hyperactivity disorder | #1 |
hyperactivity databases | #1 |
onset chronological age | #1 |
african children adhd | #1 |
female gender boys | #1 |
d10s2327 | #1 |
population screen | #1 |
sud nicotine dependence | #1 |
qms adhd | #1 |
palau early | #1 |
p758e08 | #1 |
highiq youths adhd | #1 |
adhd dyscalculia | #1 |
fidgety philipp | #1 |
74±77 | #1 |
c2orf82 | #1 |
studies attention | #1 |
24 gm day | #1 |
impairments adults | #1 |
dat1 vntr | #1 |
greater risk add | #1 |
bpi disorder relatives | #1 |
subjects adhd | #1 |
bpd bpdsud | #1 |
neuropsychologic function schizophrenia | #1 |
rs3776512 | #1 |
adhd chinese population | #1 |
trypotphan hydroxylase | #1 |
motor skills attention | #1 |
snps drd4 gene | #1 |
autism‐associated brain regions | #1 |
“3 | #1 |
patients attentional disorders | #1 |
adhdliability | #2 |
dsmiv adhd | #2 |
asrs health organization | #2 |
internal distractibility | #2 |
rates odd | #2 |
genome‐wide association data | #2 |
target features | #2 |
subjects criteria | #2 |
viloxazine extendedrelease | #2 |
adhd report | #2 |
comorbid conduct disorder | #2 |
cnvs copy variants | #2 |
hyperactivity female humans | #2 |
checklist scales | #2 |
infancy complications | #2 |
parents major depression | #2 |
relatives | #2 |
efficacy stimulants | #2 |
disorders suds | #2 |
lallele homozygotes | #2 |
odd girls | #2 |
methodological complexities | #2 |
cbcl desr | #2 |
617 years | #2 |
bpd sud | #2 |
structure adult adhd | #2 |
underlying bipolarity | #2 |
health organization asrs | #2 |
attentional control effects | #2 |
reward‐related activation | #2 |
childhoodonset adhd | #2 |
probands relatives | #2 |
iii adhd | #2 |
oral prescription | #2 |
initial stimulant | #2 |
stimulants | #2 |
comorbidity probands | #2 |
girls adhd | #2 |
combinedtype | #2 |
levels comorbidity | #2 |
mirsky | #2 |
age onset distribution | #2 |
cigarette smoking suds | #2 |
treatment childhood adhd | #2 |
adhd icv | #2 |
support genetic factors | #2 |
versus controls | #2 |
work needed | #2 |
6p243 | #2 |
comorbid conduct problems | #2 |
6 17 years | #2 |
rs40184 | #2 |
neuropsychoanalytic treatment | #2 |
informant source | #2 |
activation trigger | #2 |
aggressive symptoms | #2 |
probands | #2 |
cbsk | #2 |
amses | #2 |
adhdonly | #2 |
hrscz | #2 |
antisocial disorders | #2 |
bidirectional overlap | #2 |
2q143 | #2 |
relatives add | #2 |
comorbid oppositional defiant | #2 |
child comorbidity illness | #2 |
adhd choice | #2 |
addicted | #2 |
adhd autism symptoms | #2 |
candidate genetic pathways | #2 |
galantamine hbr placebo | #2 |
function deficits | #2 |
n328917 | #2 |
ncrl wky | #2 |
young adult years | #2 |
adhd surface area | #2 |
sex differences adhd | #2 |
familial risk analysis | #2 |
studies adderall | #2 |
hyperactivity attention deficit | #2 |
stimulants adults | #2 |
subthreshold diagnoses | #2 |
symptoms neuropsychological | #2 |
association data | #2 |
wky ncrl | #2 |
blind raters | #2 |
millennium consortium | #2 |
familial association | #2 |
adhd disability | #2 |
risk factor adhd | #2 |
attention‐deficit hyperactivity | #2 |
wky nhsd | #2 |
correlates adhd | #2 |
items screener | #2 |
small literature | #2 |
adults attention | #2 |
findings children | #2 |
disorder findings | #2 |
adhd outcomes | #2 |
adhd relatives | #2 |
dsmjbd | #2 |
deficits efds | #2 |
male psychiatric | #2 |
background attention | #2 |
deficit sustained attention | #2 |
disorder impact | #2 |
wiatii | #2 |
p161e05 | #2 |
adhd genetics | #2 |
n‐acetylcysteine treatment | #2 |
disease humans receptors | #2 |
10092 | #2 |
adhd acc | #2 |
unweighted screener asrs | #2 |
adhd major | #2 |
adverse effects subjects | #2 |
adhd adults | #2 |
comorbidity adhd | #2 |
disorders similarities | #2 |
drug abuse dependence | #2 |
familybased studies | #2 |
n3199 | #2 |
dysfunction offspring | #2 |
wm deficits | #2 |
modest evidence | #2 |
persistent attention | #2 |
adhd risk gene | #2 |
dsmiv subtypes | #2 |
specific haplotype | #2 |
hypothesis adhd | #2 |
cbcljbd children | #2 |
rs6938431 | #2 |
d2s410 | #2 |
large controlled | #2 |
eye vergence | #2 |
5 loci adhd | #2 |
checklist clinical | #2 |
developmental subtype | #2 |
serum neuroleptic activity | #2 |
youth attention | #2 |
adhd neuropsychological tests | #2 |
ldsc heritability | #2 |
wwwhapmaporg | #2 |
bpd adhd | #2 |
major depression findings | #2 |
schizophrenia parahippocampal gyrus | #2 |
hypothetical task | #2 |
dsm adhd | #2 |
schizophrenia twin studies | #2 |
adhd odd | #2 |
adult samples | #2 |
adhd control subjects | #2 |
adhd neuropsychological deficits | #2 |
association mtbi | #2 |
disorders adhd | #2 |
diagnosis attention | #2 |
juvenile bipolar phenotype | #2 |
adhd method | #2 |
add probands | #2 |
galantamine hbr | #2 |
siblings youth | #2 |
adhd combined subtype | #2 |
schizotaxia discussion | #2 |
stimulant therapy | #2 |
trauma adhd | #2 |
child behavioral inhibition | #2 |
disorder add | #2 |
stin2vntr | #2 |
enigma adhd | #2 |
neuropsychological function girls | #2 |
disorder children | #2 |
deficits sustained attention | #2 |
scz data | #2 |
adhd psychiatric disorders | #2 |
hyperactivity impulsiveness | #2 |
adhd risk factor | #2 |
comorbidity disorders comorbidity | #2 |
youth meaningful | #2 |
g72 daao | #2 |
adhd ldx | #2 |
separation attention deficit | #2 |
genetic transmission | #2 |
unipolar relatives | #2 |
rates bpd | #2 |
adhd conduct | #2 |
nonpsychotic relatives | #2 |
key cognitive phenotypes | #2 |
adra2a polymorphism | #2 |
status rating scales | #2 |
preventing schizophrenia | #2 |
adhd adhd patients | #2 |
hyperactivity diagnostic | #2 |
adhd suds | #2 |
adhd major depression | #2 |
twin studies adhd | #2 |
adhd impact | #2 |
psychotic relatives | #2 |
multigenic inheritance | #2 |
dsmiiir adhd | #2 |
n17666 | #2 |
suggestive linkage loci | #2 |
chromosomes inclusion | #2 |
systematized delusions | #2 |
scales sex | #2 |
strong heritability | #2 |
comparative profile analysis | #2 |
masxr | #2 |
postcleavage | #2 |
adults adhd | #2 |
immune disorder | #2 |
cognition youth | #2 |
assessed structured | #2 |
schizophrenia genetic studies | #2 |
disorder adolescent | #2 |
adhd lower | #2 |
subjects desr | #2 |
consortium neuroscience | #2 |
concurrent attention | #2 |
cbcl clinical | #2 |
expanded versions | #2 |
qtl linkage adhd | #2 |
neuroleptic dose reduction | #2 |
current adult adhd | #2 |
juvenile antisocial | #2 |
emf impairments | #2 |
parental anxiety disorders | #2 |
adhd combined | #2 |
euphorigenic effects | #2 |
relatives simplex families | #2 |
n11221 | #2 |
adhd genes | #2 |
tourette spectrum | #2 |
adolescents substance disorder | #2 |
rates adhd | #2 |
pilot adult | #2 |
allele schizophrenia | #2 |
structured diagnostic | #2 |
child comorbidity | #2 |
investigator ratings | #2 |
adhd comparison subjects | #2 |
rs1800955 | #2 |
qualitative literature review | #2 |
enigma adventure | #2 |
adhd height | #2 |
patterns comorbidity | #2 |
adhd comparison | #2 |
subsequent substance | #2 |
140 girls | #2 |
schizophrenia pedigrees | #2 |
schizotypy handedness | #2 |
subjects adults | #2 |
18 dsm | #2 |
adhd growth | #2 |
adhd assessed | #2 |
psychoactive substance disorders | #2 |
control subjects adhd | #2 |
expanded symptom criteria | #2 |
disorder background | #2 |
idiopathic adhd | #2 |
association meta analysis | #2 |
evidence adhd | #2 |
role adhd | #2 |
cpt oih | #2 |
derived phenotypes | #2 |
risk panic disorder | #2 |
d10s1432 | #2 |
comorbidity disorder | #2 |
antisocial disorders relatives | #2 |
models adhd | #2 |
elusive indicators | #2 |
alleles attention | #2 |
deficits adults | #2 |
qualitative review | #2 |
case subjects adhd | #2 |
manic children | #2 |
adhd lifespan | #2 |
ratio081 | #2 |
hantac | #2 |
maoa comt | #2 |
n1934 | #2 |
rs1801028 | #2 |
schizophrenia interactions | #2 |
executive function outcome | #2 |
affective probands | #2 |
comorbid aggression | #2 |
aklt01 | #2 |
d0·18 | #2 |
dimesylate treatment | #2 |
comparison probands | #2 |
disease humans inhibition | #2 |
subjects conduct disorder | #2 |
7point | #2 |
adhd risk icv | #2 |
referred youth | #2 |
consecutively referred children | #2 |
stimulants adhd | #2 |
naltrexone adults | #2 |
quetiapine monotherapy treatment | #2 |
6 17 | #2 |
treatment sud patients | #2 |
relatives schizophrenic | #2 |
conners adult adhd | #2 |
selfmedicating | #2 |
performancemeasures | #2 |
hypothalamic abnormalities | #2 |
scales adolescent | #2 |
anx bipolar disorder | #2 |
nicotine substance | #2 |
disorder adults | #2 |
pdd overlap | #2 |
disorder inattentive | #2 |
personal satisfaction | #2 |
ncrl | #2 |
desr children | #2 |
jackknife procedure | #2 |
deficit hyperactivity disorder | #2 |
acpts | #2 |
chromosomes 6 14 | #2 |
adherence stimulants | #2 |
prior reports | #2 |
screening diagnosis treatment | #2 |
age onset distributions | #2 |
risk female cases | #2 |
derived diagnosis | #2 |
factors adhd | #2 |
conjfdr005 | #2 |
n2455 | #2 |
adhd mph response | #2 |
psychotic mood disorder | #2 |
adhd subjects | #2 |
actively reducing | #2 |
disorder girls | #2 |
bsfq | #2 |
somatosensory functioning | #2 |
subsyndromal manifestations | #2 |
shared genetic background | #2 |
regions studies | #2 |
adhd objective | #2 |
n2246 | #2 |
disorders findings | #2 |
comorbid conduct | #2 |
deficits executive | #2 |
variance adult | #2 |
adhd families | #2 |
childhood adolescent adhd | #2 |
molecular genetics schizophrenia | #2 |
psychiatric comorbidity | #2 |
youth rates | #2 |
spectrum phenotypes | #2 |
problems adhd | #2 |
expert clinician | #2 |
maternal smoking mothers | #2 |
factors attention | #2 |
schizophrenia calcineurin | #2 |
manic switches | #2 |
comorbidity attention | #2 |
adhd bpd | #2 |
structured diagnostic interviews | #2 |
actively reducing severity | #2 |
familial trait | #2 |
default network schizophrenia | #2 |
clinically referred children | #2 |
pediatrically | #2 |
clinically referred | #2 |
lgi regions | #2 |
weaknesses youth | #2 |
rs3746544 | #2 |
overlap mania | #2 |
psychiatrically | #2 |
parents disorder | #2 |
methylphenidate attention | #2 |
proinflammatory expansion | #2 |
testretest reliability screener | #2 |
ppv hyperactivity diagnostic | #2 |
diabetes disorders | #2 |
ermph children | #2 |
dsm subtypes | #2 |
adhd bipolar | #2 |
cacng2 genes | #2 |
cbcl profile | #2 |
efds adults | #2 |
female probands | #2 |
parent rating | #2 |
efds | #2 |
life social adjustment | #2 |
morbidity dysfunction | #2 |
relatives adhd | #2 |
bmi adhd symptoms | #2 |
families schizophrenia patients | #2 |
mood disorders adhd | #2 |
iii attention | #2 |
disorder conclusions | #2 |
effects paternal smoking | #2 |
polygenic resilience score | #2 |
disorder studies | #2 |
morning behavior | #2 |
eye vergence responses | #2 |
sud bpd | #2 |
snp12snp2ctgn | #2 |
familial adhd | #2 |
consecutively referred | #2 |
variants adhd | #2 |
adhd physical conditions | #2 |
≥210 | #2 |
bias child child | #2 |
risk add | #2 |
6‐year longitudinal study | #2 |
ldsc genetic correlations | #2 |
opioid induced hyperalgesia | #2 |
youth selfreports | #2 |
genome‐wide association scan | #2 |
scale asrs | #2 |
adhd birth | #2 |
bipolar disorder sud | #2 |
method subjects | #2 |
adhdprss | #2 |
adhd adhd children | #2 |
boys maoa | #2 |
multicenter adhd | #2 |
heterogeneity schizophrenia | #2 |
adhd case subjects | #2 |
disorder oppositional | #2 |
adhd comorbid problems | #2 |
bipolar disorder relatives | #2 |
adhd emotional symptoms | #2 |
stress adhd | #2 |
s038 | #2 |
bipolar disorder symptomatology | #2 |
adhd african americans | #2 |
drug nicotine | #3 |
tic disorders adhd | #3 |
hyperactivity bipolar | #3 |
desr | #3 |
adhd psud | #3 |
disorder conduct | #3 |
gsprs | #3 |
comorbidities adhd | #3 |
adhd systematic review | #3 |
md females | #3 |
checklist cbcl | #3 |
wonderlic personnel test | #3 |
adhd metaanalysis | #3 |
neuropsychiatric disorders similarities | #3 |
smoking probands | #3 |
“negativity | #3 |
hyperactivity central | #3 |
manic symptoms children | #3 |
remittent | #3 |
hyperactivity attention | #3 |
schizophrenia schizotaxia | #3 |
adhd rare cnvs | #3 |
dat1 | #3 |
adhd risk | #3 |
reln promoter | #3 |
adhd implications | #3 |
faraone reply | #3 |
social perception skills | #3 |
disabilities male | #3 |
cbcl scales | #3 |
psychiatric comorbidity adhd | #3 |
anxiety disorders authors | #3 |
growth deficits | #3 |
structural imaging findings | #3 |
risk panic | #3 |
67e07 | #3 |
dose response effects | #3 |
observed age | #3 |
sibling trait | #3 |
pairwise correlations disorders | #3 |
ldx amphetamine | #3 |
drd4 7 | #3 |
resilience score | #3 |
cgsq | #3 |
candidate gene studies | #3 |
familial risk factors | #3 |
highly heritable disorder | #3 |
international adhd | #3 |
interactions schizophrenia | #3 |
adult psychiatric outcomes | #3 |
7 repeat | #3 |
morning school | #3 |
adhd emotional | #3 |
adhd common | #3 |
brain methylation | #3 |
similarities genetic etiology | #3 |
association confounders | #3 |
qtl linkage | #3 |
enigma neuroimaging genetics | #3 |
control probands relatives | #3 |
morbidity risk | #3 |
adhd polygenic | #3 |
psychotic behaviour | #3 |
prenatal adversities | #3 |
lbw adhd | #3 |
conduct disorder adhd | #3 |
sud offspring | #3 |
abstraction verbal memory | #3 |
impulsivity errors | #3 |
clinically referred adults | #3 |
27 risk loci | #3 |
dsmiiir diagnosis | #3 |
vcfsadhd | #3 |
cognition comorbidity | #3 |
amphetamines attention | #3 |
schizotaxia | #3 |
learning disabilities adhd | #3 |
nmu prescription stimulants | #3 |
deficits height | #3 |
adhd mania | #3 |
potential gene | #3 |
md adhd | #3 |
adhd presence | #3 |
disease humans interviews | #3 |
comt promoter | #3 |
ptsd adhd | #3 |
european‐american | #3 |
intra‐individual variability | #3 |
tsuang | #3 |
weight effects | #3 |
adhd stimulant medication | #3 |
lambdasib | #3 |
risk factors sud | #3 |
substances symptoms | #3 |
comorbidity panic disorder | #3 |
n2323 | #3 |
stimulants treatment | #3 |
smds scz | #3 |
comorbidity diagnosis | #3 |
adhd data | #3 |
siblings young | #3 |
educational deficits | #3 |
children mania | #3 |
adhd psychiatric comorbidity | #3 |
asthma adhd | #3 |
familial nature | #3 |
disorder comorbid | #3 |
htr1e | #3 |
cigarette smoking children | #3 |
probands parental | #3 |
relationship adhd | #3 |
genetic receptors serotonin | #3 |
nervous stimulants | #3 |
adhd wm deficits | #3 |
sirolimus 12 months | #3 |
mania children | #3 |
ermph | #3 |
relatives proband groups | #3 |
adhd mdd | #3 |
vulnerability indicators | #3 |
topic adolescent | #3 |
sexdifferentiated effects | #3 |
adhdpi | #3 |
youths ocd | #3 |
snps haplotype | #3 |
impairment adhd | #3 |
adhd mtbi | #3 |
neurological polymorphism | #3 |
subjects sud | #3 |
controls 6 disorders | #3 |
parental substance disorders | #3 |
n1777 | #3 |
bpd rates | #3 |
n5827 | #3 |
naltrexone methylphenidate | #3 |
n2271 | #3 |
petronis | #3 |
asrs v11 | #3 |
firstdegree relatives | #3 |
comt adhd | #3 |
intron13 | #3 |
enigma wgs wgs | #3 |
adhd control | #3 |
adhd mental disorders | #3 |
schizophrenia neurocognitive performance | #3 |
adhd ptsd | #3 |
defined adhd | #3 |
508e7 | #3 |
model adhd | #3 |
children adhd diagnosis | #3 |
schizoaffective bipolar disorder | #3 |
schizophrenia allele | #3 |
anxiety disorders parents | #3 |
z280 | #3 |
nonpsychotic relatives persons | #3 |
alcohol adhd | #3 |
children adhd | #3 |
childhood attention‐deficit | #3 |
longitudinal follow | #3 |
drd5 marker | #3 |
persistence psychiatric disorders | #3 |
psychopathologic conditions | #3 |
major depression comorbidity | #3 |
studies square | #3 |
relatives bipolar disorder | #3 |
substance disorders adhd | #3 |
dmi addh | #3 |
variance severity | #3 |
9rcarriers | #3 |
notch4 schizophrenia | #3 |
excess transmission | #3 |
adolescent adhd | #3 |
sud youths | #3 |
children vcfsadhd | #3 |
simulated workplace laboratory | #3 |
mania disorders | #3 |
nicotine disorders | #3 |
disproportionate impairment | #3 |
deficient emotional | #3 |
adhd comorbid conditions | #3 |
adhd bipolar disorder | #3 |
13q222 | #3 |
oprm1 variants | #3 |
disorders conclusions | #3 |
zakzanis | #3 |
common disorders brain | #3 |
adolescents mania | #3 |
predisposition schizophrenia | #3 |
cpt deficits | #3 |
pdd adhd | #3 |
bipolar disease | #3 |
large battery | #3 |
methylphenidate studies | #3 |
7repeat allele | #3 |
caarsss | #3 |
atomoxetine response | #3 |
non500 | #3 |
syndromatic | #3 |
global neuroscience decade | #3 |
manic symptoms youth | #3 |
rs6565113 | #3 |
enigma global neuroscience | #3 |
schizophrenia genotype | #3 |
schizophrenic outpatients | #3 |
cortical thickness cases | #3 |
mtbi studies | #3 |
adhd combined type | #3 |
genetics initiative | #3 |
parents panic | #3 |
enuresis adhd | #3 |
npl scores | #3 |
girls attention | #3 |
sud children | #3 |
emotional dysregulation adhd | #3 |
anxiety behavioral inhibition | #3 |
parents panic disorder | #3 |
adhd pairwise correlations | #3 |
ocd groups asd | #3 |
experienced pain | #3 |
temperamental correlates | #3 |
chromosome 10q22 | #3 |
relatives persons | #3 |
inattentive subtype | #3 |
teacher reports | #3 |
evidence genetic association | #3 |
networks adhd | #3 |
asd ocd groups | #3 |
bipolar psychoses | #3 |
impact adhd | #3 |
response methylphenidate | #3 |
metadoxine extended release | #3 |
transporter genotypes | #4 |
deficits executive functioning | #4 |
d4s1644 | #4 |
support mechanism | #4 |
boys higher prevalence | #4 |
adhd participants | #4 |
psychiatrically referred | #4 |
psud | #4 |
pediatric mania | #4 |
addictive drug | #4 |
behavior checklist | #4 |
cbcljbd phenotype | #4 |
phenotypes adhd | #4 |
poor motor performance | #4 |
adhd status | #4 |
time reproduction | #4 |
motor coordination problems | #4 |
health female | #4 |
safren | #4 |
enrichment adhd | #4 |
rates psychiatric | #4 |
hemmings | #4 |
cbclaps | #4 |
adhd based | #4 |
adhd subgroups | #4 |
neuropsychological performance schizophrenia | #4 |
adhd individuals | #4 |
adults | #4 |
inattentive adhd | #4 |
rs1079727 | #4 |
17q111q12 | #4 |
46222 | #4 |
maternal smoking alcohol | #4 |
metadoxine placebo | #4 |
neuropsychoanalytic | #4 |
preterm sample | #4 |
rate switching | #4 |
fmri replication | #4 |
parental panic | #4 |
genetic heterogeneity schizophrenia | #4 |
notch4 locus | #4 |
risk variants adhd | #4 |
angerirritability | #4 |
receiver operator characteristic | #4 |
comorbid aggression adhd | #4 |
image sample | #4 |
stimulantnaïve | #4 |
disorders comorbidity | #4 |
executive function deficits | #4 |
psychiatric comorbidity risk | #4 |
enigmaadhd | #4 |
lgi age | #4 |
adhd association | #4 |
adderall methylphenidate | #4 |
presence adhd | #4 |
rels | #4 |
adhd pdd | #4 |
sud bpd sud | #4 |
snps intelligence | #4 |
relatives controls | #4 |
secondary psychotic symptoms | #4 |
schizophrenia genetic factors | #4 |
adhd pharmacogenetic studies | #4 |
risk gene schizophrenia | #4 |
families girls | #4 |
differences adults | #4 |
adhd etiology | #4 |
bipolar disorder linkage | #4 |
gender children | #4 |
strattera | #4 |
choice adhd | #4 |
anxiety disorders mdd | #4 |
subsequent substance disorders | #4 |
selenbp1 schizophrenia | #4 |
homogeneous subtypes | #4 |
height deficits | #4 |
aggregation adhd | #4 |
children comorbid adhd | #4 |
metaanalyzes | #4 |
adhd brain regions | #4 |
adhd adulthood | #4 |
disorders panic | #4 |
risk factors bpd | #4 |
d4s2361 | #4 |
vulnerability schizophrenia | #4 |
adhd symptom | #4 |
disorders neuropsychological | #4 |
mts growth | #4 |
adhd md | #4 |
nonoral routes administration | #4 |
acting formulations | #4 |
adhd control children | #4 |
parents bpd | #4 |
gxr adhd | #4 |
remittent adhd | #4 |
functioning adhd | #4 |
adhd pharmacotherapy | #4 |
pavgrnk000417 | #4 |
comorbidity humans | #4 |
global neuroscience | #4 |
impaired intellect | #4 |
subjects schizotaxia | #4 |
onset adhd | #4 |
comorbid psychiatric | #4 |
relatives normal controls | #4 |
shr ncrl | #4 |
psychiatrically referred youth | #4 |
suds adolescents | #4 |
expected height | #4 |
rs3785143 | #4 |
adhd children mph | #4 |
adhd youth | #4 |
substance disorders suds | #4 |
increased neural responses | #4 |
humans lisdexamfetamine | #4 |
adhd controls | #4 |
4year followup | #4 |
depression parental depression | #4 |
treatment stimulant medication | #4 |
hypescheme | #4 |
odd adhd | #4 |
mhlod | #4 |
rs140700 | #4 |
disorder objective | #4 |
rs3916968 | #4 |
adhd neuropsychological performance | #4 |
disease genome humans | #4 |
tests psychiatric | #4 |
adhd reported | #4 |
achievement goal orientation | #4 |
primary substance abuse | #4 |
inhibition anxiety | #4 |
4th international meeting | #4 |
rs3916971 | #4 |
handedness schizotypy | #4 |
rutter | #4 |
pord05 | #4 |
openlabel studies | #4 |
comorbid attention | #4 |
reported adhd | #4 |
maoa | #4 |
subthreshold | #4 |
psc35 | #4 |
cbcl | #4 |
attention adhd | #4 |
reward dysfunction | #4 |
coordination problems | #4 |
growing literature | #4 |
scores adhd | #4 |
treatment seeking patients | #4 |
risk factors adhd | #4 |
sd133 | #4 |
roh risk | #4 |
adolescent years | #4 |
independent transmission | #4 |
vcfs sample | #4 |
chinese sample | #4 |
child behavior checklist | #4 |
adhd impairments | #4 |
distinct disorder | #4 |
asd mood disorders | #4 |
report scale | #4 |
female probands relatives | #4 |
offspring sud | #4 |
bpd sud bpd | #4 |
lifetime dimensions | #4 |
quantitative phenotype | #4 |
treatment adhd | #4 |
treatment adult adhd | #4 |
familial vulnerability | #4 |
intelligence snps | #4 |
developmental improvement | #4 |
anxiety disorders offspring | #4 |
bpd sud patients | #4 |
vcfs adhd | #4 |
factors substance | #4 |
rutters indicators | #4 |
md individuals | #4 |
jbd | #4 |
quantitative models | #4 |
objective studies | #4 |
total score week | #4 |
snpbased | #4 |
controls basal ganglia | #4 |
panic disorder pregnancy | #4 |
disorders attention | #4 |
findings risk | #4 |
adhd substance abuse | #4 |
psychiatric gene discoveries | #4 |
reported findings | #4 |
adolescent outcome | #4 |
hechtman | #5 |
nonaffected siblings | #5 |
intellectually capable adults | #5 |
referred youths | #5 |
interview psychological | #5 |
study genetic factors | #5 |
adhd youths | #5 |
palauan | #5 |
impairment baseline | #5 |
cbcl data | #5 |
2nd cohort | #5 |
ascertainment source | #5 |
inattentive symptoms | #5 |
highly heritable | #5 |
mood disorders asd | #5 |
pdmd | #5 |
resilience project | #5 |
sud | #5 |
adhd adult | #5 |
clinical obesity | #5 |
kuntsi | #5 |
wcst scores | #5 |
3q13 | #5 |
criteria schizotaxia | #5 |
scale adhd | #5 |
boys attention | #5 |
impaired parents humans | #5 |
checklist child | #5 |
maternal reports | #5 |
inhibited children | #5 |
symptoms hyperactivity | #5 |
pathways association | #5 |
adhd inattentive type | #5 |
disorder rating | #5 |
disorder sud | #5 |
referred sample | #5 |
adult probands | #5 |
neuropsychiatric comorbidity | #5 |
growth dysregulation | #5 |
screener | #5 |
multivariate endophenotypes | #5 |
child child behavior | #5 |
humans interview | #5 |
diagnosis mania | #5 |
impairment survey | #5 |
adhdlike symptoms | #5 |
desipramine placebo | #5 |
major depression parents | #5 |
anxiety disorders anx | #5 |
psychiatric disorders study | #5 |
oppositional defiant disorder | #5 |
combined subtype | #5 |
adhd tic disorders | #5 |
sex adhd | #5 |
desistent | #5 |
d22s683 | #5 |
rs1799836 | #5 |
etiopathologies | #5 |
psychosis scale | #5 |
mania adhd | #5 |
familial risk adhd | #5 |
disorder parents | #5 |
memantine hydrochloride | #5 |
3 probands | #5 |
dsm age | #5 |
initial responsiveness | #5 |
adolescent alleles | #5 |
pleiotropic effects disorders | #5 |
prembr | #5 |
mothers anxiety disorders | #5 |
torture review | #5 |
parental adhd | #5 |
adhd bupropion | #5 |
disorders follow | #5 |
parental sud | #5 |
effects adhd | #5 |
organization adult | #5 |
auditory vigilance | #5 |
psychosis velocardiofacial syndrome | #5 |
methylphenidate adults | #5 |
youth vcfs | #5 |
aagc | #5 |
familial subtypes | #5 |
risk anxiety | #5 |
relatives female probands | #5 |
adhd ld | #5 |
cardinal symptom | #5 |
referred children | #5 |
ppp3cc schizophrenia | #5 |
comorbid disorders | #5 |
schizophrenia palau | #5 |
neuropsychological risk | #5 |
unipolar mdd | #5 |
dopamine risk | #5 |
function adhd | #5 |
hyperactivity clinical trials | #5 |
oosterlaan | #5 |
psychiatric correlates | #5 |
height weight | #5 |
hyperactivity caregivers | #5 |
children dbds | #5 |
adhd comorbid anxiety | #5 |
ncrl rats | #5 |
genetic linkage schizophrenia | #5 |
year prospective | #5 |
adolescence adhd | #5 |
nonmedical nmu | #5 |
shared haplotypes | #5 |
pdd subjects | #5 |
large collaborative study | #5 |
serum neuroleptic | #5 |
adhd treated | #5 |
familial distribution | #5 |
nt5dc1 | #5 |
social disability | #5 |
puwma | #5 |
female individuals | #5 |
disorder genetic | #5 |
report screening | #5 |
adhd response | #5 |
sms intervention | #5 |
kiddieschedule | #5 |
zmynd17 | #5 |
depression panic disorder | #5 |
risk relatives | #5 |
elevated rates | #5 |
iiv adhd | #5 |
asrs screener | #5 |
lifetime impact | #5 |
disorders psychiatric | #5 |
adhd nonaffected siblings | #5 |
panic disorder parents | #5 |
bipolar disorder pedigrees | #5 |
tass | #5 |
grubb | #5 |
disorder anxiety | #5 |
risk factors schizophrenia | #5 |
xr adults | #5 |
proband risk | #5 |
severe scores | #5 |
bipolar disorder bpd | #5 |
behavioral inhibition children | #5 |
children ldx | #5 |
conventional medications | #5 |
onset criterion | #5 |
adults adult | #5 |
parents psychiatric | #5 |
adhd cases | #5 |
adult attention | #5 |
pediatric bpd | #6 |
t518 | #6 |
pediatric bipolar | #6 |
dopamine transporter gene | #6 |
ppp3cb | #6 |
child delayed | #6 |
symptoms disorder | #6 |
druggable genome | #6 |
dsm iii | #6 |
downward extension | #6 |
neuropsychological functioning | #6 |
association studies schizophrenia | #6 |
concurrent validation | #6 |
clinical scales | #6 |
stimulant prescription | #6 |
dnajc9 | #6 |
objective marker | #6 |
depression panic | #6 |
value09 | #6 |
disorders adolescent | #6 |
cpg sites methylation | #6 |
hierarchical factor model | #6 |
hyperactivity disease models | #6 |
irmph | #6 |
life adults | #6 |
psychopathology children | #6 |
adhd variability | #6 |
literature efficacy | #6 |
loci autism | #6 |
adhd compared | #6 |
prevalence adult adhd | #6 |
groups adults | #6 |
parents major | #6 |
adhd tic | #6 |
genetic child | #6 |
parental major depression | #6 |
nhe inhibitors | #6 |
psychoactive substance | #6 |
year recall | #6 |
cognition adults | #6 |
enigma wgs | #6 |
wm performance patients | #6 |
paternal age schizophrenia | #6 |
behavioral inhibition | #6 |
bpd comorbid | #6 |
adhd mood disorders | #6 |
clinical features children | #6 |
seidman | #6 |
driving simulation | #6 |
large heterogeneous | #6 |
normal sexual dimorphism | #6 |
disorder combined | #6 |
adhd mental retardation | #6 |
risk sud | #6 |
schizophrenia g72 | #6 |
individual alleles | #6 |
environmental adversity | #6 |
140 children | #6 |
differences cortical thickness | #6 |
prior stimulant treatment | #6 |
anxiety disorder relatives | #6 |
oppositional defiant | #6 |
xp114p113 | #6 |
genetic linkage genome | #6 |
t515 | #6 |
bpd controls | #6 |
niacin schizophrenia | #6 |
schizophrenia premorbid | #6 |
scales psychometrics | #6 |
liability schizophrenia | #6 |
cognitive impairments adhd | #6 |
unfamiliar situations | #6 |
fspd | #6 |
schizophrenic probands | #6 |
relatives probands | #6 |
tmcq | #6 |
psychiatric disorders prss | #6 |
schizophrenia deficit | #6 |
adhd women | #6 |
pseudocontrols | #6 |
4634 | #6 |
adhd genetic factors | #6 |
schizophrenia spectrum schizophrenia | #6 |
referred adults | #6 |
females adhd | #6 |
adhdia | #6 |
specific predictor | #6 |
nonparanoid schizophrenia | #6 |
adults disorder | #6 |
chromosome 15 locus | #6 |
maniclike symptoms | #6 |
gxr efficacy | #6 |
pediatric mood disorders | #6 |
combined condition | #6 |
disorders relatives | #6 |
facial memory | #6 |
adhd increased risk | #6 |
bpdsud | #6 |
genome‐wide | #6 |
males adhd | #6 |
altered neural connectivity | #6 |
adhd children adults | #6 |
p1e04 | #6 |
adhd life | #6 |
familial loadings | #6 |
teenage parenthood | #6 |
symptoms adhd | #6 |
neuroleptic activity | #6 |
followup studies | #6 |
nmu | #6 |
adhd firstdegree relatives | #6 |
children relatives | #6 |
psychiatric | #6 |
criteria adhd | #6 |
taan | #6 |
oceanic palau | #6 |
hyperactivity child chromosomes | #6 |
stimulant treatment children | #6 |
placebo response response | #6 |
premorbid cognitive ability | #6 |
benefitrisk ratio | #6 |
total gray matter | #6 |
ascertained | #6 |
male odds | #6 |
combined subtypes | #6 |
interpreting estimates | #6 |
pavgrnk | #6 |
cbcljbd | #6 |
mixed amphetamine | #6 |
vulnerability indicator | #6 |
risk attention | #6 |
referred children adolescents | #6 |
qlesqsf | #7 |
ldx treatment | #7 |
chromosome workshop | #7 |
adhd sud sud | #7 |
adhd symptoms | #7 |
authors goal | #7 |
6 psychiatric disorders | #7 |
polygenic scores adhd | #7 |
attention task | #7 |
adhdct | #7 |
adhd persistence | #7 |
highrisk siblings | #7 |
kgas | #7 |
dependence rates | #7 |
ancestry attention | #7 |
development adhd | #7 |
persistence anxiety disorders | #7 |
adhd overweight obesity | #7 |
pediatric major depression | #7 |
n1031 | #7 |
methylomics | #7 |
sensorimotor timing | #7 |
members schizophrenia | #7 |
parent reports | #7 |
coming years | #7 |
markov chain analysis | #7 |
hyperactivity brain | #7 |
mph adhd adults | #7 |
adhd boys girls | #7 |
statistical measure | #7 |
skin flush response | #7 |
confusability | #7 |
velo‐cardio‐facial | #7 |
adhd substance disorders | #7 |
odd | #7 |
combined type adhd | #7 |
asd asd youth | #7 |
hraff | #7 |
nrp104 | #7 |
parents psychiatric disorders | #7 |
drd5 | #7 |
boys adhd | #7 |
adhd symptoms association | #7 |
palauans | #7 |
adhd improvement | #7 |
parents prevalence | #7 |
long repeats | #7 |
haplotype schizophrenia | #7 |
mdd pdag | #7 |
adhd emotional dysregulation | #7 |
exome chip analyses | #7 |
pdqr | #7 |
dimensional measures | #7 |
seeking substance | #7 |
childhood disorder | #7 |
teachers boys | #7 |
spn812 | #7 |
neuroimage study | #7 |
mph adhd | #7 |
candidate gene schizophrenia | #7 |
bipolar unipolar disorders | #7 |
saica | #7 |
disorder substance | #7 |
idir | #7 |
child impaired | #7 |
wonderlic | #7 |
pmee | #7 |
genome‐wide association | #7 |
flush response | #7 |
adhdrs | #7 |
studies dopamine | #7 |
implicating | #7 |
children bpd | #7 |
pdag mdd | #7 |
adhd authors | #7 |
exon15 | #7 |
disorders probands | #7 |
asd youth | #7 |
adhd criteria | #7 |
adhd asrs | #7 |
prevention schizophrenia | #7 |
children tourettes syndrome | #7 |
swedish registry data | #7 |
snap25 adhd | #7 |
children learning disorders | #7 |
relatives risk | #7 |
tomoxetine | #7 |
measures adhd | #7 |
neurocognitive performances | #7 |
association cdh13 | #7 |
nalysis | #7 |
locus haplotypes | #7 |
systematic chart review | #7 |
methylphenidate therapy | #7 |
outpatient child | #7 |
nmu prescription | #7 |
relatives schizophrenic patients | #7 |
conduct disorder girls | #7 |
myosin5b | #7 |
controls probands | #7 |
affairs cooperative | #8 |
rs3916965 | #8 |
onset bpd | #8 |
presence autistic traits | #8 |
volumetric reductions | #8 |
metaanalysis schizophrenia | #8 |
adhd stimulant | #8 |
sample youth | #8 |
bpd disorders | #8 |
mph adults | #8 |
mwq | #8 |
impulsivity adhd | #8 |
subjects children | #8 |
indicators schizophrenia | #8 |
multigenerational pedigree | #8 |
behavioral inhibition risk | #8 |
behavioral inhibition anxiety | #8 |
disorder probands | #8 |
gender effects | #8 |
disorders families | #8 |
promising directions | #8 |
disorders baseline | #8 |
diagnosed adhd | #8 |
probands risk | #8 |
schizophrenia polymorphisms | #8 |
pvalues005 | #8 |
attention deficit adhd | #8 |
control adhd | #8 |
chromosome schizophrenia | #8 |
shared familial effects | #8 |
adhd rtv | #8 |
symptoms impairment | #8 |
avoidant disorder | #8 |
offspring trios | #8 |
unaffected siblings adhd | #8 |
negative symptoms scale | #8 |
adhdcd | #8 |
crossover comparison | #8 |
controls relatives | #8 |
adhd dat1 | #8 |
attention | #8 |
adhd adolescence | #8 |
adhdhi | #8 |
agreement measures | #8 |
impaired motor performance | #8 |
adhd symptom scores | #8 |
analysis association | #8 |
abbreviated questionnaire | #8 |
cadhd | #8 |
notch4 | #8 |
human aggression | #8 |
autistic traits children | #8 |
pliszka | #8 |
nonpsychotic | #8 |
stimulanttreated | #8 |
child diagnostic | #8 |
adhd boys | #8 |
studies provide | #8 |
schizophrenia members | #8 |
adhd unaffected | #8 |
adhd associations | #8 |
adhd remission | #8 |
childhood mania | #8 |
treatment sirolimus | #8 |
n1314 | #8 |
10q223 | #8 |
familybased association study | #8 |
participants adhd | #8 |
behavior attention | #8 |
familial aggregation adhd | #8 |
diagnosis major depression | #8 |
ordered subsets | #8 |
differential utility | #8 |
link adhd | #8 |
rs3916966 | #8 |
symptoms behaviors | #8 |
aversion adhd | #8 |
pempirical | #8 |
male multifactorial inheritance | #8 |
adhd manic symptoms | #8 |
polygenic associations | #8 |
biological relatives | #8 |
adhd inattentive | #8 |
dimesylate ldx | #8 |
substantial evidence | #8 |
disease humans polymorphism | #8 |
psychiatric genomics | #8 |
treatment lead | #8 |
therapeutic dilemmas | #8 |
euphoria | #8 |
nonverbal social | #8 |
biederman | #8 |
hemideletion | #8 |
prescription stimulant | #8 |
adult symptoms | #9 |
adderall | #9 |
ldps | #9 |
n41 | #9 |
mdd youth | #9 |
39 datasets | #9 |
nuremberg code | #9 |
moderate sensitivity | #9 |
symptoms mania | #9 |
endophenotypic | #9 |
disruptive behavior disorders | #9 |
hyperactivity automobile | #9 |
ecpbhs | #9 |
adhd article | #9 |
lag sequential analysis | #9 |
taiwanese families | #9 |
rasd2 | #9 |
nonparanoids | #9 |
disorders sex interaction | #9 |
adhdi | #9 |
adhd enuresis | #9 |
comparison girls | #9 |
festschrift | #9 |
sustained attention schizophrenia | #9 |
genes risk factors | #9 |
adhd loci | #9 |
addh | #9 |
substantial risk | #9 |
hyperactivity humans | #9 |
orosmph irmph | #9 |
rpdr | #9 |
snp7 | #9 |
aisrs | #9 |
deficit disruptive | #9 |
dao gene | #9 |
schizotaxic | #9 |
children assessed | #9 |
neuropsychologic function | #9 |
nonreplications | #9 |
childhood psychosis | #9 |
rs685012 | #9 |
ads individuals | #9 |
comorbidity female | #9 |
adult report | #9 |
netherlands twin registry | #9 |
sud bipolar disorder | #9 |
gwas psychiatric disorders | #9 |
male nuclear | #9 |
haplotype snps | #9 |
blindly | #9 |
g×s interaction disorders | #9 |
serotonin gene polymorphisms | #9 |
inattentive | #9 |
adhd healthy | #9 |
pregnancy depression | #9 |
25e07 | #9 |
schizophrenia resilience | #9 |
extendedrelease methylphenidate | #9 |
alzheimer disease schizophrenia | #9 |
hhrr | #9 |
subtypes adhd | #9 |
depression offspring | #9 |
etiologically | #9 |
hum genet | #9 |
proband groups | #9 |
serotonin genes | #9 |
diagnostic efficiency | #9 |
stimulant medication | #9 |
untreated adhd | #10 |
small effects | #10 |
comorbidity | #10 |
adhd quality | #10 |
drd4 | #10 |
bipolar disorder probands | #10 |
normal sexual | #10 |
d4 receptor gene | #10 |
gwas adhd | #10 |
sexual dimorphisms | #10 |
risk md | #10 |
reassessed | #10 |
shared neurobiology | #10 |
nephews | #10 |
adult years | #10 |
severity adhd | #10 |
slod | #10 |
association dat1 | #10 |
childhood adhd symptoms | #10 |
pthreshold | #10 |
adhd substance disorder | #10 |
caadid | #10 |
amphetamine salts | #10 |
comorbidity depressive | #10 |
systematic qualitative review | #10 |
anxiety disorders children | #10 |
stimulants humans | #10 |
genes disorders | #10 |
comorbid odd | #10 |
probands bpd | #10 |
adhd childhood | #10 |
genetics network | #10 |
kruglyak | #10 |
conduct disorder | #10 |
linkage analyses | #10 |
ascertainment methods | #10 |
cbclap | #10 |
comorbid bpd | #10 |
disorder age | #10 |
groups boys | #10 |
adulthood association | #10 |
genetic vulnerability schizophrenia | #10 |
panic depression | #10 |
asd tourette syndrome | #10 |
aged attention | #10 |
psychiatric clinic | #10 |
preteen | #10 |
irmph orosmph | #10 |
stimulants child | #10 |
deficits adhd | #10 |
sleep problems adhd | #10 |
case identification | #10 |
parent‐of‐origin effects | #10 |
young adult outcome | #10 |
image project | #10 |
4th | #10 |
psychiatric genetic studies | #10 |
new specialty | #10 |
adhd unaffected siblings | #10 |
noninhibited | #10 |
adhd sud | #10 |
dms1 | #10 |
rorb | #10 |
association death | #10 |
nonpharmacologic treatments | #10 |
evidence genetic | #10 |
diminished risk | #10 |
adhd difficulties | #10 |
preschool depressive | #10 |
rates abuse | #10 |
n136 | #11 |
adhd psychopathology | #11 |
adhd intellectual disability | #11 |
shared familial | #11 |
deficits schizophrenia patients | #11 |
release methylphenidate | #11 |
adhd substance | #11 |
gene adhd | #11 |
study perspective | #11 |
adhd female humans | #11 |
female relatives | #11 |
familybased association test | #11 |
maternal antenatal anxiety | #11 |
disorders | #11 |
juvenile mania | #11 |
sample adults | #11 |
dimesylate | #11 |
agoraphobia anxiety | #11 |
hyperactivity child cross | #11 |
differences parents | #11 |
rora rorb | #11 |
nonadhd controls | #11 |
vcfs | #11 |
cutraits | #11 |
achievement adolescent | #11 |
preschool depressive disorder | #11 |
4372 | #11 |
nosologists | #11 |
rs1137070 | #11 |
markers adhd | #11 |
differences adhd | #11 |
paternal smoking | #11 |
disease humans schizophrenia | #11 |
serotonin genetic receptor | #11 |
children bipolar | #11 |
major depression adhd | #11 |
neuropsychological test scores | #11 |
defiant disorder | #11 |
inattentive type | #11 |
children addh | #11 |
adolescents adhd | #11 |
adhd time | #11 |
psychiatric disorders youth | #11 |
adult relatives | #11 |
informativeness | #11 |
ldx placebo | #11 |
disorders mothers | #11 |
youth bpd | #11 |
symptom subtype | #11 |
differentiated genetic | #11 |
growth delays | #11 |
polymorphism 5 | #11 |
attention deficit disorder | #11 |
studies mtbi | #11 |
dopamine d5 receptors | #11 |
fbatpc | #11 |
comorbidity patterns | #11 |
cardinal symptoms | #11 |
remission adhd | #11 |
panic disorder comorbidity | #11 |
shr model | #11 |
hydrochloride attention | #11 |
pediatric bipolar disorder | #11 |
effects genes | #11 |
multiple domains | #11 |
etiology pathophysiology | #11 |
prodromal psychosis | #11 |
ppp3cc | #11 |
diagnosis adults | #11 |
real progress | #11 |
inhibition adhd | #11 |
disorder pedigrees | #11 |
adhd onset | #11 |
lisdexamfetamine ldx | #11 |
offspring bipolar parents | #11 |
defiant | #12 |
treatment paliperidone | #12 |
sample consisted | #12 |
salts extended | #12 |
unaffected sibs | #12 |
psychotic mood disorders | #12 |
treatment attention | #12 |
adult outcome | #12 |
lossavoidance | #12 |
disorder subjects | #12 |
sexually dimorphic effects | #12 |
effects time | #12 |
impulsivity children | #12 |
test wcst | #12 |
psychotic behavior | #12 |
rs778293 | #12 |
nhe9 | #12 |
obesity adhd | #12 |
cbcl children | #12 |
onelevel | #12 |
assessment adhd | #12 |
n1397 | #12 |
thalamic activation | #12 |
psychiatric genetics | #12 |
stimulant medication children | #12 |
girls relationship | #12 |
comorbidity diagnostic | #12 |
adolescent adult age | #12 |
neurocognitive measures | #12 |
systematized | #12 |
adhd dopamine | #12 |
adhd symptoms adults | #12 |
probands siblings | #12 |
perceived motor competence | #12 |
twins humans models | #12 |
adhd age | #12 |
convergent functional | #12 |
adhd core symptoms | #12 |
sec23ip | #12 |
symptom rating | #12 |
kappa coefficients | #12 |
cnvs risk | #12 |
40–48 | #12 |
amfetamine | #12 |
dat1 polymorphism | #12 |
youths bpd | #12 |
disorder adult | #12 |
sud adhd | #12 |
multiplex schizophrenia | #12 |
epilepsy mothers | #12 |
adhd offspring | #12 |
comorbid disorder | #12 |
genes methylation | #12 |
psychiatric clinics | #12 |
juvenile bipolar | #12 |
digital treatment | #12 |
hawi | #12 |
rs947267 | #12 |
impaired parents | #12 |
striatal sensitivity | #12 |
variable age | #12 |
common psychiatric | #12 |
response atomoxetine | #12 |
impaired parents child | #12 |
scales treatment | #12 |
common disorders | #12 |
studies relatives | #12 |
covid19 restrictions children | #12 |
pleiotropic mechanisms | #12 |
ksadse | #12 |
deficits attention | #12 |
unaffected siblings individuals | #12 |
obesity risk alleles | #12 |
metan | #12 |
early psychosis study | #12 |
nonoral | #12 |
functional impairments | #12 |
sud patients adhd | #12 |
response inhibition adolescents | #13 |
adhd alterations | #13 |
pkcm | #13 |
psychotic mood | #13 |
risk parents | #13 |
adverseevents | #13 |
necrotic death | #13 |
methods subjects | #13 |
risk mood | #13 |
overanxious | #13 |
weight bmi | #13 |
adhd cognitive | #13 |
scale studies | #13 |
transdermal methylphenidate | #13 |
disorders child | #13 |
genomewide significance | #13 |
symptoms attention | #13 |
colorado springs | #13 |
psychometric measure | #13 |
girls | #13 |
longallele | #13 |
diagnostic concepts | #13 |
psychometrics reproducibility | #13 |
chi12 | #13 |
environment adolescent | #13 |
pair 6 chromosomes | #13 |
permutation testing | #13 |
familial risk schizophrenia | #13 |
studies bipolar | #13 |
velocardiofacial syndrome vcfs | #13 |
taiwanese sample | #13 |
nonoral routes | #13 |
humans methylphenidate | #13 |
robust effects | #13 |
specific hypotheses | #13 |
psychiatric risk | #13 |
disorder childhood | #13 |
114 years | #13 |
disorders sud | #13 |
persistence remission | #13 |
disorder youth | #13 |
adhd alcohol | #13 |
male samples | #13 |
cognitive impulsivity | #13 |
convergent functional genomics | #13 |
diagnostic threshold | #13 |
adderall mph | #13 |
rates comorbidity | #13 |
adhd diagnosis | #13 |
late onset | #13 |
ravg | #13 |
label studies | #13 |
adhdodd | #13 |
bpd offspring | #13 |
iiv | #13 |
morbidity risks | #13 |
disorder child | #14 |
mph adderall | #14 |
siblings probands | #14 |
stimulant abuse | #14 |
children stimulants | #14 |
attention executive | #14 |
adhd brain | #14 |
worldwide prevalence | #14 |
emotional impulsivity | #14 |
familial disorder | #14 |
factors schizophrenia | #14 |
n643 | #14 |
prss mdd | #14 |
disorder odd | #14 |
ocd scz | #14 |
genetic studies schizophrenia | #14 |
selfcontained | #14 |
symptoms psychiatric disorders | #14 |
social school | #14 |
differential heritability | #14 |
genes schizophrenia | #14 |
unaffected siblings controls | #14 |
children bipolar disorder | #14 |
adhd symptoms adulthood | #14 |
diagnosis mdd | #14 |
cautiously | #14 |
hillside | #14 |
bipolar probands | #14 |
older adults adhd | #14 |
associations adhd | #14 |
aadhd | #14 |
nimh genetics | #14 |
subcortical brain volume | #14 |
wraadds | #14 |
teachers reports | #14 |
studies adults | #14 |
mixed amphetamine salts | #14 |
early precursors | #14 |
relatives male probands | #14 |
quetiapine bipolar disorder | #14 |
lphn3 adhd | #14 |
adhd phenotype | #14 |
suds | #14 |
sud patients | #14 |
lisdexamfetamine dimesylate ldx | #14 |
disorders comorbid | #14 |
geschwind | #14 |
children criteria | #14 |
cnvs park2 | #14 |
comorbid condition | #14 |
common disorder | #14 |
siblings cases | #14 |
economic psychology | #14 |
mphmlr | #15 |
d10s1423 | #15 |
zranb2 | #15 |
male relatives | #15 |
diagnostic interviews | #15 |
adhd performance | #15 |
risk substance | #15 |
behavior disorders | #15 |
schizophrenia families | #15 |
49 children | #15 |
genderdifferences | #15 |
4669 | #15 |
seconddegree relatives | #15 |
metabolic syndrome obesity | #15 |
nhsd | #15 |
pregnancy risk factor | #15 |
disord | #15 |
adhd functional connectivity | #15 |
adhd diagnostic | #15 |
tests psychomotor | #15 |
symptoms adulthood | #15 |
wfirsp | #15 |
chi2 | #15 |
sackett | #15 |
persons schizophrenia | #15 |
methylation gene expression | #15 |
psychiatric interviews | #15 |
agents attention | #15 |
rs2652511 | #15 |
symptom count | #15 |
bipolar schizoaffective disorder | #15 |
study design features | #15 |
adhd study | #15 |
executive function theory | #15 |
interaction genotype | #15 |
velocardiofacial | #15 |
male mood | #15 |
ocd comorbid adhd | #15 |
treatment xr | #15 |
adhd disorders | #15 |
daily living administration | #15 |
asd mdd | #15 |
healthy comparison subjects | #15 |
cbclpbd | #15 |
poor perception | #15 |
association schizophrenia | #15 |
adults substance disorders | #15 |
card sorting | #15 |
substance disorder patients | #15 |
gxr children | #15 |
snps methylation | #15 |
disorder evidence | #15 |
prodromal symptoms psychosis | #15 |
adhd treatment | #15 |
paediatric bipolar disorder | #15 |
brainbody | #16 |
adhd obesity | #16 |
ntac | #16 |
adhd anxiety symptoms | #16 |
rdoc framework | #16 |
cprsr | #16 |
n424 | #16 |
adhd diagnoses | #16 |
informant assessment | #16 |
linkage findings | #16 |
regional cortical thickness | #16 |
scz risk | #16 |
familial relationship | #16 |
control participants participants | #16 |
“difficulty | #16 |
multiple test | #16 |
drug disorder | #16 |
parents anxiety disorders | #16 |
pervasive developmental disorder | #16 |
risk psychotic disorders | #16 |
factual factor analysis | #16 |
youths adhd | #16 |
adhd symptom severity | #16 |
growth children | #16 |
onset anticipation | #16 |
special classes | #16 |
longitudinal assessments | #16 |
geneenvironment interaction | #16 |
hyperkinetic disorders | #16 |
delayed action | #16 |
dbds | #16 |
dexedrine | #16 |
psychology schizotypal | #17 |
medication type | #17 |
schizophrenia psychosis | #17 |
rbfox1 | #17 |
association scan | #17 |
parents adhd | #17 |
5071 | #17 |
accn2 | #17 |
pediatric disorder | #17 |
association markers | #17 |
random forest regression | #17 |
persistent adhd | #17 |
childhood predictors | #17 |
larger sample | #17 |
response inhibition network | #17 |
depression md | #17 |
method participants | #17 |
asd ocd | #17 |
mania | #17 |
ldx children | #17 |
substance disorders sud | #17 |
disability adhd | #17 |
prospective follow | #17 |
diagnostic statistical | #17 |
nonparametric linkage | #17 |
assessment positive symptoms | #17 |
hyperactivity attitude | #17 |
combined type | #17 |
condfdr | #17 |
ocd age | #17 |
studies psychiatric | #17 |
neuropsychiatric evaluation | #17 |
prevalence adhd | #17 |
young offspring | #17 |
study adhd | #17 |
pediatric samples | #17 |
factors siblings | #17 |
a161t | #17 |
relation adhd | #17 |
samples children | #17 |
adulthood adhd | #17 |
considerable overlap | #17 |
multiple anxiety disorders | #17 |
driving behaviors | #17 |
bipolar disorder subjects | #17 |
resultsfirst | #17 |
preschool diagnostic | #18 |
prolonged therapy | #18 |
single nucleotide severity | #18 |
transporter gene | #18 |
schizophrenia patients relatives | #18 |
bipolar major | #18 |
adhd sud patients | #18 |
lisdexamfetamine dimesylate | #18 |
illness twins | #18 |
primary substance | #18 |
4286 | #18 |
conduct disorder children | #18 |
symptom overlap | #18 |
psuds | #18 |
risk disorders | #18 |
depression genetic risk | #18 |
fullsiblings | #18 |
linkage regions | #18 |
neuropsychologic | #18 |
childhood traumas | #18 |
poor tolerability | #18 |
unaffected siblings | #18 |
adhd severity | #18 |
meet criteria | #18 |
anxiety mdd | #18 |
dcdq | #18 |
minisatellite repeats | #18 |
unemotionality | #18 |
schizophrenia dtnbp1 | #18 |
operationalized | #18 |
adhd cannabis | #18 |
hrr 95 | #18 |
marijuana age | #18 |
children vcfs | #18 |
behavior scale | #18 |
potential contributor | #18 |
low dose naltrexone | #18 |
stimulant | #18 |
relatives control subjects | #18 |
bipolar choice trial | #18 |
adhd groups | #18 |
kcnj4 | #18 |
verbal memory task | #19 |
substance adhd | #19 |
rs3918342 | #19 |
improvement symptoms | #19 |
assessing outcome | #19 |
symptoms adolescent | #19 |
mcgue | #19 |
euphoric effects | #19 |
adolescent age onset | #19 |
adolescent age | #19 |
disorders adults | #19 |
disconfirmations | #19 |
casecontrol sample | #19 |
adhd neurodevelopmental | #19 |
psychosocial features | #19 |
addicted patients | #19 |
hyperconnectivity | #19 |
comorbidity rates | #19 |
candidate loci | #19 |
nature nurture | #19 |
familial transmission | #19 |
mental health human | #19 |
adhd young adults | #19 |
scz ocd | #19 |
lod1 | #19 |
action preparations | #19 |
medication trials | #19 |
gsma | #20 |
outcome attention | #20 |
pedigree selection | #20 |
controlled pilot study | #20 |
adolescent | #20 |
depression adhd | #20 |
prenatal exposure nicotine | #20 |
illness female humans | #20 |
humanhap550v3 | #20 |
notch4 gene | #20 |
parents risk | #20 |
human ortholog | #20 |
nonpsychotic siblings | #20 |
dicap | #20 |
sibpair | #20 |
response curve | #20 |
neuropsychological function | #20 |
schizophrenia attention | #20 |
parent origin | #20 |
deficits children | #20 |
transmission ratio distortion | #20 |
linkage scans | #20 |
neuropsychologically | #20 |
manual mental | #20 |
disorders polymorphism | #20 |
kiddie | #20 |
inhibition children | #20 |
neuroleptic dose | #20 |
rbfox1 gene | #20 |
mflynn | #20 |
biological families | #20 |
ratings adhd | #20 |
slc6a2 | #20 |
11year followup | #21 |
schizophrenia taiwan | #21 |
prescription stimulants | #21 |
treatment growth | #21 |
psychiatric symptoms patients | #21 |
monoamine oxidase maoa | #21 |
rat shr | #21 |
schizotypals | #21 |
motor problems | #21 |
life enjoyment | #21 |
methods age | #21 |
cacng2 | #21 |
linkage chromosomes | #21 |
prenatal exposure alcohol | #21 |
children pdd | #21 |
sodium hydrogen exchanger | #21 |
prospective longitudinal | #21 |
bipolar pedigrees | #21 |
gender comparisons | #21 |
agler | #21 |
risk offspring | #21 |
genehunterplus | #21 |
rs778294 | #21 |
chronic tics | #21 |
palau | #21 |
children comorbid | #21 |
comorbid adhd | #21 |
prevalent cases | #21 |
humans linkage | #21 |
male probands | #21 |
childhood conduct disorder | #21 |
schizophrenia disease humans | #21 |
schizophrenia united | #21 |
youth bipolar | #22 |
adhd rating scale | #22 |
niacin skin | #22 |
disruptive | #22 |
schizophrenia pgc | #22 |
amphetamine methylphenidate | #22 |
rg022 | #22 |
amygdala structure | #22 |
study methodology | #22 |
adhd impulsivity | #22 |
adhd anxiety | #22 |
controls | #22 |
polygenic overlap | #22 |
adderall xr | #22 |
neurocognitive performance schizophrenia | #22 |
partial replication | #22 |
depression treatment patients | #22 |
bpd subjects | #22 |
pre‐school | #22 |
ldx | #22 |
association prs | #22 |
adhd susceptibility | #22 |
disorders major | #22 |
6 disorders | #22 |
genetic phenotype | #22 |
stimulants children | #22 |
familiality | #22 |
youth mdd | #22 |
children attention | #22 |
10p | #22 |
overtransmission | #22 |
adhd stimulants | #22 |
neuropsychological profiles | #22 |
diagnostic interview | #22 |
syndrome vcfs | #22 |
preliminary reliability | #22 |
comprehensively | #23 |
mdd anxiety disorders | #23 |
oppositional | #23 |
syp | #23 |
phenotype definition | #23 |
snapiv | #23 |
adhd symptoms childhood | #23 |
asd scq | #23 |
disequilibrium male | #23 |
kotkin | #23 |
executive functions efs | #23 |
genetic investigation | #23 |
rs464049 | #23 |
handful | #23 |
wide linkage | #23 |
twins genetic predisposition | #23 |
serotonin receptor gene | #23 |
siblings | #23 |
propylamines | #23 |
adolescents bpd | #23 |
interacting molecules | #23 |
interview dsm | #23 |
intrinsic curvature | #23 |
metadoxine | #23 |
scq asd | #23 |
diagnostician | #23 |
male individuals | #23 |
wechsler scales | #23 |
risk studies | #23 |
notch4 receptors | #23 |
n449 | #23 |
anxious mothers | #23 |
neuroleptic withdrawal | #23 |
heterogeneity genetic | #23 |
conduct problems adhd | #24 |
0535 | #24 |
amrs | #24 |
neural activation patterns | #24 |
quantitative phenotypes | #24 |
mental control | #24 |
actigraphy studies | #24 |
expected growth | #24 |
stroop task performance | #24 |
intelligence schizophrenia | #24 |
child female humans | #24 |
adhd comorbidities | #24 |
adhd characteristics | #24 |
ocd asd | #24 |
female humans illness | #24 |
deficits | #24 |
aggression anxiety | #24 |
chromosomes 6 | #24 |
stress exposure | #24 |
sassr | #24 |
15q13 | #24 |
genome‐wide linkage scans | #24 |
age regions | #24 |
adra2a | #24 |
nonstimulant | #24 |
statistical manual | #24 |
refilled | #24 |
symptoms psychosis | #24 |
receptor d4 | #24 |
dsmiiir criteria | #24 |
guanfacine extended release | #24 |
lithium bipolar disorder | #24 |
nieces | #24 |
snorting | #24 |
children meeting | #24 |
screening scale | #25 |
–environment interactions | #25 |
decreased volume | #25 |
young relatives | #25 |
association snps | #25 |
unique profile | #25 |
splicing regulator | #25 |
clinical interviews | #25 |
task patients | #25 |
baseline assessment | #25 |
d22s283 | #25 |
efficacy atomoxetine | #25 |
wkht | #25 |
biased transmission | #25 |
neurocognitive predictors | #25 |
exposure adhd | #25 |
nudt3 | #25 |
vietnam twin registry | #25 |
major affective disorders | #25 |
psychiatric nosology | #25 |
psychometrically | #25 |
conners parent | #25 |
dapple | #25 |
symptom subtypes | #25 |
dyscalculia | #25 |
copy variants schizophrenia | #25 |
maternal criticism | #25 |
liker | #25 |
psychiatric disorders children | #25 |
understanding adhd | #25 |
bipolar choice | #25 |
slc6a3 gene | #25 |
or194 | #25 |
behavioral disinhibition | #25 |
anticipation schizophrenia | #25 |
school failure | #25 |
inrich | #26 |
prenatal health | #26 |
screening diagnosis | #26 |
controls adhd | #26 |
social impairment | #26 |
wm microstructure | #26 |
twins humans | #26 |
alcohol drug abuse | #26 |
add | #26 |
gender risk | #26 |
major depression md | #26 |
nonmedical prescription stimulants | #26 |
rs3730358 | #26 |
neurodevelopmental genes | #26 |
n81 | #26 |
label study | #26 |
behavioral disorder | #26 |
structured interviews | #26 |
association allele | #26 |
affair | #26 |
orosmethylphenidate | #26 |
efpc | #26 |
htr1d | #26 |
agreement raters | #26 |
psychometric measures | #26 |
selfmonitor | #26 |
adrenergic uptake | #26 |
core symptoms adhd | #26 |
bipolar phenotype | #26 |
adults symptoms | #26 |
adhd mothers | #26 |
maob gene | #26 |
voxel based morphometry | #26 |
t102c polymorphism | #27 |
hyperactivity disorder adhd | #27 |
d22s278 | #27 |
based association | #27 |
mdd asd | #27 |
treatment atomoxetine | #27 |
genetic susceptibility schizophrenia | #27 |
childreniv | #27 |
consecutively | #27 |
osterrieth | #27 |
weaker effects | #27 |
cnvs adhd | #27 |
greater severity | #27 |
asherson | #27 |
bipolar disorder comorbidity | #27 |
ptsd adults | #27 |
aff | #27 |
international meeting | #27 |
disorders executive | #27 |
schizophrenia genetic | #27 |
rate remission | #27 |
potential confounds | #27 |
intelligence male | #27 |
association signals | #27 |
offspring risk | #27 |
symptom reports | #28 |
symptoms inattention | #28 |
dopamine transporter binding | #28 |
male methylphenidate | #28 |
schizophrenia onset | #28 |
genetic etiology | #28 |
clinical correlates | #28 |
preliminary findings | #28 |
dopamine receptor d4 | #28 |
adults study | #28 |
adhd differences | #28 |
vigilance performance | #28 |
polysomnography actigraphy | #28 |
ocd disorders | #28 |
emotional dysregulation | #28 |
child clinical | #28 |
subjects bpd | #28 |
slc6a3 | #28 |
disorder compared | #28 |
assessment negative symptoms | #28 |
guze | #28 |
cortical gyrification | #28 |
parent teacher | #28 |
families schizophrenia | #28 |
raters | #28 |
persons bipolar disorder | #28 |
snp18 | #28 |
rest task | #28 |
image study | #28 |
genomewide studies | #28 |
6179 | #28 |
maternal adhd | #28 |
adhd autism | #28 |
new genetics | #28 |
metaalgorithm | #28 |
sustained attention deficits | #28 |
shared genetic basis | #29 |
medication usage | #29 |
comorbidity ptsd | #29 |
psychosocial dysfunction | #29 |
disorders offspring | #29 |
inattention hyperactivity impulsivity | #29 |
dsmiiir | #29 |
kcnn3 | #29 |
misuse diversion | #29 |
childhood antecedents | #29 |
adhd patients controls | #29 |
childhood diagnosis | #29 |
etiological heterogeneity | #29 |
attention‐deficit | #29 |
parents bipolar disorder | #29 |
studies genes | #29 |
infants weight | #29 |
male polymorphism | #29 |
hyperactivity impulsivity | #29 |
disorder bipolar | #29 |
african‐american | #29 |
bipolar disorder youth | #29 |
offspring parents | #29 |
medication misuse | #29 |
juvenile bipolar disorder | #30 |
hyperactive symptoms | #30 |
nonaffected | #30 |
parental predictors | #30 |
robust statistical methods | #30 |
comorbid | #30 |
caarsinv | #30 |
diagnosticians | #30 |
relatives age | #30 |
growth childhood | #30 |
specific psychopathology | #30 |
antisocial behavior asb | #30 |
bmi growth | #30 |
nicotine pregnancy | #30 |
genetic perspective | #30 |
structural brain features | #30 |
association paternal age | #30 |
treatment adolescents | #30 |
adhd child | #30 |
nimh | #30 |
individual studies | #30 |
problems attention | #30 |
95 adhd | #31 |
neuropsychologic deficits | #31 |
potential endophenotypes | #31 |
impulsivity inattention | #31 |
discriminates | #31 |
smoking substance | #31 |
depression genetic | #31 |
kif16b | #31 |
neuroimage | #31 |
bpd risk | #31 |
sex effects | #31 |
nonadhd | #31 |
genotype haplotypes | #31 |
twin concordance | #31 |
prs adhd | #31 |
reanalyzed | #31 |
lodscore | #31 |
methylphenidate | #31 |
rgs4 schizophrenia | #31 |
n305 | #31 |
extant literature | #31 |
variable tandem | #31 |
charles river | #31 |
anterior insular | #32 |
randomized crossover study | #32 |
parents child | #32 |
subfields hippocampus | #32 |
kremen | #32 |
psdq | #32 |
asd symptoms children | #32 |
10p13 | #32 |
rs206936 | #32 |
studies schizophrenia | #32 |
psychosis youth | #32 |
schizophrenia affective psychosis | #32 |
gender | #32 |
impulsecontrol | #32 |
wiscr | #32 |
adhd adolescents | #32 |
aggression attention | #32 |
bipolar disorder bpi | #32 |
child psychiatric | #32 |
attentiondeficit | #32 |
psychiatric genetic | #32 |
slc6a4 | #32 |
anxiety disorders | #32 |
studies adolescent | #32 |
70–80 | #32 |
psychiatric disorders | #32 |
repeat length | #32 |
adhd patients | #33 |
10repeat allele | #33 |
twins factor analysis | #33 |
original study | #33 |
qsf | #33 |
single snps | #33 |
disorder symptom | #33 |
neural reward processing | #33 |
children risk | #33 |
val allele | #33 |
quetiapine monotherapy | #33 |
autism symptoms | #33 |
psychiatric sample | #33 |
psychiatric status | #33 |
current adhd | #33 |
animal model adhd | #33 |
youth bipolar disorder | #33 |
rs1130214 | #33 |
aspd bpd | #33 |
wfirs | #33 |
neuropsychological deficits | #33 |
neuropsychiatric sle | #33 |
maternal smoking pregnancy | #33 |
prior findings | #33 |
pharmacotherapy trials | #33 |
subcortical brain | #33 |
adhd evidence | #33 |
briefa | #33 |
ld adhd | #33 |
comorbidity cross | #33 |
mood anxiety | #33 |
association genes | #33 |
frontopolar | #33 |
rhobtb3 | #33 |
inattention | #34 |
social anxiety children | #34 |
structural brain asymmetries | #34 |
treatment memantine | #34 |
treatment sud | #34 |
cognition interaction | #34 |
linkage studies | #34 |
young adults adhd | #34 |
pharmacotherapy adhd | #34 |
snp4 | #34 |
risk psychiatric disorders | #34 |
disorder traits | #34 |
md risk | #34 |
candidate gene polymorphisms | #34 |
grm5 | #34 |
gxr | #34 |
disorders mood | #34 |
disorders diagnostic | #34 |
psychological tests | #34 |
emerging consensus | #34 |
harvard | #34 |
dsm5 dsmiv | #34 |
hyperactive disorder | #35 |
n64 | #35 |
choice impulsivity | #35 |
humans intelligence | #35 |
lifetime rates | #35 |
adhd rating | #35 |
bipolar spectrum disorders | #35 |
schizophrenia schizotypy | #35 |
risk females | #35 |
familial risk | #35 |
schizophrenia relatives | #35 |
bipolar disorder offspring | #35 |
plink | #35 |
schizophrenia gene | #35 |
adhd sleep problems | #35 |
catechol‐o‐methyltransferase | #35 |
lithium quetiapine | #35 |
complex figure | #35 |
htr1b | #35 |
sample description | #35 |
participants bpd | #35 |
#35 | |
n265 | #35 |
recall patients | #35 |
infant gender | #36 |
annett | #36 |
young adult females | #36 |
structure psychopathology | #36 |
adhd drug | #36 |
adhd control groups | #36 |
d6s274 | #36 |
neurotransmissions | #36 |
disorder bpd | #36 |
term neuropsychological | #36 |
siblings controls | #36 |
orosmph | #36 |
schizophrenia genes | #36 |
overanxious disorder | #36 |
groups adhd | #36 |
neurocognitive markers | #36 |
nocebo response | #36 |
comorbidity children | #36 |
adult antisocial | #36 |
suny | #36 |
intracranial volume icv | #36 |
stimulant medications | #36 |
n185 | #36 |
retrospective recall | #36 |
95 siblings | #36 |
gypc | #36 |
odd dimensions | #37 |
disorder severity | #37 |
dat1 gene | #37 |
functioning adults | #37 |
adhd asd | #37 |
n278 | #37 |
predictive utility | #37 |
genetics | #37 |
delayedaction preparations | #37 |
studies comorbidity | #37 |
slc22a16 | #37 |
mapping genomic loci | #37 |
child behavioral | #37 |
rs5 | #37 |
combined sample | #37 |
parents adhd children | #37 |
tests schizophrenia | #37 |
symptom criteria | #37 |
lisdexamfetamine | #37 |
offspring association | #37 |
pik4ca | #38 |
height children | #38 |
unfamiliar | #38 |
methylphenidate treatment | #38 |
genome‐wide search | #38 |
familial risk depression | #38 |
kiddie schedule | #38 |
dsm criteria | #38 |
genetic risk schizophrenia | #38 |
family‐based | #38 |
rs2391191 | #38 |
boys | #38 |
d15s1360 | #38 |
polymorphism gene | #38 |
adhd problems | #38 |
16 genes | #38 |
pediatric adhd | #38 |
school age children | #38 |
nonparanoid | #39 |
suggestive | #39 |
mood stabilization | #39 |
antisocial traits | #39 |
markers genetic | #39 |
dsm5 criteria | #39 |
manic symptoms | #39 |
adhd behavior | #39 |
asthma systematic review | #39 |
increased risk adhd | #39 |
washu | #39 |
test association | #39 |
git1 | #39 |
mlod | #39 |
structural brain abnormalities | #39 |
iii personality | #39 |
behavioral traits | #39 |
onset children | #39 |
pharmacologic treatment | #39 |
ocd adhd | #39 |
female cases | #39 |
mdd ocd | #39 |
wisconsin card | #39 |
dsmiv criteria | #40 |
brainspan | #40 |
familial effects | #40 |
rare copy variants | #40 |
rs2283265 | #40 |
heinrichs | #40 |
genetics schizophrenia | #40 |
reln gene | #40 |
cardiovascular adverse effects | #40 |
genetic studies | #40 |
bipolars | #40 |
onset | #40 |
genome scan | #40 |
gxe | #40 |
diagnosis bipolar disorder | #40 |
chromosome 10p | #40 |
anx | #40 |
male parents | #41 |
parent‐of‐origin | #41 |
chromosomes 6q | #41 |
pediatric subjects | #41 |
bdnf adhd | #41 |
schizophrenia severity illness | #41 |
normal comparison subjects | #41 |
sibpairs | #41 |
neuropsychiatr | #41 |
methylphenidate response | #41 |
psychosocial adversity | #41 |
methodological advances | #41 |
fhrs | #41 |
sirolimus patients | #41 |
effects growth | #41 |
male panic | #42 |
sorting test | #42 |
schizophrenia | #42 |
individual items | #42 |
adhd deficits | #42 |
child female | #42 |
gwas meta | #42 |
tic disorders | #42 |
fiveyear followup | #42 |
disorder social | #42 |
schizophrenia disorders | #42 |
n262 | #42 |
serotonergic pathway | #42 |
diagnostic comorbidity | #42 |
dtnbp1 schizophrenia | #42 |
neuropsychological tasks | #43 |
practitioner review | #43 |
n242 | #43 |
snp1 | #43 |
adhd depression | #43 |
n176 | #43 |
digs | #43 |
youngadult | #43 |
brain scans | #43 |
mri study | #43 |
massachusetts general | #43 |
adhd prs | #43 |
n232 | #43 |
children enuresis | #43 |
candidate endophenotype | #43 |
p094 | #43 |
p023 | #43 |
disorder prevalence | #43 |
neuropsychological differences | #43 |
simplex families | #43 |
treatment adult | #44 |
dopamine d5 | #44 |
adolescents attention | #44 |
secondborns | #44 |
odds ratio association | #44 |
prior studies | #44 |
asd adults | #44 |
nosologic | #44 |
n140 | #44 |
mental disorders diseases | #44 |
sidp | #44 |
multidimensionality | #44 |
immediaterelease | #44 |
tcerg1l | #45 |
institute mental | #45 |
schizophrenia genome | #45 |
suggestive associations | #45 |
uncaring | #45 |
baseline adhd | #45 |
risk schizophrenia | #45 |
snpbased heritability | #45 |
pharmacogenetic studies | #45 |
adhd parents | #45 |
behavior rating | #45 |
illness stress | #45 |
inflation rate | #45 |
prevalence psychiatric | #45 |
altered brain activation | #45 |
pooled size | #45 |
volume reductions | #45 |
risk reduction strategies | #45 |
cep85l | #45 |
offspring adhd | #45 |
substance disorder | #45 |
wnl | #45 |
genetic underpinnings | #45 |
controls subjects | #45 |
genetic loading | #45 |
neuropsychological performance | #46 |
lyons | #46 |
machine learning study | #46 |
previous findings | #46 |
10year followup | #46 |
referral bias | #46 |
response mph | #46 |
converging evidence | #46 |
stronger connectivity | #46 |
nat genet | #46 |
sex bias | #46 |
gender influences | #46 |
12 months treatment | #46 |
adhd effects | #46 |
familial coaggregation | #46 |
n164 | #46 |
cbt intervention | #46 |
natural reward | #46 |
n280 | #47 |
or125 | #47 |
baiap2 | #47 |
desipramine dmi | #47 |
childhood disorders | #47 |
psychiatric status rating | #47 |
genetic study | #47 |
loci chromosomes | #47 |
comt | #47 |
oppositional symptoms | #47 |
velocardiofacial syndrome | #47 |
shared polygenic risk | #47 |
compromised | #47 |
parents depression | #47 |
meehl | #47 |
schizophrenia alleles | #47 |
ocd mdd | #47 |
association bipolar disorder | #47 |
trauma risk | #47 |
abstract objective | #47 |
disorders studies | #47 |
pooled odds ratio | #47 |
rtv | #48 |
association test | #48 |
n27 | #48 |
nullhypothesis | #48 |
adhd dyslexia | #48 |
disorder case | #48 |
scientific foundation | #48 |
n103 | #48 |
1711 | #48 |
effects gender | #48 |
mpp3 | #48 |
adhd prevalence | #48 |
revised | #48 |
shared heritability | #48 |
disorder cognitive | #49 |
mental disorders children | #49 |
rs2494732 | #49 |
negative schizotypy | #49 |
nurture | #49 |
schizophrenia cognition | #49 |
familial loading | #49 |
weak evidence | #49 |
snap‐25 | #49 |
serotonin plasma | #49 |
volume differences | #49 |
hyperactivity autism | #49 |
inbred wky rats | #49 |
anxa7 | #49 |
drug holidays | #49 |
dsmiv dsm5 | #50 |
genomic relationships | #50 |
intergenerational effects | #50 |
impulsivity symptoms | #50 |
parent teacher ratings | #50 |
vdm | #50 |
rocf | #50 |
wiat | #50 |
extended pedigrees | #50 |
life outcomes | #50 |
maoauvntr | #50 |
studies biomarkers | #50 |
geneenvironment interactions | #50 |
caseness | #50 |
early onset schizophrenia | #50 |
n168 | #50 |
pair 6 | #50 |
proteins polymorphism | #50 |
wais | #50 |
adhd knowledge | #51 |
substantial role | #51 |
adults ocd | #51 |
manovas | #51 |
peer affiliation | #51 |
1542 | #51 |
psychology adult | #51 |
gender association | #51 |
common psychiatric disorders | #51 |
disorders children | #51 |
epilepsy adhd | #51 |
male personality | #51 |
compelling | #51 |
bpd | #51 |
a218c | #52 |
metaanalysis association | #52 |
major depression | #52 |
adra1a | #52 |
oros methylphenidate | #52 |
schizophrenia controls | #52 |
growth height | #52 |
bipolar disorder children | #52 |
selenbp1 | #52 |
asdadhd | #52 |
intracranial volume | #52 |
chronic schizophrenia patients | #52 |
youth asd | #52 |
gray matter alterations | #52 |
combined adhd | #52 |
schizophrenia sex | #52 |
psychopathology | #53 |
tourettes disorder | #53 |
snps candidate genes | #53 |
placebo children | #53 |
ppm1h | #53 |
risk analysis | #53 |
dopamine plasma | #53 |
mania depression | #53 |
adhdc | #53 |
adoption study | #53 |
parahippocampal gyrus | #53 |
scales schizophrenia | #53 |
smoking schizophrenia | #53 |
risktaking behavior | #53 |
n138 | #53 |
extended‐release | #53 |
schizophrenia adolescent | #53 |
dnms | #54 |
genetic reproducibility | #54 |
psychlit | #54 |
bpd children | #54 |
jackknife | #54 |
pregnancy time | #54 |
ablim1 | #54 |
schizophrenia psychotic disorders | #54 |
onset bipolar | #54 |
risk study | #54 |
alcohol drug | #54 |
chromosome 6p | #54 |
unphased | #54 |
longitudinal case | #55 |
1252 | #55 |
neuropsychological studies | #55 |
disorders risk | #55 |
endophenotype | #55 |
gene interaction | #55 |
viloxazine | #55 |
mid adolescence | #55 |
sample children | #55 |
childhood trauma exposure | #55 |
children diagnosis | #55 |
disorders prevalence | #55 |
emotional lability | #55 |
tova | #55 |
child behavior | #55 |
flat affect | #55 |
subfield | #56 |
extendedrelease | #56 |
tics children | #56 |
schizophrenia offspring | #56 |
pair chromosomes | #56 |
n43 | #56 |
alcohol substance | #56 |
degree relatives | #56 |
disorder agoraphobia | #56 |
cotwin | #56 |
entry points | #56 |
children siblings | #56 |
hyperactive | #56 |
rating inventory | #57 |
model attention | #57 |
etdt | #57 |
zdhhc8 | #57 |
methylphenidate hydrochloride | #57 |
atomoxetine hydrochloride | #57 |
shared genetic etiology | #57 |
oddsratio | #57 |
interregional profiles differences | #57 |
barkley | #57 |
apol | #57 |
brain structure function | #57 |
compelling evidence | #58 |
controls children | #58 |
analysis schizophrenia | #58 |
childhood young adulthood | #58 |
100 children | #58 |
adhd atomoxetine | #58 |
vntr polymorphisms | #58 |
heritable receptors | #58 |
function schizophrenia | #58 |
repeat alleles | #58 |
single snp | #58 |
dbq | #58 |
association comt | #58 |
controlled study | #58 |
conners | #58 |
children | #58 |
tests attention | #58 |
comorbid psychiatric disorders | #58 |
risk siblings | #59 |
rtn4r | #59 |
neuroleptic | #59 |
mdd adhd | #59 |
schizophrenia smoking | #59 |
comt schizophrenia | #59 |
risk psychiatric | #59 |
mdd children | #59 |
disorders including | #60 |
disruptive behavior disorder | #60 |
reported associations | #60 |
functional remission | #60 |
3 domains | #60 |
lphn3 | #60 |
inattention hyperactivity | #60 |
executive functioning | #60 |
abuse dependence | #60 |
generalize | #60 |
duval | #60 |
dysregulation profile | #61 |
cronbachs alpha | #61 |
uninhibited | #61 |
homogeneous subgroups | #61 |
disorders asd | #61 |
disruptive behavior | #61 |
13q32 | #61 |
unipolars | #61 |
comparison subjects | #61 |
uncles | #61 |
study adherence | #61 |
wide scan | #61 |
oih | #61 |
study adults | #61 |
relatives schizophrenia | #62 |
substantial heritability | #62 |
mph treatment | #62 |
tdts | #62 |
maternal psychopathology | #62 |
factors anxiety | #62 |
symptoms | #62 |
inhibition memory | #62 |
1537 | #62 |
polygenic risk schizophrenia | #62 |
4 year | #62 |
schizophrenia human | #62 |
bipolar youth | #62 |
stability time | #63 |
risk severity | #63 |
ksads | #63 |
n179 | #63 |
schizophrenia schizophrenic | #63 |
disorders bipolar | #63 |
treatments adhd | #63 |
structured interview | #63 |
neurocognitive | #63 |
accounted | #63 |
behavioral dysregulation | #63 |
methylphenidate mph | #64 |
rating scales | #64 |
methylphenidate adhd | #64 |
risk trauma | #64 |
childhood onset | #64 |
qlesq | #64 |
endosomal | #64 |
treatment desipramine | #64 |
linkage | #64 |
40 countries | #64 |
males association | #64 |
children mph | #64 |
methylation cpg sites | #64 |
adhd 95 | #64 |
prefrontal dysfunction | #64 |
child | #64 |
europeanamerican | #64 |
phacking | #64 |
diagnostic utility | #64 |
disorders genetic | #65 |
neuropsychological impairments | #65 |
controls siblings | #65 |
adhd epilepsy | #65 |
etiology schizophrenia | #65 |
schizophrenic | #65 |
emotional regulation | #65 |
net gene | #65 |
zcchc4 | #65 |
oxidase gene | #65 |
comorbid diagnosis | #65 |
marry | #65 |
temperamental | #65 |
small sample size | #65 |
occurrence adhd | #65 |
prior work | #65 |
function female | #65 |
male siblings | #65 |
emo | #65 |
afternoons | #66 |
tourettes syndrome | #66 |
global ratings | #66 |
children mental retardation | #66 |
extended release | #66 |
simple phobia | #66 |
adhd dcd | #66 |
attention hyperactivity | #66 |
behavioral genetic | #66 |
neuropsychological profile | #66 |
study studies | #66 |
tic disorder | #66 |
cbcldp | #66 |
disorder chromosome | #66 |
vswm | #66 |
ci105 | #66 |
subjects | #67 |
substance disorder sud | #67 |
grade retention | #67 |
mental diseases | #67 |
treatment quetiapine | #67 |
risk bipolar | #67 |
entire sample | #67 |
patients bipolar disorders | #67 |
findings association | #67 |
nonrighthandedness | #67 |
variance attention | #67 |
questionnaires treatment | #67 |
parents teachers | #67 |
chronic tic disorder | #67 |
label trial | #67 |
n217 | #67 |
hypofrontality | #68 |
snparray | #68 |
delay aversion | #68 |
naturalistic | #68 |
brain gene | #68 |
qms | #68 |
conceptual issues | #68 |
offspring | #68 |
people adhd | #69 |
low adherence | #69 |
symptom checklist | #69 |
stress response genes | #69 |
panic disorder | #69 |
ctgn | #69 |
humans schizophrenia | #69 |
illicit substances | #69 |
impulsivity hyperactivity | #69 |
clarifying | #69 |
regulatory enzymes | #69 |
polymorphism schizophrenia | #69 |
scale assessment | #69 |
chronological age | #69 |
physical anhedonia | #69 |
smoking children | #70 |
subsequent diagnosis | #70 |
nonrandom mating | #70 |
latrophilin | #70 |
oros mph | #70 |
interactions genes | #70 |
core adhd symptoms | #70 |
new diagnoses | #70 |
a2bp1 | #70 |
linkage scan | #70 |
npl | #70 |
neuropsychological consequences | #70 |
vergence | #71 |
objective examine | #71 |
genes role | #71 |
neuroimaging genetics | #71 |
genetic | #71 |
mspi polymorphism | #71 |
treated children | #71 |
adhd anxiety disorders | #71 |
adhd behaviors | #71 |
methodological issues | #72 |
genetic receptors | #72 |
digital health intervention | #72 |
boys age | #72 |
ocd subjects | #72 |
learning disorders | #72 |
digital intervention | #72 |
school functioning | #72 |
molecular genetic | #72 |
3372 | #73 |
cellular models | #73 |
patients rest | #73 |
disorders childhood | #73 |
schizophrenia genetics | #73 |
poison control centers | #73 |
candidate endophenotypes | #73 |
youth | #73 |
etiological | #73 |
relapse depression | #73 |
adhd subtype | #73 |
cortical abnormalities | #73 |
adult | #73 |
anxiety adhd | #73 |
kagan | #73 |
adhd medications | #73 |
logodds | #73 |
transmission disequilibrium | #74 |
reaction time variability | #74 |
based diagnosis | #74 |
allele association | #74 |
preferential transmission | #74 |
age schizophrenia | #74 |
desipramine | #74 |
pfkfb2 | #74 |
referred | #75 |
weight body mass | #75 |
adhd traits | #75 |
efficacy outcome | #75 |
onset anxiety | #75 |
linkage schizophrenia | #75 |
neale | #75 |
drd4 gene | #75 |
child china | #75 |
akl | #75 |
slc1a1 | #75 |
impairment children | #75 |
antisocial | #75 |
mind wandering | #75 |
hyperactivity adhd | #75 |
risk sample | #75 |
chronic tic | #76 |
centers disease control | #76 |
disorders brain | #76 |
depression pregnancy | #76 |
yates | #76 |
child depressive | #76 |
child humans | #76 |
schizophrenia young | #76 |
nondeficit | #76 |
adhd total | #76 |
positive schizotypy | #76 |
wcst performance | #77 |
childhood adhd | #77 |
lod score | #77 |
cortex schizophrenia | #77 |
atomoxetine children | #77 |
performance schizophrenia | #77 |
psychological male | #77 |
performance adhd | #77 |
rare copy | #78 |
adhd impairment | #78 |
disorders female | #78 |
bipolar disorder adhd | #78 |
women antidepressants | #78 |
bpi | #78 |
local gyrification | #78 |
pharmacologic treatments | #78 |
predixcan | #78 |
disorder panic | #79 |
genetic linkage studies | #79 |
pregnancy mothers | #79 |
student athletes | #79 |
retrospective assessment | #79 |
additive effects | #79 |
nosological | #79 |
cardinal | #79 |
studies relationship | #79 |
age adhd | #79 |
patients adhd | #79 |
n46 | #79 |
schizophrenic patients | #79 |
obesity metabolic syndrome | #79 |
anxiety separation | #79 |
total brain | #80 |
adhd drugs | #80 |
adhd rats | #80 |
siblings schizophrenia | #80 |
maternal smoking | #80 |
linkage chromosome | #80 |
clinical interview | #80 |
hacking | #81 |
differences age | #81 |
body mass diabetes | #81 |
bipolar disorder | #81 |
interregional profiles | #81 |
disliking | #81 |
children parents | #81 |
treatment adults | #81 |
oral routes | #81 |
eyhs | #81 |
pathophysiology adhd | #81 |
endophenotypes | #81 |
major diagnostic | #81 |
subcortical brain volumes | #81 |
behavior assessment | #82 |
symptoms diagnosis | #82 |
cumulative evidence | #82 |
association maternal smoking | #82 |
impaired quality life | #82 |
genes pathways | #82 |
gene schizophrenia | #82 |
comorbidity survey | #82 |
frontopolar cortex | #82 |
square distribution | #82 |
auditory verbal | #82 |
adults asd | #82 |
comorbidity disorders | #82 |
substance disorders | #83 |
tests risk | #83 |
oros | #83 |
paterson | #83 |
unreliability | #83 |
adult form | #83 |
illness | #83 |
neurocognitive functioning | #83 |
disorders anxiety | #83 |
management adhd | #83 |
multifactorial inheritance | #83 |
adhd adhd symptoms | #84 |
21 months | #84 |
complex disorder | #84 |
women adhd | #84 |
15q133 | #84 |
atomoxetine | #85 |
adhd subtypes | #85 |
brain asymmetry | #85 |
hyperkinetic disorder | #85 |
wide significance | #85 |
linkage loci | #85 |
buprenorphine maintenance | #85 |
adhd assessment | #85 |
recycling endosome | #85 |
genomics consortium | #85 |
european samples | #85 |
adhdrsiv | #85 |
9r | #85 |
humans risk | #85 |
monitoring response | #85 |
siblings children | #86 |
child conduct | #86 |
parents | #86 |
findings implications | #86 |
pord | #86 |
paranoid | #86 |
affective psychosis | #86 |
humans inhibition | #86 |
comparison children | #87 |
synaptosomal protein | #87 |
ptsd trauma | #87 |
putamen volume | #87 |
risk alleles | #87 |
n203 | #87 |
3utr | #87 |
bipolar spectrum disorder | #87 |
bipolar | #87 |
hyperkinetic | #88 |
comorbid psychopathology | #88 |
common risk | #88 |
drug effects | #88 |
druggable | #88 |
bonferroni correction | #88 |
machine learning analysis | #89 |
euphoric | #89 |
auditory attention | #89 |
2455 | #89 |
nucleotide schizophrenia | #89 |
comprehensive identification | #89 |
caars | #89 |
metaanalytic review | #89 |
chrna2 | #89 |
empirically | #89 |
prenatal nicotine exposure | #89 |
22 studies | #89 |
verbal ability | #90 |
linkage genome | #90 |
association metaanalysis | #90 |
antidepressants pregnancy | #90 |
1month | #90 |
watt | #90 |
male neuropsychological | #90 |
242 | #90 |
snps haplotypes | #90 |
pervasive | #90 |
attention deficit hyperactivity | #90 |
assertion | #91 |
identified studies | #91 |
naturalistic study | #91 |
adhd males | #91 |
adhd efficacy | #91 |
callousness | #91 |
complicates | #91 |
wcst | #91 |
adhd treatments | #91 |
cortical brain | #91 |
parental socioeconomic status | #91 |
treatment mania | #92 |
studies association | #92 |
adults schizophrenia | #92 |
candidate gene | #92 |
raise | #92 |
documenting | #92 |
studies sex | #92 |
h2snp | #92 |
rate adult | #93 |
controls participants | #93 |
standardized differences | #93 |
lifetime cannabis | #93 |
narrowly | #93 |
ymrs | #93 |
referral consultation | #93 |
brain case | #94 |
adhd measures | #94 |
sustained attention | #94 |
performance variability | #94 |
growing body | #94 |
gprc5b | #94 |
aldh1l1 | #94 |
gottman | #94 |
social development | #94 |
hfasd | #94 |
underachievement | #94 |
hyperactivity autistic | #94 |
cdh13 | #94 |
studies differences | #95 |
adolescents bipolar | #95 |
total brain volume | #95 |
asd study | #95 |
infa | #95 |
minisatellite | #95 |
executive | #95 |
mdd bip | #95 |
cadps2 | #95 |
uvntr | #96 |
behavior rating inventory | #96 |
nxph1 | #96 |
nominally | #96 |
scq | #96 |
chromosome 9q34 | #96 |
phenotype polymorphism | #96 |
genome‐wide association study | #97 |
children tics | #97 |
adolescent onset | #97 |
low cardiorespiratory fitness | #97 |
studies asthma | #97 |
hcadherin | #97 |
7q36 | #97 |
wdpcp | #98 |
identically | #98 |
massachusetts general hospital | #98 |
concerta | #98 |
hyperactivity brazil | #98 |
bipolar disorder risk | #98 |
induced hyperalgesia | #98 |
syn2 | #98 |
linkage study | #98 |
nonfamilial | #98 |
driving behavior | #98 |
oppositionality | #98 |
single nucleotide receptor | #98 |
xp114 | #99 |
abuse potential | #99 |
adhd role | #99 |
disease genetics | #99 |
metaanalysis trials | #99 |
neurodevelopmental processes | #99 |
methodssubjects | #99 |
nonspecificity | #99 |
disorder diagnosis | #99 |
medication effects | #99 |
substrains | #99 |
chd6 | #99 |
psychoactive | #99 |
motor timing | #99 |
reticence | #100 |
terror | #100 |
hippocampal subfield volumes | #100 |
12year | #100 |
clinical effects | #100 |
obesity abdominal obesity | #100 |
pelham | #100 |
adhd methylphenidate | #100 |
schizophrenia psychotic | #101 |
cosegregation | #101 |
genetic risk scores | #101 |
depression pregnant women | #101 |
genomewide | #101 |
tsls | #101 |
slc6a4 gene | #101 |
harlan | #101 |
roh | #101 |
neurocognitive impairments | #101 |
addictive drugs | #101 |
diagnostic boundaries | #101 |
torture | #101 |
upsit | #101 |
advanced paternal age | #101 |
empirical test | #101 |
klf13 | #102 |
individuals aud | #102 |
inhibition psychological | #102 |
parents offspring | #102 |
sob | #102 |
disorder psychiatric | #102 |
functional pathways | #102 |
male neuropsychological tests | #102 |
treatment seeking | #102 |
pgc | #103 |
touchstone | #103 |
schizophrenia mood disorders | #103 |
ocd children | #103 |
patients 12 months | #103 |
symptom profile | #103 |
clinical picture | #103 |
genome wide association | #103 |
genetic pedigree polymorphism | #103 |
genetic mechanism | #104 |
motor competence | #104 |
tourette disorder | #104 |
schizophrenia metaanalysis | #104 |
individual sites | #104 |
controlled studies | #104 |
1934 | #104 |
genomic region | #104 |
school dropout | #105 |
dsmiv diagnosis | #105 |
academic problems | #105 |
adhd review | #105 |
current article | #105 |
drug dyskinesia | #105 |
neuropsychological dysfunction | #105 |
schizophrenia probands | #105 |
children odd | #106 |
children methylphenidate | #106 |
cogs | #106 |
humans lod | #106 |
mothers adhd | #107 |
functional correlates | #107 |
matter volumes | #107 |
lenticular | #107 |
disorder female | #107 |
adolescents bipolar disorder | #107 |
consecutive sample | #107 |
daao | #107 |
ldn | #107 |
chronic tic disorders | #107 |
sequential analysis | #107 |
oral methylphenidate | #107 |
λs | #107 |
growth outcomes | #107 |
origin effects | #108 |
aged psychiatric | #108 |
site differences | #108 |
pervasive developmental | #108 |
nesarc | #108 |
n197 | #108 |
association cigarette smoking | #108 |
antimanic agents | #108 |
afni | #108 |
maternal warmth | #108 |
symptoms childhood | #108 |
918 | #108 |
proband | #108 |
pediatric psychopharmacology | #108 |
longitudinal trajectories | #109 |
adhd medication | #109 |
total scores | #109 |
depression bipolar | #109 |
worthy | #109 |
psychosis proneness | #109 |
gabra6 | #109 |
risk bipolar disorder | #109 |
neuroleptic medication | #109 |
irrespective | #109 |
enlistment | #110 |
adult adhd symptoms | #110 |
adhd parent | #110 |
linkage association | #110 |
markers genome | #110 |
rat models | #110 |
affective symptoms | #111 |
5httlpr genotype | #111 |
symptom ratings | #111 |
dimorphisms | #111 |
selective reporting | #111 |
n107 | #111 |
affective psychoses | #111 |
dao | #111 |
impact exposure | #112 |
unmedicated | #112 |
childhood risk factors | #112 |
dopamine d4 receptors | #112 |
pediatric obsessive | #112 |
bipolar parents | #112 |
factors social | #112 |
substantial proportion | #112 |
brain gene expression | #112 |
independent studies | #112 |
male prevalence | #113 |
neuropsychological functions | #113 |
xr | #113 |
cronbach | #113 |
omim | #114 |
analysis statistical | #114 |
comorbid anxiety | #114 |
functional neuroanatomy | #114 |
genet | #115 |
nuclear families | #115 |
–r | #115 |
schizophrenia severity | #115 |
n34 | #115 |
liability | #115 |
endorsed | #115 |
neuropsychological | #116 |
wm abnormalities | #116 |
diseases twins | #116 |
formulating | #116 |
schizophrenic psychology | #116 |
polygenic association | #117 |
neurocognitive endophenotypes | #117 |
z29 | #117 |
quality life outcomes | #117 |
prenatal smoking | #117 |
current symptoms | #117 |
unipolar | #117 |
coordinated analysis | #117 |
trait impulsivity | #117 |
academic functioning | #118 |
spm2 | #118 |
grandfathers | #118 |
large study | #118 |
grandiosity | #118 |
definitively | #118 |
prevention science | #118 |
major female | #118 |
satisfaction questionnaire | #118 |
genetic receptor serotonin | #118 |
method data | #119 |
midadolescence | #119 |
dopaminergic genes | #119 |
efd | #119 |
schizophrenia linkage | #119 |
naa ratio | #119 |
t01 | #120 |
differences children | #120 |
misunderstandings | #120 |
new avenues | #121 |
subfield volumes | #121 |
disorder autism | #121 |
remittance | #121 |
aunts | #121 |
n108 | #121 |
cgibp | #121 |
neurocognitive deficits | #121 |
neuropsychiatric disorders | #122 |
adhd comorbidity | #122 |
msit | #122 |
male risk | #122 |
levels adhd | #122 |
refute | #122 |
brain alterations | #122 |
pabs | #122 |
disregard | #122 |
psychopathology symptoms | #122 |
structural brain alterations | #122 |
urvs | #122 |
anxious | #122 |
v11 | #122 |
disorder depressive | #122 |
schizoaffective | #122 |
adcy2 | #123 |
adhd ocd | #123 |
wechsler | #123 |
clinical status | #123 |
age initiation | #123 |
chr psychosis | #123 |
trios | #124 |
twothirds | #124 |
treatment subjects | #124 |
drug placebo | #124 |
p097 | #124 |
laboratory observations | #124 |
maximum lod score | #124 |
g×s interaction | #124 |
longitudinal sample | #124 |
attention regulation | #124 |
wechsler intelligence scale | #124 |
9q34 | #124 |
patients chronic schizophrenia | #125 |
caregiver strain | #125 |
machine learning prediction | #125 |
psychosis individuals | #125 |
disorder risk | #125 |
anxiety problems | #125 |
segregation analysis | #125 |
drug disorders | #126 |
familial influences | #126 |
biological parents | #126 |
parent version | #126 |
developmental aspects | #126 |
positive negative symptoms | #126 |
odd conduct disorder | #126 |
complex genetics | #126 |
memory adhd | #126 |
genes | #127 |
drd2 | #127 |
attention child | #127 |
taiwanese population | #127 |
psychiatric diagnoses | #127 |
stevenson | #127 |
adult alleles | #127 |
disinhibited | #127 |
aged 6 | #128 |
neuropsychological measures | #128 |
familial | #129 |
opiate antagonists | #129 |
intactness | #129 |
implicate | #129 |
behavioral outcome | #129 |
n102 | #129 |
personality assessment | #129 |
1990a | #130 |
retrospective data analysis | #130 |
adhd inattention | #130 |
families | #130 |
incapacitation | #131 |
mood anxiety disorders | #131 |
kinesthesia | #131 |
pair 15 chromosomes | #131 |
moderating effects | #131 |
adolescents ocd | #131 |
bip mdd | #131 |
strong evidence | #131 |
register study | #131 |
snps | #131 |
differed | #131 |
animals attention | #131 |
n79 | #132 |
sodas | #132 |
child cognition | #132 |
childhood anxiety disorders | #132 |
learning disabilities | #132 |
hkd | #132 |
male prospective | #132 |
late adolescents | #132 |
entire brain | #132 |
large european cohort | #132 |
p074 | #132 |
linkage humans | #132 |
heroin dependence | #133 |
mph | #133 |
onset bipolar disorder | #133 |
preliminary examination | #134 |
children adults | #134 |
vntr | #134 |
disorders social | #134 |
male massachusetts | #135 |
association analyses | #135 |
social deficits | #135 |
tspan8 | #136 |
olfactory identification | #136 |
relied | #136 |
social environments | #136 |
sorcs3 | #136 |
adolescents young | #136 |
risk factors smoking | #136 |
firstborns | #136 |
schizophrenia affective disorders | #137 |
memantine treatment | #137 |
studies examined | #137 |
adolescent bipolar | #137 |
expressed emotion | #137 |
longitudinal evidence | #137 |
psychological male memory | #137 |
gaming | #137 |
association asthma | #137 |
mtor activation | #138 |
control individuals | #138 |
6q | #138 |
evidence association | #138 |
asds | #138 |
biomarkers diagnosis | #138 |
neuropsychiatric | #139 |
mgh | #139 |
schizophrenia studies | #139 |
symptoms disorders | #139 |
meet | #139 |
n129 | #139 |
fhr | #139 |
n115 | #140 |
intriguing | #140 |
parental anxiety | #140 |
schizotypal traits | #140 |
disorder comorbidity | #141 |
prss | #141 |
genetic vulnerability | #141 |
emotional symptoms | #141 |
haplotype block | #141 |
22q112 deletion syndrome | #142 |
disorders psychotic | #142 |
neurotrophic | #142 |
disorders personality | #142 |
5ht1b receptors | #142 |
covid19 restrictions | #142 |
conduct | #143 |
risk factors obesity | #143 |
hydrogen exchangers | #143 |
peripheral biomarkers | #143 |
fetal movement | #143 |
molecular genetics | #143 |
diagnostic procedure | #144 |
diagnosed attention | #144 |
elston | #144 |
statistical female humans | #144 |
g72 | #144 |
rfg | #144 |
child psychopathology | #144 |
humans linear | #144 |
agents tricyclic | #144 |
blind study | #144 |
pcb exposure | #145 |
affs | #145 |
genetic heterogeneity | #145 |
studies depressive | #145 |
common genetic variants | #145 |
p00018 | #145 |
major psychoses | #145 |
drug alcohol | #145 |
early initiation | #145 |
n105 | #145 |
genome‐wide association studies | #145 |
individual symptoms | #145 |
twin studies | #146 |
oppositional behavior | #146 |
atypicality | #146 |
intelligence quotient | #146 |
genders | #146 |
adult psychopathology | #146 |
prenatal nicotine | #146 |
warranted | #146 |
comprising | #147 |
abbreviated | #147 |
lras | #147 |
intraindividual variability | #147 |
p0016 | #147 |
histrionic | #147 |
adolescent young | #148 |
single locus | #148 |
cognitive variables | #148 |
basc | #148 |
sabp | #148 |
adhd symptoms children | #149 |
brain correlates | #149 |
risk mdd | #149 |
schizotypy | #149 |
cdrsr | #149 |
parental substance | #149 |
highlighting | #150 |
adhd relationship | #150 |
nonmedical | #150 |
categorical | #150 |
sud treatment | #150 |
impulsive | #150 |
chrnb2 | #150 |
consisted | #151 |
synaptic biology | #151 |
higher burden | #151 |
functional impairment | #152 |
atxn1 | #152 |
placebo subjects | #152 |
copy variants cnvs | #152 |
httlpr | #152 |
schizophrenia diagnosis | #152 |
diagnostic systems | #152 |
undegraded | #152 |
xq21 | #152 |
linkage disequilibrium mapping | #152 |
large sample | #152 |
metaanalytic | #152 |
increases risk | #152 |
implicates | #152 |
parent report | #152 |
autistic traits | #152 |
demoralization | #153 |
5 httlpr | #153 |
genomewide linkage | #153 |
alcohol conditions | #153 |
marginally | #153 |
schizophrenia deficits | #153 |
schizophrenia bipolar disorder | #153 |
caucasian children | #153 |
editions | #153 |
humans learning | #153 |
disorder phenotype | #154 |
schizophrenia magnetic resonance | #154 |
emphasizing | #154 |
atomoxetine placebo | #154 |
exposure maternal | #154 |
dsm | #154 |
wisc | #154 |
year follow | #155 |
humans polymorphism | #155 |
genomewide scan | #155 |
snpheritability | #155 |
ncsr | #155 |
clarification | #155 |
tests male | #156 |
prospective controlled study | #156 |
genetic risk | #156 |
n84 | #156 |
interpersonal functioning | #156 |
600000 | #156 |
new knowledge | #157 |
panic disorder agoraphobia | #157 |
dopamine d4 | #157 |
enigma consortium | #157 |
htr2c | #158 |
adolescents | #158 |
greatest | #158 |
clinical diagnostic | #158 |
ppp2r2b | #158 |
oprm1 | #158 |
cognitive tempo | #158 |
genetic linkage | #158 |
myo5b | #158 |
sledai | #158 |
primary setting | #158 |
drd4 genotype | #158 |
teachers parents | #159 |
adult human brain | #159 |
dav | #159 |
nonpersistent | #159 |
quetiapine treatment | #159 |
patients substance | #159 |
selfratings | #159 |
separation anxiety disorder | #160 |
smds | #160 |
medial temporal | #160 |
age onset | #160 |
humans impulsive | #160 |
hyperactivity disorders | #161 |
genetic component | #161 |
schizophrenia bipolar | #161 |
adult adhd patients | #161 |
tic symptoms | #161 |
population samples | #161 |
behavioral difficulties | #161 |
empirical tests | #162 |
disorder clinical | #162 |
cooccurring disorders | #162 |
140 | #162 |
ksadspl | #162 |
rats wky | #162 |
disorder depression | #162 |
dn cells | #163 |
dsmiv | #163 |
neuropsychological tests | #163 |
paternal age | #163 |
neurobiology | #163 |
5htt | #163 |
sample | #163 |
impairments | #164 |
complex phenotype | #164 |
illness schizophrenia | #164 |
familial liability | #164 |
diagnostic status | #164 |
anxiety attention | #164 |
washington university | #165 |
neurocognitive performance | #165 |
risk subsequent | #165 |
boys girls | #165 |
years children | #165 |
12–14 | #166 |
domain criteria | #166 |
shared environment | #166 |
earlyonset schizophrenia | #166 |
genetic influence | #166 |
antidepressant therapy | #166 |
receptor gene | #166 |
alcohol disorders aud | #166 |
linkage genetic | #166 |
symptom reduction | #166 |
cotwins | #166 |
moderates | #167 |
association obesity | #167 |
ipsych | #167 |
leonard | #168 |
neurocognitive functions | #168 |
polygenic architecture | #168 |
children 6 years | #168 |
wisciii | #168 |
duration illness | #169 |
multifactorial | #169 |
perseverations | #169 |
international congress | #169 |
n111 | #169 |
matter microstructure | #169 |
genetic association analysis | #169 |
pharmacodynamic properties | #170 |
lgi | #170 |
anxiety child | #170 |
single nucleotide schizophrenia | #170 |
disorders young | #170 |
cfg | #170 |
conditional probability | #170 |
risk gene | #170 |
arrb2 | #170 |
traumas | #170 |
genesets | #171 |
child psychiatry | #171 |
functional laterality humans | #171 |
n91 | #171 |
treatment studies | #172 |
inattention impulsivity | #172 |
immune disorders | #172 |
enuresis | #173 |
disorders study | #173 |
interpersonal sensitivity | #173 |
gabbr1 | #174 |
male mental | #174 |
large samples | #175 |
tics | #175 |
subsyndromal | #175 |
confounds | #176 |
mph placebo | #176 |
development schizophrenia | #176 |
disorders sex | #177 |
independent datasets | #177 |
suicide death | #177 |
patients opioid | #177 |
ascertainment | #177 |
kraepelin | #177 |
confounded | #177 |
hyperactive children | #177 |
parent rated | #178 |
cortical surface | #178 |
strong genetic component | #178 |
n78 | #178 |
pregnancy children | #179 |
strongest evidence | #179 |
behaviorally | #179 |
gene interactions | #179 |
atomoxetine atx | #179 |
genetic confounding | #179 |
underpinnings | #179 |
cvlt | #180 |
copy variants | #180 |
nagelkerke | #180 |
connectivity networks | #180 |
perceptual disorders | #181 |
combinatory | #181 |
mothers pregnancy | #181 |
unemotional traits | #181 |
htr4 | #182 |
phenocopies | #182 |
structured | #182 |
control participants | #182 |
scz bip | #182 |
271 | #182 |
genotype humans | #183 |
mechanistic target | #183 |
studies gwas | #183 |
psychometric testing | #183 |
rating | #183 |
wei | #184 |
based morphometry | #184 |
reading difficulties | #184 |
effects atomoxetine | #184 |
n‐acetylcysteine | #185 |
phenocopy | #185 |
long acting | #185 |
allison | #185 |
reward sensitivity | #185 |
pdd | #185 |
genome human | #185 |
predominately | #186 |
218 | #186 |
statistical female | #186 |
biomarker studies | #186 |
hyperactivity symptoms | #186 |
risperidone placebo | #187 |
schizophrenia evidence | #187 |
schizophrenia major depression | #187 |
stratifying | #187 |
autocorrelation | #188 |
blood biomarkers | #188 |
depression treatment | #188 |
3 untranslated region | #188 |
parahippocampus | #188 |
enigma | #188 |
bna | #189 |
genetic correlations | #189 |
differential association | #189 |
undertreatment | #189 |
medication adhd | #190 |
childhood | #190 |
linkage evidence | #190 |
scwt | #190 |
functioning children | #190 |
clarify | #191 |
schedule female | #191 |
fsiq | #191 |
mph children | #191 |
mood disorder | #191 |
social dysfunction | #191 |
psychiatric phenotypes | #191 |
greater activation | #191 |
implicated | #191 |
dopamine genes | #191 |
iasp | #192 |
612 years | #192 |
association response | #192 |
freedman | #194 |
inconsistent findings | #194 |
joseph | #194 |
clinical global | #195 |
cognitive endophenotypes | #195 |
placebo p001 | #195 |
polymorphisms snps | #195 |
sza | #195 |
dependence symptoms | #197 |
perinatal complications | #197 |
overactivity | #197 |
neural substrates | #197 |
wm performance | #197 |
arhgef9 | #197 |
mdd scz | #198 |
ptk2b | #198 |
lifetime diagnosis | #198 |
snps schizophrenia | #198 |
g×s | #198 |
developmentally | #198 |
bsd | #199 |
male | #199 |
asic1a | #199 |
raises | #199 |
specific genes | #199 |
childhood symptoms | #199 |
male phenotype | #199 |
small samples | #200 |
neuropsychological battery | #200 |
mri data | #200 |
asd adhd | #200 |
childhood attention | #200 |
disruptive disorders | #200 |
catecholomethyltransferase | #201 |
parents schizophrenia | #201 |
functional genomics | #201 |
disorder humans | #201 |
cognitive flexibility | #202 |
pain tolerance | #202 |
unaffected | #203 |
pdq | #203 |
genetic liability | #203 |
neuropsychological correlates | #203 |
childhood adulthood | #203 |
control association | #203 |
stopsignal task | #203 |
concurrent validity | #204 |
extend | #204 |
schizophreniform | #204 |
adolescent psychiatry | #204 |
microsatellite marker | #204 |
respond | #204 |
attentional control | #204 |
genes risk | #206 |
uptodate | #206 |
nonshared | #206 |
selfdirectedness | #206 |
sluggish cognitive tempo | #207 |
method drug | #207 |
parental alcohol | #208 |
susceptibility schizophrenia | #208 |
prolactin levels | #208 |
prkg1 | #208 |
baseline follow | #209 |
clinical benefits | #209 |
variable expression | #209 |
acds | #210 |
maudsley | #210 |
park2 | #210 |
correspondence | #210 |
5year followup | #210 |
n96 | #210 |
60mg | #210 |
vntr polymorphism | #211 |
greater risk | #211 |
predisposition disease | #211 |
dimensional models | #212 |
ps005 | #212 |
adult patients adhd | #212 |
hkdc1 | #212 |
grm7 | #212 |
stroop task | #212 |
apoe4 allele | #212 |
trauma ptsd | #213 |
sought | #213 |
sampling strategy | #213 |
negative outcomes | #213 |
replication studies | #213 |
continuous performance test | #214 |
suggestive evidence | #214 |
schizophrenia chinese | #214 |
humans neuropsychological | #214 |
rare cnvs | #214 |
disorders models | #214 |
cvltii | #214 |
adult cognition | #215 |
lifetime version | #215 |
bilag | #215 |
male mental disorders | #215 |
functional mri study | #216 |
vivo correlation | #216 |
chromosome 15 | #217 |
glr | #217 |
antisocial personality | #217 |
male schizophrenia | #217 |
parental | #218 |
panic | #218 |
gene based | #218 |
trim31 | #218 |
hippocampal subfield | #218 |
misunderstood | #219 |
study selection | #219 |
polygenic | #219 |
snpa | #220 |
drug double | #220 |
normal controls | #220 |
studies cognition | #221 |
triangularis | #221 |
irritable mood | #221 |
telephone interview | #221 |
symptoms adults | #221 |
parental psychopathology | #221 |
score male | #222 |
methyltransferase comt | #222 |
diagnoses | #222 |
n76 | #222 |
patient engagement | #222 |
childhoodonset | #222 |
revisited | #223 |
study findings | #223 |
learning disability | #223 |
sensing ion | #224 |
gria2 | #224 |
adhd sleep | #224 |
abnormalities schizophrenia | #224 |
axis disorders | #224 |
effective treatments | #224 |
default network | #225 |
coordination disorder | #225 |
bipolar spectrum | #225 |
children placebo | #226 |
inattentiveness | #226 |
subfields | #226 |
hk3 | #226 |
scales psychotic | #227 |
individual variability | #227 |
disorder study | #227 |
unemotional | #227 |
criteria diagnosis | #227 |
subcortical regions | #227 |
dependent variables | #227 |
comorbid anxiety disorders | #228 |
control based | #228 |
male twins | #228 |
atomoxetine treatment | #228 |
age subjects | #228 |
birth complications | #229 |
overlapped | #229 |
structural abnormalities | #229 |
equally | #229 |
psychiatric outcomes | #230 |
risk indicators | #231 |
international multicenter | #231 |
4years | #231 |
heritable | #231 |
commission errors | #231 |
differences prevalence | #232 |
serotonin transporter gene | #232 |
hyperactivity behavior | #232 |
study sample | #234 |
candidate genes | #234 |
worse performance | #234 |
disorder medication | #235 |
discriminating | #235 |
probabilistic forecasts | #235 |
shr wky rats | #236 |
fifty years | #238 |
agoraphobia | #238 |
reliably | #238 |
route administration | #238 |
placebo response | #238 |
allelic heterogeneity | #239 |
acid oxidase | #240 |
patients siblings | #240 |
scientific data | #240 |
healthy siblings | #240 |
nosology | #240 |
pdag | #240 |
adequately | #241 |
adolescent offspring | #241 |
doubleblind | #241 |
symptoms quality | #241 |
disorder asd | #241 |
neurodevelopmental model | #242 |
joint analysis | #242 |
impulsive choice | #242 |
reward processing | #242 |
psychiatric comorbidities | #242 |
sodium hydrogen | #242 |
onset obsessive | #243 |
female | #243 |
aggressive behaviors | #243 |
patients relatives | #243 |
valid | #243 |
n74 | #244 |
giftedness | #244 |
adversity | #245 |
paliperidone | #245 |
interregional | #245 |
population differences | #245 |
5ht2a receptor | #245 |
disorder ptsd | #245 |
cadm2 | #246 |
expression genetic | #246 |
dsmivtr | #246 |
community controls | #246 |
812 | #247 |
motor performance | #247 |
chinese families | #248 |
epigenetic studies | #248 |
cigarette smoking | #248 |
studies associations | #248 |
developmental disorder | #249 |
behavioral characteristics | #251 |
childs | #251 |
german patients | #252 |
hypoactivation | #252 |
genomewide association | #253 |
intellect | #253 |
female subjects | #253 |
tourette | #253 |
iqs | #253 |
benzodiazepine | #254 |
kappas | #254 |
study schizophrenia | #254 |
cpt performance | #254 |
studies metaanalysis | #254 |
schizophrenia adult | #254 |
conduct problems | #255 |
larsson | #256 |
biochemical studies | #256 |
shared genetic | #256 |
cacna1c gene | #256 |
children adhd symptoms | #257 |
carlson | #257 |
parental depression | #259 |
year study | #259 |
endorsement | #259 |
n61 | #260 |
piq | #260 |
diagnosis | #261 |
anxiety depressive disorders | #261 |
pharmacotherapy | #261 |
dexamphetamine | #261 |
fluid intelligence | #263 |
genomewide linkage scan | #263 |
sex factors | #263 |
selfreports | #263 |
22q11ds | #263 |
obsessive compulsive disorder | #263 |
confirm | #264 |
adverse health | #264 |
conceptualized | #264 |
distinct subtypes | #264 |
disorder personality | #264 |
attention problems | #264 |
long term outcomes | #265 |
new models | #266 |
diagnostic validity | #266 |
ptsd risk | #266 |
schizophrenia cases | #266 |
5090 | #266 |
phenotype schizophrenia | #267 |
scz mdd | #267 |
neuropsychological impairment | #268 |
genetic approaches | #268 |
strong support | #268 |
diagnosis schizophrenia | #268 |
years baseline | #269 |
test scores | #269 |
diagnostic process | #269 |
withdrawn | #270 |
age effects | #270 |
segregate | #270 |
phlda1 | #270 |
largest | #270 |
sibling pairs | #271 |
genetic overlap | #271 |
circadian genes | #271 |
symptoms assessed | #271 |
social adversity | #271 |
adult psychiatric | #271 |
diagnostic issues | #272 |
structural brain | #272 |
alcohol smoking | #273 |
rora | #273 |
search terms | #273 |
schizophrenia siblings | #273 |
444 | #273 |
age | #273 |
4year | #273 |
statistics topic | #273 |
szs | #273 |
22 years | #274 |
sleep behavior | #274 |
maf1 | #275 |
reading disability | #275 |
surgency | #275 |
underlie | #275 |
familial schizophrenia | #276 |
2q | #276 |
t102c | #276 |
missingness | #276 |
nicotinic schizophrenia | #277 |
adhd healthy controls | #277 |
adolescent risk | #277 |
mania symptoms | #277 |
growing evidence | #277 |
synaptosomal | #278 |
clinical setting | #278 |
manual | #278 |
nr3c1 | #278 |
early psychosis | #278 |
ocd | #279 |
silico approach | #279 |
nicotine dependence | #279 |
intelligence scale | #279 |
cognition female | #280 |
rating scale | #280 |
abuser | #280 |
brain volumes | #280 |
n47 | #280 |
child parent | #280 |
acting | #280 |
polygenic risk | #280 |
remitted | #280 |
disorders adult | #281 |
individuals | #281 |
psychotic bipolar | #281 |
premature death | #281 |
phenotyped | #281 |
onset ocd | #282 |
reading problems | #282 |
collaborative analysis | #282 |
5ht1b | #282 |
response inhibition | #282 |
titrated | #283 |
velo | #283 |
antisocial behaviors | #283 |
continue | #283 |
aspd | #284 |
neoffi | #285 |
neuroanatomical | #285 |
3untranslated region | #285 |
normal variation | #285 |
gria3 | #285 |
quantitative traits | #285 |
clues | #286 |
quantitative analyses | #286 |
swanson | #286 |
scale children | #286 |
explication | #286 |
siblings patients | #286 |
effects age | #287 |
schizophrenia abnormalities | #288 |
deficit schizophrenia | #288 |
bmisds | #289 |
postmortem brain | #289 |
22q112 | #290 |
disease haplotypes | #290 |
pediatric ocd | #290 |
psychiatric traits | #290 |
subcortical volumes | #291 |
low serum levels | #291 |
publication bias | #291 |
substrain | #292 |
groups children | #293 |
modest | #293 |
cognition disorders | #294 |
salary | #294 |
hypertensive rat | #294 |
subjective responses | #294 |
psychosis schizophrenia | #295 |
adverse impact | #295 |
post‐traumatic stress disorder | #295 |
dtnbp1 | #295 |
european populations | #295 |
risk factors children | #295 |
interference control | #295 |
ldsc | #296 |
continuous performance | #296 |
executive functions | #296 |
asd traits | #297 |
anxiety disorder | #297 |
obesity overweight | #297 |
early onset | #297 |
discriminated | #298 |
reanalysis | #298 |
diagnostic approach | #298 |
predisposition | #299 |
negative symptom | #299 |
effects stress | #300 |
qvalues | #300 |
cortical thickness | #300 |
roc analysis | #301 |
psychiatric hospitalization | #301 |
cognitive measures | #301 |
states adolescent | #302 |
emotional problems | #302 |
intrasubject variability | #302 |
published literature | #302 |
prefrontal function | #302 |
height body | #303 |
permuted | #303 |
psychometrics | #303 |
psychiatric conditions | #304 |
795 | #304 |
interviewers | #305 |
affective disorders | #305 |
case subjects | #305 |
manifest | #305 |
aggressive behavior | #305 |
ats | #305 |
dsm5 | #305 |
early morning | #306 |
dopamine transporter | #306 |
n62 | #307 |
learning disorder | #307 |
general psychopathology | #308 |
spencer | #309 |
omission errors | #309 |
gene environment | #309 |
membrane transport | #309 |
documented | #309 |
perseveration | #309 |
myh9 | #309 |
memory wm | #310 |
genetic schizophrenia | #310 |
life social support | #310 |
adolescent aggression | #310 |
efficacy treatment | #310 |
motor domain | #310 |
rdoc | #311 |
mainstays | #312 |
gender age | #312 |
childhood adolescence | #312 |
stroop test | #312 |
mapping female | #313 |
npsr1 | #313 |
underscore | #314 |
genetic analyses | #314 |
bedtimes | #315 |
risk estimation | #315 |
replicated | #317 |
dorsolateral prefrontal cortex | #317 |
asb | #317 |
schizophrenia review | #318 |
demonstrable | #318 |
individual genes | #319 |
5ht2c | #319 |
n55 | #319 |
adolescent adrenergic | #320 |
gene | #321 |
intelligence tests | #321 |
shared genetic influences | #321 |
addictive disorders | #321 |
risperidone treatment | #322 |
bipolar type | #322 |
robins | #322 |
127 | #322 |
humans longitudinal | #322 |
time variability | #323 |
abusers | #323 |
nolan | #324 |
conceptual models | #324 |
guanfacine | #324 |
manic | #325 |
sex characteristics | #326 |
yielded | #326 |
neonatal abstinence syndrome | #326 |
impaired | #327 |
status female | #327 |
xq26 | #327 |
spurious | #327 |
etiologic | #328 |
comprised | #328 |
disorders pervasive | #329 |
8q | #329 |
metaanalyses | #330 |
overrepresented | #330 |
sexdifferences | #330 |
scores patients | #331 |
htr2a | #331 |
drug response | #331 |
women schizophrenia | #332 |
expression brain | #333 |
txndc5 | #333 |
familial factors | #333 |
naltrexone | #333 |
multiple comparisons | #334 |
cognitive dysfunctions | #334 |
obesity diabetes | #334 |
mood disorders | #335 |
forthcoming | #335 |
24weeks | #335 |
adler | #335 |
methylphenidate placebo | #336 |
persist | #336 |
inferior parietal lobule | #336 |
humans mental | #336 |
rey | #336 |
neuropsychological test | #337 |
777 | #337 |
tph2 | #337 |
asd individuals | #337 |
mobp | #337 |
disentangle | #338 |
patients attention | #339 |
replications | #339 |
psychopathological | #339 |
evening | #339 |
exclusion criteria | #340 |
pnmt | #340 |
evidence linkage | #340 |
consistently | #340 |
disorder ocd | #340 |
placebo effects | #341 |
intelligence | #341 |
treatment bipolar | #341 |
encompassing | #341 |
maoa genotype | #342 |
phobic | #342 |
visual memory | #342 |
bipolarity | #342 |
multicenter analysis | #342 |
neuroimaging studies | #342 |
integrated analysis | #344 |
mood problems | #344 |
tbv | #344 |
schizoaffective disorder | #344 |
comorbid diagnoses | #344 |
frontal pole | #344 |
systematically | #345 |
catechol methyltransferase | #345 |
casecontrol studies | #345 |
864 | #346 |
gifts | #346 |
confused | #347 |
study genotype | #347 |
mdd bpd | #347 |
converging | #348 |
psychotic | #348 |
tic severity | #348 |
temporal processing | #349 |
schizotypal personality disorder | #349 |
collaborative study | #349 |
methylphenidate atomoxetine | #350 |
aetiological | #350 |
adolescent anxiety | #350 |
suspiciousness | #351 |
receptor genes | #352 |
adults children | #352 |
disequilibrium | #352 |
distractibility | #352 |
disease genome | #353 |
impairing | #353 |
gabra1 | #354 |
disorders middle | #354 |
brain atlas | #354 |
executive attention | #354 |
child attention | #354 |
substantial | #354 |
maob | #354 |
genetic environmental | #354 |
reln | #354 |
rgs4 | #355 |
prodh | #355 |
dsmiii | #355 |
male adolescent | #355 |
heterogeneous disorder | #356 |
phobic disorders | #356 |
schizophrenia data | #356 |
measures attention | #357 |
chrna7 | #357 |
children anxiety disorders | #357 |
gottesman | #358 |
deviant | #359 |
psychiatric symptoms | #359 |
disorder patients | #359 |
maternal cigarette smoking | #359 |
persists | #359 |
symptom scores | #360 |
linkage analysis | #360 |
chromosomal regions | #361 |
n54 | #361 |
neuroleptic treatment | #361 |
social adjustment | #362 |
dorsolateral prefrontal | #363 |
genetic findings | #364 |
tid | #365 |
paralimbic | #365 |
core symptoms | #366 |
confirmation | #366 |
elevated risk | #366 |
memory load | #367 |
pediatric populations | #367 |
771 | #367 |
risk psychopathology | #368 |
study entry | #368 |
bpd mdd | #368 |
comparison groups | #368 |
differential involvement | #369 |
hyperactivityimpulsivity | #369 |
702 | #369 |
young adulthood | #369 |
representativeness | #370 |
differential susceptibility | #370 |
nervousness | #370 |
current concepts | #371 |
schizophrenia risk | #371 |
damphetamine | #371 |
replicate | #372 |
endorse | #372 |
comt gene | #372 |
prevention strategies | #372 |
5httlpr | #373 |
genomewide association studies | #373 |
executive function | #373 |
small sample | #374 |
driving performance | #374 |
snp heritability | #374 |
dozens | #375 |
wide analysis | #375 |
916 | #375 |
scz | #375 |
emphases | #376 |
medication children | #376 |
teenage | #376 |
memory short | #377 |
sas | #377 |
child adolescent | #377 |
data studies | #377 |
children medication | #377 |
genetic architecture | #377 |
impression | #378 |
schizotypal personality | #378 |
children adolescents | #378 |
marriages | #379 |
control adults | #379 |
youths | #380 |
converged | #380 |
pearson | #380 |
opd | #380 |
ht1b | #380 |
culmination | #381 |
general cognitive ability | #381 |
overlap | #381 |
disorder diagnostic | #381 |
relevant articles | #381 |
receptors dopamine | #381 |
methylphenidate children | #381 |
invaluable | #381 |
adolescent patients | #382 |
chisquare | #382 |
carefully | #383 |
antimanic | #383 |
psychopathologies | #383 |
psychopharmacological treatment | #383 |
researched | #384 |
summary statistics | #384 |
7r | #385 |
gad2 | #385 |
treatment children | #386 |
18p | #386 |
multigenerational | #386 |
chinese subjects | #387 |
neural activation | #387 |
evenings | #388 |
contrasted | #388 |
versa | #388 |
npas2 | #388 |
adhd symptomatology | #389 |
childhood depression | #389 |
disorder symptoms | #390 |
studies children | #390 |
lefthandedness | #390 |
handedness | #390 |
brain circuits | #390 |
perinatal morbidity | #390 |
interaction genetic | #391 |
genetic predisposition | #391 |
lambert | #392 |
comorbid substance | #392 |
schizophrenia susceptibility | #392 |
p54 | #393 |
genes expression | #394 |
substance users | #394 |
hippocampal subfields | #395 |
dopamine norepinephrine | #395 |
function humans | #395 |
adolescents adults | #396 |
3methoxy4hydroxyphenylglycol | #397 |
schizophrenia disorder | #397 |
psychometric | #397 |
fbat | #397 |
mental health children | #397 |
disorders schizophrenia | #397 |
spm8 | #398 |
wandering | #398 |
earlier onset | #398 |
clinical risk psychosis | #398 |
neuropsychological testing | #400 |
control sample | #401 |
academic outcomes | #402 |
inattention symptoms | #402 |
suffocation | #402 |
core symptom | #402 |
relations male | #403 |
implications findings | #403 |
inconsistencies | #403 |
psychostimulants | #405 |
hyperparameter | #405 |
n52 | #406 |
vntrs | #406 |
diagnosis children | #406 |
neuropsychiatric conditions | #406 |
parahippocampal | #406 |
attending | #407 |
childhood risk | #408 |
cognitive inhibition | #408 |
behavior genetics | #409 |
communitybased | #409 |
0038 | #409 |
substance | #410 |
distinct subsets | #410 |
dextroamphetamine | #411 |
reading comprehension | #411 |
impulsive behavior | #411 |
twin study | #411 |
children studies | #411 |
tourette syndrome | #412 |
interview | #412 |
childhood anxiety | #412 |
neanderthal | #412 |
consistent evidence | #412 |
psychotic disorders | #412 |
apoe4 | #412 |
systematic literature search | #413 |
anticipation | #413 |
moderated | #413 |
performance tests | #414 |
151 | #414 |
reviewing | #414 |
polymorphism snp | #415 |
volition | #415 |
genetic receptor | #416 |
elucidating | #416 |
schizotypal | #416 |
effects brain | #417 |
functional effects | #417 |
adult intelligence | #418 |
conferred | #418 |
adolescent psychiatric | #418 |
genetic association | #419 |
questionnaires adolescent | #419 |
srsa | #419 |
deletion syndrome | #419 |
antidepressive agents | #420 |
dopamine d4 receptor | #420 |
kdm4a | #420 |
daily doses | #420 |
sexes | #421 |
adult subjects | #421 |
modestly | #421 |
cdis | #422 |
drug dependence | #422 |
iccs | #422 |
operating characteristic | #422 |
tricyclic | #423 |
reliability validity | #423 |
medicated | #423 |
characteristic curve | #424 |
gcta | #424 |
discovery sample | #425 |
transport proteins | #425 |
subtests | #425 |
cardiff | #426 |
parent ratings | #426 |
hum | #427 |
attain | #427 |
brain volume | #428 |
spectrum disorders | #428 |
diversion | #428 |
persistent symptoms | #429 |
male obsessive | #430 |
disentangling | #431 |
personality development | #431 |
teacher | #432 |
operating characteristics | #432 |
uniquely | #433 |
peps | #434 |
wistarkyoto | #435 |
cprs | #436 |
12q | #436 |
frequency genotype | #436 |
perceptual organization | #436 |
1433 | #436 |
disorder brain | #437 |
grin2a | #437 |
relatives patients | #437 |
lower scores | #437 |
toddlerhood | #438 |
visual learning | #438 |
adolescent psychopathology | #438 |
correlation coefficients | #438 |
srs2 | #438 |
impulsiveness | #438 |
22q112ds | #439 |
genetic genetic predisposition | #439 |
nominal | #439 |
risk psychosis | #439 |
digit span | #439 |
major risk factor | #440 |
method female | #440 |
snps association | #440 |
aged neuropsychological | #440 |
white matter microstructure | #441 |
gmo | #441 |
meaningful | #441 |
allelic association | #441 |
post hoc analysis | #441 |
corroborated | #441 |
trex | #441 |
planum temporale | #442 |
female functional | #442 |
adult analysis | #442 |
disorders autism | #442 |
logistic regression model | #442 |
virtual histology | #442 |
n80 | #443 |
emphasize | #444 |
differential female | #444 |
conferring | #444 |
10 year | #444 |
disorders surveys | #444 |
pcdh10 | #445 |
nucleotide receptors | #446 |
534 | #446 |
862 | #446 |
statistic | #446 |
ntrk3 | #446 |
holland | #447 |
motor coordination | #448 |
originally | #448 |
genome wide | #448 |
behavior child | #448 |
earlier age | #449 |
expressiveness | #449 |
early response | #450 |
wistar kyoto | #450 |
risk variants | #450 |
sex | #451 |
exceptions | #451 |
clinical expression | #452 |
subsequent risk | #452 |
brain abnormalities | #452 |
prevalence correlates | #452 |
children adolescent | #456 |
chat | #456 |
79 | #457 |
zscores | #457 |
psychiatry | #457 |
preliminary study | #458 |
independently | #458 |
masse | #458 |
structural magnetic | #458 |
22q112 deletion | #460 |
lander | #460 |
522 | #460 |
genetic correlation | #460 |
polygenic risk score | #460 |
psychotic disorders schizophrenia | #460 |
smoking pregnancy | #461 |
hyperkinesis | #461 |
jw | #462 |
d4 | #463 |
neuroanatomy | #465 |
affection | #465 |
life treatment | #465 |
decrements | #465 |
pregnancy complications | #465 |
gene sets | #466 |
control rates | #466 |
runs | #466 |
anxiety depressive | #467 |
mini | #467 |
inbred wky | #467 |
bpad | #468 |
subjects patients | #469 |
disorders treatment | #470 |
patient adherence | #470 |
genetic effects | #470 |
cacna1c | #470 |
remission relapse | #471 |
receiver operating | #471 |
psychology adolescent | #472 |
risk allele | #472 |
chrna4 | #473 |
response remission | #473 |
norepinephrine transporter | #474 |
environmental risk factors | #474 |
plp1 | #474 |
developmental coordination | #476 |
cautious | #476 |
opioid addiction | #476 |
obesity children | #477 |
multiple measures | #477 |
broader | #478 |
multiplex families | #479 |
dysthymia | #479 |
5th | #479 |
humans | #480 |
symptom | #480 |
genetic risk variants | #480 |
adds | #480 |
semistructured | #481 |
cortex child | #481 |
diagnostic categories | #481 |
data extraction | #482 |
maternal anxiety | #482 |
genotyped | #482 |
arithmetic | #483 |
etiology | #483 |
verbal learning | #484 |
conception | #484 |
sml | #484 |
nfil3 | #484 |
treatment methylphenidate | #484 |
adulthood | #485 |
agents bipolar | #485 |
756 | #485 |
epidemiologically | #486 |
baseline age | #486 |
outcome variables | #486 |
adult anxiety | #487 |
symptom dimensions | #487 |
evaluates | #487 |
123 | #487 |
spontaneity | #488 |
female adolescents | #489 |
unpublished | #489 |
genetic disorders | #489 |
longterm effects | #489 |
neuropsychiatric disorder | #490 |
administration schedule | #490 |
shared environmental | #490 |
schizophrenia autism | #490 |
schizophrenia age | #492 |
common variant | #492 |
smoking prevention | #492 |
pnds | #493 |
overlapping | #493 |
frequency genetic | #495 |
late adolescence | #495 |
antisocial personality disorder | #495 |
schizophrenia patients | #497 |
pair human | #497 |
psychobiology | #497 |
restlessness | #497 |
anxiety | #497 |
separation anxiety | #497 |
bonferroni | #498 |
longitudinal studies | #498 |
addressed | #499 |
candidate | #499 |
genetic mechanisms | #499 |
daoa | #499 |
placebos | #499 |
comt val158met polymorphism | #500 |
identifying | #500 |
case reports | #500 |
d4 receptors | #501 |
rat strains | #501 |
nocebo | #501 |
verbal memory | #503 |
865 | #503 |
additional evidence | #503 |
child executive | #505 |
circadian clock genes | #505 |
n26 | #506 |
fallacy | #506 |
subscale | #506 |
cooperativeness | #507 |
continued | #507 |
tobacco disorder | #508 |
reflecting | #508 |
developing schizophrenia | #509 |
delay discounting | #509 |
agg | #510 |
educational status | #511 |
shared | #511 |
dichotomous | #511 |
identifiable | #512 |
obsessive compulsive | #512 |
p80 | #512 |
95 death | #512 |
lod | #513 |
risk haplotype | #513 |
coaggregation | #514 |
disproportionate | #514 |
assessments | #515 |
disorders depression | #515 |
morning | #515 |
phis | #515 |
normal control | #516 |
total sample | #516 |
cognitive traits | #517 |
n39 | #517 |
contributing | #517 |
15q | #518 |
missing link | #519 |
environmental influences | #520 |
pbat | #520 |
fn1 | #520 |
gyrus cinguli | #521 |
dichotic | #521 |
specificity ppv | #521 |
selfreport | #522 |
social class | #522 |
polymorphism single | #522 |
disorder obsessive | #522 |
dibenzothiazepines | #523 |
attention memory | #523 |
adult bipolar | #524 |
dmi | #524 |
phg | #524 |
assortative | #524 |
dedication | #524 |
disorder treatment | #525 |
covariates | #525 |
sciencedirect | #525 |
pacific island | #525 |
clinical diagnoses | #525 |
affiliations | #526 |
criminality | #527 |
functioning | #527 |
persistence | #527 |
symptomatic remission | #528 |
design study | #528 |
depression anxiety disorders | #528 |
adolescent children | #528 |
adverse life events | #528 |
ruled | #529 |
compulsive disorder | #529 |
community samples | #529 |
parental reports | #529 |
abrupt | #529 |
flnc | #529 |
tagsnps | #530 |
control children | #530 |
increased burden | #531 |
strongest | #531 |
medications | #531 |
autism schizophrenia | #532 |
n40 | #532 |
existing studies | #532 |
subjects age | #533 |
clinical sample | #533 |
analyses conducted | #534 |
temperament character | #534 |
intercorrelations | #535 |
selective review | #535 |
asd | #535 |
parsing | #537 |
global impression | #537 |
autistic symptoms | #538 |
child adhd | #538 |
models genetic | #538 |
d4 receptor | #539 |
milder | #541 |
personality factors | #541 |
lobe humans | #542 |
taiwanese | #543 |
single nucleotide | #543 |
disease genotype | #543 |
independent samples | #544 |
severe symptoms | #544 |
complexities | #544 |
ld | #545 |
population sample | #545 |
cognitive impairments | #546 |
choice behavior | #546 |
genetic influences | #547 |
functional variant | #548 |
computer program | #548 |
healthy control subjects | #548 |
oral route | #549 |
dichotomized | #549 |
risk children | #549 |
nonclinical sample | #549 |
schizophrenia study | #549 |
behavior male | #549 |
patients schizophrenia | #549 |
clash | #549 |
fam | #550 |
765 | #550 |
genetic pathways | #550 |
case control | #551 |
motor inhibition | #551 |
ideally | #551 |
define | #551 |
major diagnosis | #552 |
performance test | #552 |
verbal | #553 |
n29 | #553 |
preadolescent | #554 |
prs schizophrenia | #555 |
viewed | #555 |
release oral | #555 |
suggests | #555 |
spectrum disorder | #556 |
phenotypic features | #556 |
nogo task | #557 |
child anxiety | #557 |
neuropsychiatric diseases | #557 |
neurodevelopmental | #558 |
equivocal | #558 |
africanamerican | #558 |
justify | #559 |
gray matter volumes | #560 |
response variability | #560 |
higher rate | #561 |
caregivers children | #563 |
profoundly | #563 |
risk smoking | #565 |
adolescents risk | #565 |
intermediate phenotypes | #566 |
risky behaviors | #566 |
4th edition | #566 |
twins female | #566 |
patients sud | #566 |
neurocognitive impairment | #567 |
haplotype | #567 |
3050 | #567 |
unaffected relatives | #568 |
replication study | #569 |
environment interaction | #570 |
10−8 | #570 |
onsets | #570 |
diverging | #570 |
birthday | #571 |
risk genes | #571 |
keywords | #571 |
dose reduction | #573 |
obesity body mass | #574 |
white matter abnormalities | #574 |
irritability | #574 |
questionnaires adult | #575 |
inbred shr | #575 |
gyri | #576 |
spaced | #576 |
asd diagnosis | #576 |
medical genetics | #577 |
chromosomes human | #577 |
individually | #577 |
schizophrenia sample | #577 |
parent | #577 |
82 | #578 |
finetuning | #578 |
impulsivity | #578 |
symptoms children | #579 |
subsample | #579 |
development anxiety | #580 |
preschool age | #580 |
5httlpr polymorphism | #580 |
cold pressor test | #580 |
haplotype analysis | #581 |
drd1 | #582 |
rdc | #582 |
psychiatric association | #582 |
apol1 | #582 |
delinquent behavior | #583 |
3rd | #583 |
new approaches | #584 |
hk1 | #584 |
separately | #585 |
data children | #585 |
fine mapping | #585 |
neuroanatomical correlates | #586 |
traumatized | #587 |
nback task | #588 |
defaultmode network | #588 |
examine | #588 |
compared controls | #588 |
138 | #589 |
haplotypes humans | #590 |
estonian | #591 |
patients comorbid | #591 |
behavior adult | #591 |
40mg | #591 |
criticism | #593 |
2005 | #594 |
concordant | #594 |
brain child | #595 |
cognition schizophrenia | #596 |
overrepresentation | #596 |
snap25 | #597 |
nonpharmacologic | #597 |
generalizable | #597 |
discounted | #597 |
899 | #598 |
affymetrix | #598 |
new directions | #598 |
differences brain | #600 |
genetic factors | #601 |
specific phobia | #603 |
diagnosing | #604 |
clinical settings | #604 |
diagnostic specificity | #604 |
performance children | #606 |
cognitive outcomes | #606 |
clinician | #606 |
disorganized | #606 |
social environment | #607 |
personality traits | #607 |
small fraction | #608 |
sizeable | #608 |
4 6 | #608 |
antisocial behavior | #609 |
executive dysfunctions | #609 |
true | #609 |
gold standard | #609 |
functional outcomes | #610 |
polygenic risk scores | #610 |
informant | #611 |
pleiotropic | #612 |
complex disorders | #612 |
chromosome 6 | #613 |
schizophrenia brain | #614 |
grandmothers | #614 |
educational achievement | #614 |
snp markers | #615 |
disease etiology | #615 |
curve analysis | #615 |
behavior disorder | #615 |
genetic epidemiology | #616 |
memory deficits | #616 |
prevalence severity | #616 |
tscores | #617 |
genome scans | #617 |
genetic associations | #618 |
african children | #618 |
differ | #618 |
val158met | #618 |
correcting | #619 |
digeorge | #619 |
vigilance | #620 |
genetic markers | #620 |
md | #621 |
antisocial behaviour | #621 |
confer | #622 |
adverse health outcomes | #623 |
juvenile delinquency | #624 |
receptor serotonin | #624 |
misconceptions | #625 |
executive control | #625 |
executive dysfunction | #625 |
mood stabilizers | #626 |
hrr | #627 |
attentional deficits | #627 |
seeks | #627 |
fibromyalgia | #629 |
child gender | #629 |
treatment disorder | #629 |
schizophrenia findings | #630 |
deficits schizophrenia | #631 |
reject | #631 |
teacher ratings | #632 |
needed | #633 |
girls boys | #634 |
genetic basis | #635 |
tiny | #637 |
obsessivecompulsive disorder | #638 |
generalisability | #638 |
icv | #638 |
disease genotype humans | #639 |
longitudinal | #640 |
advertisement | #641 |
adult outcomes | #641 |
ranks | #641 |
illness duration | #642 |
gateway | #643 |
inconsistent | #643 |
expression genes | #644 |
twin pairs | #645 |
premorbid | #645 |
functioning autism | #646 |
subjects schizophrenia | #646 |
exacerbate | #647 |
methodological | #648 |
17 years | #649 |
galantamine | #650 |
gene association | #652 |
treatment effects | #652 |
avoidant | #652 |
physical conditions | #653 |
hyperactivity inattention | #653 |
128 | #653 |
federation | #654 |
stroop | #654 |
intergenerational transmission | #655 |
random allocation rats | #656 |
reward anticipation | #656 |
bipolar disorder schizophrenia | #656 |
studies evidence | #657 |
boldness | #658 |
impairment | #658 |
psychosocial treatment | #658 |
groups compared | #658 |
volumes | #659 |
hypomanic | #659 |
association exposure | #660 |
core feature | #661 |
poorer performance | #661 |
peer relations | #662 |
referrals | #662 |
structural alterations | #662 |
lowlevel | #665 |
permission | #665 |
digeorge syndrome | #665 |
dacc | #666 |
subcortical | #666 |
psychiatric illnesses | #667 |
mood | #668 |
prominent | #669 |
swedish population | #669 |
phenotypic expression | #672 |
neurobiological | #675 |
time children | #676 |
impulsive behaviors | #677 |
unselected | #678 |
disorders memory | #678 |
129 | #679 |
sleep difficulties | #679 |
mental disorders humans | #680 |
middle childhood | #680 |
psychopathological symptoms | #680 |
neurotic | #681 |
gene frequency | #681 |
soviet union | #682 |
trait | #682 |
quetiapine | #682 |
semantic fluency | #682 |
severe phenotype | #683 |
east asian | #685 |
remitting | #685 |
scales | #685 |
p0019 | #687 |
17q | #688 |
children groups | #688 |
chromosomal region | #688 |
postmortem brains | #689 |
younger children | #689 |
fibromyalgia patients | #689 |
average age | #694 |
disorder schizophrenia | #694 |
tcas | #694 |
testretest reliability | #695 |
participants | #696 |
parcellation | #696 |
cortical surface area | #696 |
4–5 | #697 |
5years | #697 |
pharmacokinetic profile | #697 |
122 | #699 |
drug abuse | #699 |
relevant studies | #699 |
effects methylphenidate | #700 |
quota | #701 |
illness surveys | #701 |
adult mental | #701 |
nonrandom | #701 |
pleiotropic effects | #704 |
treatmentnaïve | #704 |
gwa studies | #704 |
follow studies | #705 |
preschool years | #706 |
pathogenesis schizophrenia | #706 |
adaptive functioning | #706 |
autism spectrum | #708 |
p009 | #709 |
school settings | #709 |
children diagnosed | #710 |
informative | #713 |
chronic schizophrenia | #713 |
maternal report | #714 |
dysphoric | #714 |
eric | #714 |
prs | #714 |
misuse | #714 |
stress disorder | #715 |
728 | #715 |
disorders substance | #715 |
ethanol consumption | #715 |
641 | #716 |
3 weeks | #716 |
contradictory | #717 |
abstraction | #719 |
groundwork | #719 |
meta‐analysis | #720 |
multiple genes | #721 |
clinical population | #721 |
household income | #722 |
recurrence risk | #722 |
memory | #723 |
cognitive load | #724 |
proponents | #725 |
cinguli | #725 |
male adolescents | #726 |
lateonset | #726 |
gender dysphoria | #726 |
common snps | #726 |
attention deficits | #727 |
schizophrenics | #727 |
statistical | #728 |
dizygotic | #728 |
assortative mating | #729 |
structured clinical interview | #729 |
fmri study | #730 |
786 | #730 |
metabotropic glutamate | #731 |
prevention programs | #732 |
voxel based | #733 |
correlates | #733 |
git | #733 |
finding | #734 |
phenotypic heterogeneity | #734 |
wky | #735 |
health intervention | #737 |
life cycle | #737 |
gyrification | #737 |
opioid dependence | #738 |
substancerelated disorders | #738 |
polygenic score | #739 |
inflation | #739 |
validating | #740 |
rapid cycling | #741 |
refill | #742 |
caudate | #742 |
boston | #742 |
time task | #743 |
amphetamines | #744 |
comparators | #744 |
topic twins | #745 |
soviet | #745 |
bupropion | #745 |
neuropsychological status | #746 |
compulsive | #746 |
manifested | #747 |
duplications | #748 |
child interaction | #748 |
adrb1 | #749 |
examining | #750 |
934 | #750 |
twins dizygotic | #752 |
fulfilling | #752 |
molecular genetic analysis | #754 |
347 | #754 |
comt val158met | #755 |
post hoc | #755 |
mental disorders | #756 |
neuroleptics | #756 |
bipolar depression | #756 |
recalled | #756 |
schizophrenia scz | #757 |
nhe | #757 |
disease haplotypes humans | #759 |
renewal | #760 |
sads | #761 |
variation genome | #762 |
artifact | #763 |
matter abnormalities | #764 |
workday | #764 |
likelihoods | #765 |
humans logistic | #765 |
autism asd | #766 |
people schizophrenia | #767 |
substance misuse | #768 |
disinhibition | #769 |
emerged | #772 |
comt polymorphism | #772 |
performance patients | #774 |
birth rates | #776 |
parent reported | #776 |
human pair | #777 |
depressive | #777 |
behavioral phenotypes | #777 |
phenotypes | #778 |
deletion polymorphism | #779 |
euthymic | #779 |
risky behavior | #780 |
schizophrenia relationship | #780 |
weaknesses | #780 |
inheritance | #781 |
wky rats | #782 |
iowa gambling task | #782 |
combined analysis | #783 |
fourth edition | #783 |
questioning | #783 |
mega | #784 |
emerging roles | #784 |
teaes | #785 |
reformulation | #785 |
faced | #786 |
pbd | #787 |
963 | #787 |
adolescence | #787 |
niacin | #788 |
child temperament | #789 |
medial temporal lobe | #790 |
spelling | #791 |
cgi | #791 |
behavioral | #791 |
subtypes | #792 |
clinical criteria | #793 |
individuals schizophrenia | #793 |
motivations | #794 |
symptom burden | #794 |
association polymorphisms | #794 |
caveats | #796 |
delinquent | #796 |
separate | #797 |
363 | #800 |
additional studies | #800 |
genomic regions | #802 |
prenatal exposure | #803 |
dopamine d1 receptors | #803 |
randomized clinical trials | #804 |
stimulant drugs | #804 |
dysfunction | #805 |
superior frontal | #805 |
clinically | #805 |
latent classes | #806 |
novelty seeking | #806 |
male memory | #806 |
dorsolateral | #806 |
developmental perspective | #807 |
lobule | #808 |
hdrs | #809 |
ucla | #810 |
dopamine function | #810 |
phonemic | #811 |
adjusting | #811 |
preschool female humans | #811 |
dopamine serotonin | #811 |
blind | #813 |
coadministration | #815 |
mhpg | #816 |
declarative | #816 |
cfb | #817 |
quantitative measures | #817 |
lasting | #817 |
breakthroughs | #817 |
tryptophan hydroxylase | #817 |
single gene | #818 |
memory attention | #818 |
substance dependence | #818 |
epigenetic factors | #818 |
meeting | #820 |
cortical development | #820 |
patients psychotic disorders | #821 |
counties | #821 |
rated | #821 |
switches | #822 |
hme | #822 |
transcriptomic analysis | #824 |
prefrontal regions | #824 |
parental report | #824 |
rare coding variants | #825 |
common genetic | #825 |
adolescents asd | #827 |
humans models | #827 |
s100a6 | #828 |
treatment interventions | #829 |
timeframe | #830 |
multipoint | #830 |
multiple testing | #831 |
prevalent | #831 |
lifetime prevalence | #831 |
conduct disorders | #832 |
association tests | #832 |
liabilities | #833 |
college students | #834 |
gray | #837 |
n60 | #837 |
sleep disorder | #837 |
inbred shr rats | #838 |
matter humans | #838 |
aversion | #838 |
obstetric complications | #839 |
symptom profiles | #839 |
prescription | #839 |
neurocognition | #841 |
parenthood | #842 |
sporadic cases | #843 |
participants completed | #843 |
biological basis | #844 |
consensus statement | #844 |
facial emotion recognition | #845 |
n35 | #846 |
dnm | #847 |
exception | #847 |
dysregulated | #848 |
dgcr8 | #848 |
gwas summary | #848 |
factor model | #851 |
prefrontal | #855 |
nonsignificant | #857 |
putative | #857 |
schizophrenia healthy | #858 |
heightened risk | #858 |
estimated prevalence | #858 |
putamen | #858 |
6p | #859 |
nineteen | #859 |
preschool | #861 |
handbook | #862 |
heterogeneity | #863 |
delayed effects | #865 |
global assessment | #866 |
seventy | #866 |
glossary | #866 |
crosssectional studies | #867 |
nnt | #869 |
mental | #869 |
hypothesized | #869 |
neurobiological basis | #870 |
specialized | #872 |
753 | #873 |
shr rats | #874 |
pediatric | #874 |
perseverative errors | #874 |
comorbidity depression | #875 |
existing evidence | #875 |
hypotheses | #876 |
positive symptoms | #876 |
manova | #876 |
genetic counseling | #876 |
test performance | #877 |
externalizing disorders | #879 |
gender differences | #879 |
sizes | #881 |
memory functions | #882 |
association genetic | #883 |
altered | #884 |
12p | #886 |
psychedelics | #886 |
171 | #887 |
dynamism | #888 |
delayed | #890 |
cpts | #891 |
n17 | #893 |
n95 | #893 |
obsessive | #893 |
bonn | #894 |
decade | #894 |
veterans affairs | #895 |
480 | #897 |
164 | #898 |
cortical thinning | #902 |
biological psychiatry | #903 |
anterior cingulate | #903 |
reinforcer | #904 |
aptitude | #904 |
bipolar illness | #904 |
weight body | #904 |
sibling | #904 |
genetic contribution | #904 |
visit | #905 |
psychosocial functioning | #906 |
826 | #906 |
late childhood | #906 |
adult aggression | #907 |
standardized difference | #909 |
morphometric | #910 |
ggc | #911 |
symptom control | #911 |
amygdala reactivity | #912 |
pedigrees | #912 |
psychosocial | #912 |
visuospatial memory | #913 |
complications pregnancy | #913 |
underlying pathophysiology | #914 |
versions | #914 |
association age | #916 |
school performance | #917 |
disorder specific | #917 |
cousins | #918 |
sleep children | #920 |
177 | #923 |
screening tool | #924 |
pharmacogenetic | #924 |
vulnerability | #925 |
dysthymic | #925 |
wide | #926 |
dividing | #927 |
developmental trajectories | #927 |
affective disorder | #928 |
cpg sites | #930 |
nucleotide | #930 |
participating | #930 |
heroin addiction | #933 |
permutation | #933 |
194 | #933 |
20mg | #934 |
d5 | #935 |
adolescence young adulthood | #935 |
smoking risk | #936 |
environment interactions | #936 |
3040 | #937 |
study designs | #938 |
female genotype | #938 |
diagnostic | #938 |
irrs | #940 |
robustly | #940 |
critics | #941 |
severe form | #941 |
tdt | #943 |
gwas | #946 |
brain regions | #946 |
sles | #948 |
22q | #948 |
risk developing | #949 |
albeit | #950 |
fetal exposure | #950 |
subtest | #952 |
personality disorder | #954 |
amphetamine | #954 |
relapsers | #954 |
behavioral treatment | #955 |
effects sex | #956 |
prompted | #956 |
112 | #959 |
qam | #960 |
clinical disorders | #960 |
cytoarchitecture | #962 |
female frontal | #963 |
clinical assessment | #963 |
children epilepsy | #963 |
tandem repeat | #965 |
scores | #965 |
cgis | #965 |
dopamine uptake | #965 |
body height | #966 |
scarce | #966 |
heritability estimates | #967 |
cuneus | #968 |
splicing factor | #968 |
freesurfer | #969 |
mtbi | #970 |
examined | #970 |
schizophrenia association | #970 |
pharmacological treatment | #970 |
medication treatment | #971 |
risky sexual behavior | #972 |
aggression | #972 |
262 | #973 |
chromosome mapping | #974 |
diva | #975 |
autism spectrum disorder | #976 |
fluphenazine | #977 |
vmat2 | #978 |
psychosis risk | #978 |
resolve | #978 |
neurodevelopmental disorder | #980 |
2–4 | #980 |
educational | #982 |
pertaining | #982 |
459 | #982 |
seriousness | #985 |
logistic regression models | #986 |
symptoms age | #986 |
alleles | #986 |
patients sle | #987 |
difficulties | #988 |
tci | #990 |
ranked | #990 |
small proportion | #990 |
depressed mothers | #991 |
polymorphism genetic | #994 |
pathway analysis | #995 |
colleagues | #996 |
temporal stability | #996 |
internal consistency | #997 |
comorbid conditions | #998 |
detoxification | #999 |
diathesis | #999 |
keystone | #999 |
adolescent analysis | #1000 |
child child | #1001 |
stata | #1003 |
interviews | #1003 |
comparative efficacy | #1004 |
haplotypes | #1006 |
0016 | #1007 |
confounding factors | #1007 |
preschool cohort | #1007 |
allele | #1007 |
daughter | #1007 |
long‐term outcome | #1007 |
norms | #1008 |
structural mri | #1008 |
qualifications | #1009 |
risk alcohol | #1009 |
multiplex | #1009 |
posttraumatic stress disorder | #1009 |
discriminant | #1010 |
genes environment | #1012 |
ltc | #1014 |
7 years | #1014 |
maturational | #1020 |
metabotropic | #1020 |
conclusive | #1021 |
risk prediction | #1024 |
relates | #1024 |
insufficient | #1026 |
pharmacotherapies | #1027 |
004 | #1027 |
persistent | #1028 |
obsessive – | #1028 |
pharmacologic | #1029 |
weiss | #1030 |
analytic | #1031 |
wwwclinicaltrialsgov | #1031 |
frontostriatal | #1031 |
patients panic disorder | #1032 |
symptoms child | #1032 |
preface | #1034 |
predicted | #1034 |
73 | #1034 |
– compulsive | #1034 |
negative symptoms | #1035 |
total score | #1035 |
rodent models | #1035 |
brain disorders | #1035 |
eventual | #1037 |
exploratory analyses | #1037 |
major depressive episode | #1039 |
general framework | #1040 |
serotonin | #1041 |
general intelligence | #1041 |
twin | #1043 |
mental health treatment | #1044 |
gaf | #1044 |
heightened | #1045 |
relate | #1045 |
antecedents | #1046 |
inv | #1046 |
ffi | #1050 |
late gestation | #1051 |
subtle | #1052 |
onset schizophrenia | #1052 |
benzodiazepines | #1053 |
disorders post | #1054 |
school age | #1055 |
psychiatric morbidity | #1056 |
vice | #1056 |
nogo | #1058 |
major humans | #1058 |
youth report | #1060 |
obscure | #1060 |
adolescence adulthood | #1061 |
bipolar disorders | #1062 |
illicit | #1063 |
199 | #1063 |
genes involved | #1063 |
memory disorders | #1064 |
paediatric patients | #1065 |
europe female | #1065 |
childhood trauma | #1068 |
paranoia | #1068 |
awakenings | #1068 |
heritability | #1068 |
pooled | #1068 |
memantine | #1069 |
negative impact | #1069 |
emotional | #1069 |
word reading | #1070 |
human genetics | #1070 |
memory impairments | #1070 |
reading ability | #1071 |
risk scores | #1071 |
controlled clinical | #1071 |
social problems | #1071 |
single nucleotide receptors | #1071 |
genetic model | #1071 |
character inventory | #1072 |
4q | #1072 |
validity | #1073 |
associations | #1073 |
obesity risk | #1074 |
3′utr | #1075 |
studying | #1075 |
general hospital | #1076 |
mapping chromosomes | #1077 |
schizophrenia spectrum disorders | #1078 |
exposure delayed | #1080 |
transdiagnostic | #1080 |
schizophrenia social | #1082 |
adult antipsychotic | #1082 |
anxiety children | #1083 |
contiguous | #1084 |
psds | #1086 |
autoreceptors | #1086 |
onset psychosis | #1086 |
european continental | #1088 |
alcohol marijuana | #1089 |
distinctive | #1090 |
subtype | #1090 |
development disorders | #1092 |
polygenic scores | #1092 |
obsessivecompulsive disorder ocd | #1093 |
gifted | #1094 |
scientific literature | #1096 |
irritable | #1096 |
semistructured interview | #1096 |
smoking | #1099 |
metaanalysis | #1102 |
daughters | #1103 |
future work | #1103 |
external validity | #1103 |
cnvs | #1104 |
odds | #1106 |
diagnostic groups | #1107 |
10 weeks | #1107 |
psychosis | #1107 |
emotional behavioral | #1108 |
bip | #1108 |
prioritized | #1110 |
experimental test | #1110 |
psychoses | #1110 |
10−5 | #1111 |
share | #1111 |
male children | #1112 |
depressive disorder | #1113 |
new developments | #1114 |
effects children | #1116 |
discusses | #1117 |
schizophrenia subjects | #1119 |
psychotropic | #1121 |
children anxiety | #1122 |
632 | #1123 |
exchangers | #1123 |
556 | #1124 |
mts | #1125 |
coexisting | #1125 |
projects | #1127 |
dysthymic disorder | #1128 |
enriched | #1128 |
quantifies | #1128 |
similarities | #1128 |
investigator | #1129 |
weighting | #1130 |
adult alcoholism | #1130 |
attention performance | #1134 |
n28 | #1134 |
psychiatric diagnosis | #1135 |
birth outcomes | #1136 |
independent sample | #1136 |
blood pressure response | #1138 |
laterality humans | #1138 |
susceptibility loci | #1139 |
clinical samples | #1142 |
social phobia | #1142 |
signal task | #1144 |
prodromal | #1145 |
cognitive domains | #1145 |
early adolescent | #1145 |
demographic factors | #1146 |
measurement invariance | #1147 |
emotionality | #1147 |
normal volunteers | #1147 |
refine | #1149 |
humans intellectual | #1150 |
discriminability | #1150 |
discounting | #1150 |
children association | #1150 |
developmental model | #1152 |
quick | #1152 |
continents | #1152 |
normals | #1153 |
refinements | #1153 |
generalizability | #1153 |
sensory gating | #1154 |
clinical profiles | #1154 |
alspac | #1154 |
uncorrected | #1160 |
differential humans | #1160 |
ht2c | #1160 |
phenotype | #1161 |
” “ | #1163 |
review findings | #1163 |
studies data | #1164 |
phobia | #1164 |
neurocognitive function | #1165 |
affective | #1166 |
clinical groups | #1166 |
deteriorated | #1166 |
congress | #1167 |
catecholaminergic | #1168 |
medication status | #1169 |
social outcomes | #1170 |
292 | #1171 |
quality measures | #1174 |
mspi | #1175 |
cohen | #1176 |
bpd patients | #1176 |
gwas data | #1176 |
genetic risk factors | #1177 |
nicotine exposure | #1177 |
male subjects | #1178 |
clinical validation | #1178 |
study gwas | #1179 |
persisting | #1182 |
cinguli humans | #1182 |
reward | #1182 |
childhood exposure | #1182 |
nonverbal | #1183 |
triads | #1184 |
addressing | #1184 |
paradox | #1184 |
standardized | #1187 |
functional polymorphisms | #1188 |
dysbindin | #1189 |
hydrochloride | #1189 |
64 | #1190 |
child preschool | #1192 |
psychology | #1193 |
assess | #1194 |
parenting behavior | #1197 |
addictions | #1198 |
compulsivity | #1198 |
onequarter | #1198 |
wm | #1199 |
placebo | #1199 |
asian continental | #1200 |
230 | #1200 |
wisconsin | #1201 |
morbidity | #1202 |
sib | #1204 |
systematic search | #1204 |
millennium | #1207 |
nationwide cohort study | #1209 |
externalizing symptoms | #1209 |
problems children | #1209 |
neuropsychology | #1210 |
conceptualizations | #1210 |
p004 | #1211 |
term treatment | #1215 |
sample sizes | #1218 |
male mass | #1219 |
lbw | #1220 |
underlying | #1220 |
antecedent | #1221 |
child cognitive | #1222 |
prospects | #1222 |
study role | #1224 |
profile | #1226 |
approximated | #1227 |
partly | #1227 |
0011 | #1229 |
subgroup | #1232 |
molecular alterations | #1232 |
refining | #1232 |
poster | #1233 |
health organization | #1234 |
pregnancy prenatal | #1234 |
gprotein | #1235 |
children ages | #1235 |
shortcomings | #1237 |
educational attainment | #1239 |
tandem repeats | #1242 |
brain structure | #1242 |
interpersonal relations | #1244 |
short form | #1245 |
avenues | #1247 |
kf | #1247 |
enjoyment | #1247 |
risk asthma | #1247 |
psychosocial outcomes | #1248 |
cidi | #1248 |
cpg islands | #1249 |
delineate | #1251 |
roc | #1251 |
debilitating | #1252 |
alcohol disorders | #1255 |
risk ratio | #1256 |
serotonin transporter | #1256 |
summarize | #1256 |
goal | #1257 |
nervous | #1257 |
dysfunctions | #1257 |
onset depression | #1259 |
combine | #1260 |
consensus statements | #1263 |
characterize | #1266 |
onset age | #1267 |
likewise | #1270 |
logistic regression analyses | #1271 |
child mental | #1273 |
statistical methods | #1274 |
386 | #1277 |
entire | #1277 |
developmental pathways | #1277 |
n24 | #1278 |
study evidence | #1281 |
04 | #1281 |
priori | #1282 |
paternal | #1282 |
hopes | #1283 |
neuroimaging | #1283 |
increased rates | #1283 |
behavior adolescent | #1283 |
variance | #1284 |
spontaneously hypertensive | #1285 |
general cognitive | #1286 |
087 | #1286 |
orbitofrontal | #1288 |
somatic complaints | #1288 |
male nerve | #1288 |
warmth | #1289 |
aspect | #1289 |
1hmrs | #1291 |
dual psychiatry | #1291 |
posttraumatic | #1291 |
unmyelinated | #1291 |
clomipramine | #1292 |
misclassification | #1292 |
quantitative trait | #1292 |
animal conditioning | #1292 |
negative emotion | #1295 |
pvalue | #1297 |
136 | #1297 |
chromosomes | #1298 |
cures | #1301 |
atx | #1303 |
1520 | #1305 |
935 | #1305 |
cortical volume | #1306 |
prediction accuracy | #1309 |
sgas | #1309 |
vin | #1310 |
extant | #1310 |
risperidone | #1311 |
arrests | #1312 |
motor speed | #1313 |
factor analyses | #1313 |
criteria | #1314 |
76 | #1315 |
factors smoking | #1316 |
class analysis | #1317 |
minds | #1317 |
adolescents children | #1318 |
current findings | #1320 |
hypothetical | #1321 |
predictability | #1322 |
parents adolescents | #1323 |
short | #1323 |
polymorphism | #1324 |
hypothesis | #1325 |
response treatment | #1327 |
confusion | #1330 |
influencing | #1330 |
defining | #1331 |
measures | #1334 |
polysubstance | #1334 |
psychopharmacology | #1335 |
253 | #1335 |
authors | #1336 |
genetic background | #1336 |
nonuse | #1337 |
obsessive–compulsive disorder | #1338 |
fronto | #1338 |
longterm outcome | #1342 |
clinical phenotypes | #1342 |
542 | #1344 |
registry data | #1344 |
llysine | #1345 |
explaining | #1345 |
interpretation statistical | #1349 |
compared children | #1353 |
early adulthood | #1353 |
psychoticism | #1355 |
cocaine abuse | #1356 |
loci genetic | #1356 |
diagnostic tool | #1356 |
simon | #1357 |
flush | #1357 |
variabilities | #1357 |
seekers | #1358 |
gene discovery | #1359 |
antidepressive | #1359 |
broad spectrum | #1361 |
middle frontal gyrus | #1362 |
mammalian target | #1362 |
intergenerational | #1365 |
abcd | #1367 |
uptake inhibitors | #1369 |
unexplored | #1369 |
neuronal development | #1369 |
school teachers | #1369 |
reliance | #1370 |
intellectual functioning | #1371 |
observer variation | #1374 |
covert | #1377 |
larger | #1378 |
pallidum | #1380 |
inositol | #1382 |
ghr | #1385 |
thought disorder | #1386 |
new onset | #1386 |
highlighted | #1386 |
dimensional approach | #1389 |
prodrome | #1391 |
treatment depression | #1391 |
familial aggregation | #1391 |
6 years | #1391 |
illicit drugs | #1393 |
vendors | #1394 |
manuscripts | #1395 |
satisfying | #1395 |
rats shr | #1395 |
thalamic | #1395 |
racial | #1398 |
timely | #1399 |
emotional stimuli | #1399 |
lability | #1400 |
suggesting | #1400 |
17 | #1402 |
sufficient | #1403 |
blinded | #1403 |
brain region | #1404 |
hippocampal volumes | #1405 |
placebo treatment | #1407 |
hama | #1408 |
create | #1409 |
preparations | #1410 |
personality inventory | #1412 |
1998 | #1413 |
issue | #1414 |
shyness | #1414 |
independent | #1415 |
impressions | #1416 |
prepubertal children | #1416 |
332 | #1417 |
logical | #1419 |
carry | #1419 |
humans memory | #1421 |
parents children | #1422 |
discoveries | #1422 |
exploratory factor analysis | #1423 |
greater | #1426 |
dosed | #1427 |
linkage disequilibrium | #1430 |
163 | #1431 |
taps | #1431 |
interaction effects | #1432 |
cognitive profiles | #1432 |
affairs | #1434 |
social perception | #1436 |
publication adult analysis | #1438 |
bche | #1439 |
academic | #1443 |
holidays | #1444 |
personality | #1447 |
psychotic illness | #1448 |
443 | #1448 |
chp | #1449 |
hydroxylase | #1450 |
prevalence obesity | #1450 |
ratings | #1451 |
height | #1453 |
78 | #1453 |
square | #1453 |
ewas | #1453 |
population stratification | #1454 |
hypermethylation | #1454 |
switching | #1455 |
dorsal striatum | #1457 |
replicability | #1457 |
collaborations | #1457 |
generalized anxiety | #1458 |
comparisons | #1459 |
severe depression | #1462 |
stronger | #1463 |
biological pathways | #1463 |
treatment duration | #1464 |
principal | #1467 |
discordant | #1467 |
partial remission | #1468 |
valuable | #1468 |
untranslated | #1468 |
groups differences | #1469 |
hippocampi | #1469 |
contrast effects | #1472 |
cognition patients | #1474 |
openlabel | #1474 |
statistically | #1474 |
amygdala volume | #1477 |
risk relapse | #1479 |
conducted | #1480 |
medication | #1481 |
cortex dlpfc | #1487 |
prodromal symptoms | #1488 |
issues | #1489 |
apt | #1492 |
adrb2 | #1493 |
hypomethylation | #1495 |
mri studies | #1497 |
allele carriers | #1497 |
smaller | #1497 |
twins monozygotic | #1499 |
lifespan | #1499 |
small sample sizes | #1499 |
converge | #1500 |
populationbased study | #1501 |
patients bipolar | #1502 |
cpt | #1503 |
male mothers | #1505 |
ddc | #1505 |
multisite | #1505 |
examination | #1508 |
salience network | #1510 |
manifestation | #1510 |
objectivity | #1511 |
existing literature | #1511 |
attained | #1513 |
emotions female | #1513 |
reports | #1513 |
messaging | #1514 |
cognitive ability | #1515 |
pedigree | #1516 |
screening instrument | #1517 |
eicosapentaenoic acid | #1517 |
repeat | #1518 |
criminal behavior | #1519 |
165 | #1521 |
114 | #1523 |
topic | #1523 |
cna | #1523 |
inconsistency | #1526 |
bipolar patients | #1526 |
inferior frontal | #1528 |
psychiatric disorder | #1528 |
nacetylaspartate | #1528 |
symptomatology | #1530 |
512 | #1535 |
began | #1536 |
arntl | #1540 |
nucleotide risk | #1541 |
default | #1541 |
poses | #1542 |
adult life | #1542 |
dopamine receptor | #1542 |
stress disorders | #1543 |
gwass | #1544 |
yale | #1545 |
treatment schizophrenia | #1545 |
omission | #1547 |
traits | #1549 |
card | #1551 |
problem behaviors | #1554 |
influenced | #1554 |
automobile | #1556 |
857 | #1556 |
failed | #1559 |
early exposure | #1559 |
loci | #1560 |
0009 | #1561 |
0013 | #1564 |
insular | #1565 |
subscales | #1565 |
475 | #1565 |
interpersonal | #1566 |
humans interpersonal | #1569 |
wise | #1570 |
swedish | #1573 |
191 | #1573 |
consortium | #1573 |
depression children | #1574 |
neurochemistry | #1575 |
attempted | #1576 |
life quality | #1579 |
meta | #1579 |
selfreport questionnaires | #1580 |
gene networks | #1580 |
located | #1582 |
single nucleotide polymorphism | #1582 |
findings studies | #1582 |
cutoffs | #1583 |
models male | #1583 |
network dmn | #1583 |
social functioning | #1584 |
hyperactivation | #1587 |
rs4680 | #1588 |
firstepisode schizophrenia | #1588 |
major depressive | #1588 |
genetic data | #1589 |
pain patients | #1589 |
edinburgh | #1590 |
advent | #1591 |
55 | #1592 |
phobias | #1593 |
temperament | #1594 |
subcortical structures | #1596 |
162 | #1596 |
symptom presentation | #1598 |
moderators | #1599 |
tpv | #1599 |
statistics nonparametric | #1601 |
psychotropic medications | #1601 |
jan | #1602 |
managed | #1603 |
utr | #1604 |
suffer | #1604 |
spontaneously | #1605 |
heritabilities | #1606 |
classifying | #1608 |
academic achievement | #1609 |
proneness | #1610 |
1979 | #1610 |
monoamine oxidase | #1611 |
emotional faces | #1613 |
alcoholism | #1613 |
status | #1614 |
ancestry female | #1615 |
male maternal | #1616 |
drawn | #1619 |
broadly | #1620 |
distinguishing | #1622 |
large body | #1622 |
risk mental | #1622 |
hbr | #1624 |
childhood asthma | #1624 |
snp | #1626 |
paucity | #1626 |
ht2a receptor | #1627 |
spatial organization | #1627 |
louis | #1628 |
dysphoria | #1628 |
genomics humans | #1629 |
verbal behavior | #1629 |
study children | #1630 |
kyoto | #1630 |
emrs | #1631 |
ambiguous | #1631 |
memory task | #1631 |
198 | #1633 |
susceptibility gene | #1634 |
supporting | #1635 |
mental illnesses | #1637 |
positive predictive | #1638 |
lag | #1639 |
brain female | #1640 |
alpha7 | #1643 |
rack1 | #1643 |
tendency | #1643 |
social communication | #1643 |
bprs | #1644 |
potential effects | #1646 |
socially | #1647 |
interrelations | #1649 |
treating | #1650 |
rea | #1653 |
controlled | #1653 |
nucleotide polymorphisms | #1655 |
adolescents age | #1657 |
detect | #1658 |
maximize | #1658 |
require | #1659 |
psychotic disorder | #1659 |
personality disorders | #1661 |
symptom severity | #1662 |
comorbid depression | #1663 |
presentations | #1663 |
asm | #1664 |
510 | #1665 |
mood symptoms | #1666 |
chronic patients | #1666 |
dlpfc | #1666 |
association analysis | #1667 |
indexed | #1670 |
human rights | #1670 |
bipolar disorder patients | #1671 |
13 years | #1672 |
transmitted | #1673 |
asd symptoms | #1674 |
early signs | #1675 |
statements | #1675 |
alcohol spectrum | #1675 |
53 | #1677 |
calling | #1678 |
registers | #1678 |
introns | #1678 |
social anxiety | #1679 |
homogeneous | #1679 |
seat | #1680 |
beagle | #1680 |
mathematical models | #1682 |
mildly | #1684 |
46 | #1684 |
prescribed | #1684 |
memory deficit | #1685 |
ancestries | #1685 |
autistic disorder | #1689 |
github | #1689 |
mdd | #1689 |
psychotropic drugs | #1692 |
agenda | #1692 |
impulse control | #1693 |
motor skills | #1698 |
recruited | #1698 |
diagnose | #1699 |
91 | #1702 |
item | #1704 |
memory consolidation | #1704 |
conceptualization | #1705 |
middle frontal | #1710 |
reduced activation | #1711 |
personality characteristics | #1712 |
rater | #1712 |
neuroscience | #1712 |
health records | #1712 |
schizophrenia spectrum | #1713 |
net | #1716 |
perpetrators | #1725 |
nhe1 | #1728 |
autistic | #1729 |
epigenetics | #1730 |
107 | #1731 |
inhibitory control | #1731 |
cbs | #1732 |
hindered | #1733 |
machine | #1735 |
highlight | #1735 |
stand | #1736 |
identical | #1736 |
predictors | #1739 |
aimed | #1739 |
dopamine receptors | #1741 |
sex age | #1743 |
forum | #1746 |
curated | #1746 |
longitudinal analysis | #1747 |
cognitive difficulties | #1748 |
pds | #1749 |
occipital lobe | #1750 |
tremors | #1752 |
02 | #1753 |
selfreport measures | #1753 |
questionnaires young | #1755 |
sertraline | #1756 |
326 | #1756 |
5ht2a | #1758 |
120 | #1758 |
social | #1761 |
genetic models | #1761 |
ventral striatum | #1761 |
drowsiness | #1763 |
bipolar affective | #1763 |
includes | #1765 |
chance | #1765 |
adult onset | #1766 |
operant | #1768 |
mystery | #1768 |
reflects | #1769 |
sisters | #1770 |
dopamine | #1772 |
treatment implications | #1773 |
dizygotic twins | #1773 |
depressive episode | #1775 |
patients systemic | #1775 |
patients adult | #1776 |
267 | #1776 |
mental recall | #1777 |
establishing | #1777 |
utrs | #1779 |
10−7 | #1780 |
early childhood | #1781 |
commonalities | #1786 |
higher doses | #1786 |
major | #1786 |
social anxiety disorder | #1787 |
defined | #1789 |
male motor | #1791 |
frustration | #1791 |
transdermal | #1793 |
disorder mdd | #1795 |
harbor | #1796 |
causal variants | #1797 |
positive association | #1797 |
disabilities | #1797 |
autism spectrum disorders | #1800 |
reporters | #1801 |
members | #1801 |
aged models | #1801 |
genetic variance | #1802 |
chapters | #1803 |
shr | #1804 |
females | #1805 |
families children | #1806 |
based analysis | #1807 |
covariation | #1807 |
168 | #1809 |
nucleotide polymorphism | #1812 |
expanded | #1812 |
european descent | #1813 |
146 | #1813 |
aetiology | #1813 |
frequently | #1815 |
internationality | #1815 |
purchases | #1816 |
brain imaging | #1816 |
lds | #1819 |
hippocampal volume | #1819 |
cohens | #1819 |
correlate | #1823 |
suicide attempt | #1825 |
endpoint | #1827 |
followup | #1830 |
splenium | #1831 |
binocular | #1833 |
foundation | #1833 |
psychotic patients | #1837 |
suggested | #1838 |
94 | #1840 |
patterns | #1841 |
neural activity | #1841 |
trauma exposure | #1842 |
assessment tools | #1842 |
twins | #1845 |
initiative | #1845 |
distinctions | #1845 |
literacy | #1846 |
pertinent | #1847 |
psychological | #1847 |
warrant | #1848 |
environmental risk | #1848 |
polymorphisms | #1849 |
limited | #1850 |
vocabulary | #1851 |
fearful | #1851 |
individual | #1851 |
nonparametric | #1852 |
differentiating | #1853 |
young | #1853 |
brainderived neurotrophic factor | #1853 |
persons | #1855 |
abuse | #1856 |
auditory hallucinations | #1856 |
prevalence | #1859 |
tph | #1859 |
incentives | #1860 |
behavioral measures | #1860 |
cnb | #1861 |
affiliation | #1861 |
8p | #1862 |
obstacle | #1864 |
poison | #1865 |
vocalization | #1865 |
switch | #1865 |
multilevel | #1865 |
severely | #1867 |
18 | #1869 |
structural functional | #1875 |
constitute | #1876 |
manuscript | #1877 |
roc curve | #1879 |
histograms | #1879 |
shrs | #1880 |
animal model | #1880 |
delusions | #1881 |
afb | #1882 |
longer duration | #1882 |
common genetic variation | #1883 |
genome | #1885 |
false | #1888 |
differs | #1888 |
metaanalysis studies | #1890 |
substance abuse | #1890 |
heterogeneous | #1894 |
spanning | #1894 |
susceptibility genes | #1896 |
latent class analysis | #1899 |
maintained | #1899 |
correspondences | #1901 |
psychostimulant | #1902 |
analyses | #1903 |
chinese | #1903 |
illicit drug | #1904 |
actigraphy | #1905 |
increasingly | #1907 |
specific symptoms | #1907 |
emotion | #1908 |
majority | #1909 |
epidemiologic | #1909 |
ads | #1910 |
disorders mental | #1911 |
support vector machine | #1911 |
structural differences | #1912 |
generation antipsychotics | #1913 |
africanamericans | #1915 |
χ2 | #1916 |
10h | #1920 |
inform | #1921 |
satisfied | #1923 |
liking | #1923 |
association maternal | #1923 |
child cross | #1926 |
aggregate | #1926 |
overview | #1927 |
sleep problems | #1928 |
251 | #1928 |
advertising | #1928 |
empirical studies | #1929 |
ssri | #1930 |
95 cis | #1934 |
asd children | #1934 |
borderline personality disorder | #1937 |
simulation study | #1937 |
exomes | #1938 |
stratified | #1939 |
general | #1942 |
25 years | #1945 |
literature review | #1947 |
neurobehavioral | #1949 |
representing | #1950 |
traumatic brain injury | #1950 |
trait loci | #1952 |
accumbens | #1953 |
normal children | #1954 |
efficacious | #1957 |
msp | #1958 |
neurotransmitter release | #1959 |
mems | #1961 |
intolerant | #1962 |
micronesia | #1963 |
896 | #1964 |
sdq | #1967 |
brain networks | #1968 |
vital signs | #1969 |
sorting | #1971 |
depression | #1972 |
clinical implications | #1972 |
correctly | #1972 |
connectivity | #1974 |
hoc | #1975 |
factors surveys | #1976 |
child depression | #1977 |
repeats | #1977 |
listing | #1978 |
conflicting | #1978 |
hippocampus humans | #1981 |
ptsd | #1981 |
chinese population | #1984 |
common mental disorders | #1984 |
phase 3 trial | #1986 |
pax5 | #1986 |
secondary analysis | #1987 |
brain | #1989 |
school | #1990 |
predisposing | #1991 |
current paper | #1994 |
genetic differences | #1996 |
226 | #1997 |
fmr | #1998 |
pattern | #1999 |
diagnosed | #2001 |
comparable | #2002 |
spouses | #2003 |
asian continental ancestry | #2005 |
formulations | #2005 |
harm avoidance | #2007 |
functional variants | #2010 |
behavioral symptoms | #2011 |
nos1 | #2012 |
akt1 | #2014 |
muscle function | #2014 |
absence | #2014 |
sms | #2015 |
noradrenergic | #2015 |
possibility | #2016 |
cognitive deficits | #2016 |
prescribers | #2021 |
159 | #2023 |
schoolage children | #2023 |
serve | #2026 |
sleep disturbances | #2030 |
phenomenology | #2030 |
memory verbal | #2031 |
brain responses | #2031 |
regional brain | #2032 |
neurodevelopmental disorders | #2033 |
morbid | #2036 |
prenatally | #2037 |
receptors nicotinic | #2037 |
diminished | #2040 |
retest reliability | #2040 |
erythematosus systemic | #2041 |
asperger | #2041 |
nicotinic acetylcholine | #2045 |
cognitive processing | #2046 |
227 | #2046 |
informants | #2048 |
erythematosus | #2049 |
cognition | #2050 |
functional | #2050 |
juvenile | #2052 |
contribute | #2054 |
adolescent behavior | #2056 |
external control | #2057 |
chapman | #2058 |
insula | #2061 |
common diseases | #2061 |
educated | #2062 |
stabilizers | #2064 |
ongoing | #2065 |
overweight obesity | #2066 |
demography | #2066 |
val158met polymorphism | #2067 |
preschool humans | #2068 |
massachusetts | #2069 |
functional mri | #2069 |
0008 | #2071 |
phenotypic | #2072 |
parental education | #2072 |
psychotic symptoms | #2077 |
international consensus | #2078 |
degree | #2078 |
descent | #2079 |
wake disorders | #2079 |
heterogeneity studies | #2082 |
psychomotor | #2084 |
male gender | #2085 |
5 ht2a | #2087 |
latent class | #2090 |
43 | #2090 |
factors child | #2093 |
49 | #2095 |
wky shr | #2096 |
aud | #2096 |
subsets | #2099 |
69 | #2100 |
dopaminergic | #2100 |
142 | #2102 |
general factor | #2106 |
age children | #2107 |
ht2a | #2108 |
adult population | #2108 |
causation | #2109 |
child relations | #2112 |
specific genetic | #2112 |
nicotinic | #2112 |
279 | #2115 |
brain dysfunction | #2115 |
83 | #2117 |
relative age | #2119 |
postpartum period | #2119 |
monoamine | #2119 |
poorer | #2119 |
84 | #2121 |
pgs | #2122 |
career | #2122 |
51 | #2122 |
sixth | #2124 |
pbls | #2126 |
identifies | #2126 |
dysfunctional | #2128 |
biased | #2129 |
ovid | #2130 |
functional polymorphism | #2132 |
rates | #2134 |
episode schizophrenia | #2137 |
dbh | #2137 |
psychosocial factors | #2140 |
adversities | #2141 |
interpretability | #2141 |
discrepant | #2142 |
relevant literature | #2143 |
methods participants | #2145 |
pvs | #2145 |
behavioral disorders | #2146 |
105 | #2147 |
intraclass | #2147 |
receptors adrenergic | #2147 |
juveniles | #2148 |
abnormalities | #2149 |
represents | #2150 |
232 | #2150 |
finemapping | #2150 |
glutamatergic | #2150 |
repositioning | #2151 |
assessing | #2151 |
rrr | #2153 |
mao | #2153 |
psychiatric patients | #2155 |
abdominal obesity | #2164 |
differentiated | #2164 |
clinical assessments | #2166 |
declarative memory | #2167 |
shr wky | #2167 |
differing | #2168 |
genetic association studies | #2168 |
differential diagnostic | #2168 |
glx | #2169 |
major depressive disorder | #2170 |
mb | #2171 |
prevalences | #2171 |
adversely | #2171 |
tardive dyskinesia | #2172 |
severity | #2172 |
aggregated | #2177 |
irt | #2180 |
moderating | #2181 |
externalizing | #2181 |
environmental factors | #2183 |
author | #2185 |
report measures | #2186 |
teachers | #2187 |
thought | #2188 |
computerassisted imaging | #2188 |
differential expression | #2189 |
processing speed | #2189 |
generalized anxiety disorder | #2192 |
scale | #2192 |
regular | #2192 |
serotonin 5 | #2193 |
imaging fmri | #2195 |
conceptual | #2197 |
lifecycle | #2197 |
pharmacological agents | #2199 |
achievement | #2200 |
ages | #2201 |
confounding | #2201 |
double | #2205 |
brain mapping | #2206 |
developing brain | #2206 |
abstract background | #2207 |
ottawa | #2209 |
169 | #2209 |
remained | #2209 |
accidents | #2210 |
surveys questionnaires | #2210 |
homozygosity | #2210 |
antenatal | #2211 |
illness severity | #2211 |
genetic relationship | #2212 |
occurrences | #2217 |
adverse event | #2217 |
intronic | #2219 |
biologically | #2220 |
hippocampal formation | #2220 |
complex diseases | #2220 |
completed | #2220 |
autism | #2221 |
val66met | #2222 |
cognitive task | #2225 |
visuospatial | #2225 |
20th | #2226 |
replicating | #2227 |
single | #2228 |
caudate putamen | #2229 |
trail making | #2230 |
clinical profile | #2232 |
attainment | #2234 |
community sample | #2235 |
controls age | #2238 |
hexokinase | #2241 |
prototypical | #2241 |
implications | #2242 |
qualities | #2244 |
insensitivity | #2245 |
consultation | #2246 |
preliminary data | #2248 |
hamilton | #2253 |
val66met polymorphism | #2254 |
pubertal development | #2257 |
treatment guidelines | #2260 |
genomic analysis | #2260 |
cognitive deficit | #2263 |
novo mutations | #2263 |
earlier | #2264 |
cigarette | #2264 |
criterion | #2265 |
pathways | #2266 |
bds | #2266 |
rewards | #2266 |
clinical measures | #2267 |
evident | #2273 |
overdiagnosis | #2274 |
remain | #2275 |
gray matter volume | #2275 |
axis | #2275 |
cognitive development | #2275 |
tend | #2276 |
random allocation | #2277 |
mtl | #2277 |
imaging male | #2277 |
systemic lupus | #2279 |
apneahypopnea | #2279 |
lithium | #2283 |
moderation | #2283 |
psychiatric illness | #2285 |
cognitive | #2287 |
controlling | #2290 |
minority | #2292 |
update | #2293 |
physical health | #2294 |
diverse populations | #2294 |
regions | #2294 |
socialization | #2295 |
retained | #2297 |
monitored | #2298 |
11 years | #2299 |
corticotropin | #2301 |
biology | #2304 |
clinic | #2304 |
239 | #2304 |
adjunctive | #2306 |
virtue | #2307 |
consisting | #2308 |
difficult | #2310 |
lupus | #2310 |
enormous | #2311 |
pregnancy | #2313 |
brain anatomy | #2313 |
edition | #2315 |
behaviors | #2317 |
adequate | #2318 |
performance reaction | #2319 |
brain systems | #2321 |
tests | #2321 |
fmri | #2325 |
casecontrol study | #2326 |
memory performance | #2328 |
higher prevalence | #2330 |
257 | #2331 |
questionnaires | #2332 |
organ size | #2332 |
subset | #2333 |
mind | #2334 |
archives | #2335 |
covariate | #2335 |
disorganization | #2335 |
early risk | #2336 |
depression female | #2340 |
lesser extent | #2342 |
utility | #2342 |
functional networks | #2344 |
nature | #2344 |
20th century | #2345 |
cingulate | #2346 |
schedule | #2350 |
time perception | #2353 |
providing | #2353 |
mapping child | #2358 |
powered | #2362 |
adolescent brain | #2364 |
endosome | #2365 |
factor structure | #2367 |
limited evidence | #2368 |
concurrently | #2368 |
symptoms schizophrenia | #2369 |
smallest | #2369 |
efforts | #2376 |
social cognitive | #2377 |
catecholamine | #2379 |
antipsychotic agents | #2379 |
tapping | #2384 |
predicts | #2385 |
ecologically | #2386 |
gyrus | #2388 |
drugs abuse | #2391 |
unresolved | #2393 |
convergence | #2395 |
raising | #2395 |
problem solving | #2398 |
essence | #2401 |
gray matter | #2401 |
frontal | #2403 |
pubmed | #2406 |
addictive | #2407 |
sirolimus | #2407 |
adolescent alcohol | #2408 |
distinguished | #2410 |
validate | #2412 |
preserved | #2414 |
genetic factor | #2417 |
statistical significance | #2418 |
alternative | #2418 |
modules | #2419 |
illumina | #2422 |
starting | #2423 |
classified | #2425 |
salience | #2426 |
disease genetic | #2426 |
143 | #2428 |
bdnf | #2429 |
term outcome | #2429 |
fmri data | #2431 |
confounders | #2431 |
protein interactions | #2433 |
clinical trial | #2433 |
241 | #2433 |
protein interaction | #2436 |
analyzes | #2440 |
careful | #2443 |
intellectual | #2447 |
dimorphism | #2448 |
timepoints | #2448 |
items | #2449 |
multiple studies | #2450 |
deconvolution | #2452 |
mvr | #2452 |
prefrontal cortical | #2456 |
systemic lupus erythematosus | #2456 |
overweight children | #2456 |
moderately | #2458 |
myoinositol | #2459 |
genetic susceptibility | #2459 |
anxiety symptoms | #2460 |
brain maturation | #2460 |
traumatic stress | #2461 |
logistic | #2461 |
concordance | #2461 |
autosomes | #2462 |
crossover study | #2464 |
sex distribution | #2464 |
factor bdnf | #2466 |
hungary | #2469 |
unique | #2473 |
unclear | #2473 |
relatedness | #2482 |
brain activation | #2486 |
reaction time | #2488 |
higher scores | #2489 |
prescriptions | #2489 |
psychomotor performance | #2491 |
cerebrum | #2494 |
normative data | #2495 |
hoc analysis | #2496 |
180 | #2496 |
caucasian | #2497 |
israeli | #2500 |
workplace | #2502 |
establish | #2504 |
original | #2504 |
random forest | #2507 |
interactome | #2509 |
randomized placebo | #2511 |
preschool diagnosis | #2512 |
21st | #2512 |
heterosis | #2513 |
quotient | #2515 |
thresholds | #2515 |
preceded | #2516 |
tricyclic antidepressants | #2518 |
evaluate | #2521 |
perceptual | #2523 |
temporal gyrus | #2526 |
12 years | #2528 |
rel | #2531 |
alterations | #2532 |
october | #2532 |
preliminary report | #2533 |
indicators | #2534 |
thinner | #2539 |
limitations | #2541 |
categories | #2545 |
neurosecretory | #2546 |
medication adherence | #2548 |
animals anxiety | #2550 |
psychotic features | #2553 |
risky | #2553 |
depressive disorders | #2554 |
exploratory study | #2555 |
quantitative | #2555 |
neural responses | #2555 |
bipolar affective disorder | #2557 |
memory tasks | #2557 |
chronological | #2560 |
income | #2560 |
risk loci | #2560 |
assisted magnetic | #2561 |
060 | #2562 |
273 | #2563 |
demographic characteristics | #2565 |
447 | #2565 |
sensation seeking | #2569 |
174 | #2570 |
discontinued | #2571 |
document | #2572 |
numerous | #2573 |
30 years | #2573 |
19 years | #2574 |
cool | #2575 |
depressed | #2576 |
socioeconomic | #2579 |
osmosis | #2580 |
smoking alcohol | #2581 |
adolescent females | #2584 |
correction | #2585 |
elucidate | #2585 |
pvalues | #2586 |
brothers | #2586 |
problems | #2586 |
pituitary adrenal | #2587 |
baseline | #2591 |
post traumatic | #2594 |
exist | #2595 |
disrupted | #2595 |
229 | #2596 |
brain response | #2598 |
internalizing externalizing | #2598 |
temporal pole | #2600 |
encouraging | #2601 |
iowa | #2603 |
simplex | #2603 |
n10 | #2605 |
neo | #2606 |
percentile | #2607 |
literature | #2608 |
infrequent | #2610 |
increased activation | #2611 |
advances | #2611 |
occipital | #2612 |
draft | #2614 |
lateralization | #2616 |
surveys humans | #2619 |
pooling | #2620 |
genotype | #2623 |
evidence role | #2624 |
multiple levels | #2624 |
kynurenine | #2625 |
psycinfo | #2625 |
mothers | #2630 |
imaging studies | #2633 |
bdnf gene | #2633 |
preliminary | #2634 |
institute | #2636 |
odors | #2638 |
182 | #2639 |
fetal alcohol | #2642 |
global functioning | #2642 |
preschool female | #2644 |
behavior | #2644 |
genetic variants | #2644 |
medical conditions | #2645 |
inability | #2645 |
future | #2648 |
borderline personality | #2652 |
brain derived | #2655 |
tmax | #2659 |
dysregulation | #2663 |
electronic health | #2664 |
periodicals | #2665 |
puzzle | #2665 |
n14 | #2666 |
089 | #2669 |
health disorders | #2669 |
genetic evidence | #2670 |
88 | #2670 |
chromosome | #2670 |
polysomnography | #2671 |
spectrum | #2675 |
pcps | #2675 |
inconclusive | #2676 |
mediating | #2676 |
partially | #2676 |
physiotherapy | #2678 |
adolescent development | #2678 |
memory tests | #2678 |
maternal behavior | #2679 |
increased activity | #2681 |
disadvantaged | #2685 |
adrenergic | #2687 |
widespread | #2688 |
age range | #2689 |
triad | #2689 |
conditional | #2689 |
listening | #2690 |
reading | #2692 |
entry | #2692 |
promoter region | #2694 |
evaluating | #2695 |
tfs | #2696 |
evidenced | #2698 |
immaturity | #2698 |
extended | #2700 |
chr | #2701 |
attenuate | #2702 |
neurite | #2702 |
interrogation | #2702 |
flares | #2703 |
ext | #2707 |
delinquency | #2707 |
hemispheric asymmetry | #2709 |
internalizing problems | #2710 |
404 | #2713 |
occurring | #2714 |
aggressive | #2714 |
quarter | #2718 |
positively correlated | #2719 |
purposes | #2721 |
choosing | #2723 |
thinking | #2724 |
internalizing | #2726 |
hold | #2727 |
teens | #2731 |
curve | #2731 |
awakening | #2732 |
systematic literature review | #2733 |
thicker | #2733 |
doubt | #2733 |
alcohol dependence | #2736 |
potential association | #2740 |
pdi | #2752 |
prepubertal | #2753 |
cortices | #2753 |
eventually | #2755 |
collaboration | #2760 |
naa | #2760 |
patients bipolar disorder | #2760 |
gt | #2761 |
manifestations | #2762 |
unadjusted | #2765 |
4 years | #2765 |
created | #2768 |
ccs | #2769 |
reproducibility | #2773 |
psychiatric diseases | #2773 |
phencyclidine | #2775 |
depression severity | #2776 |
preventive measures | #2777 |
25 | #2777 |
clinical heterogeneity | #2783 |
mechanisms underlying | #2783 |
bivariate | #2784 |
children symptoms | #2784 |
panic attacks | #2785 |
6 12 | #2788 |
tactile | #2790 |
411 | #2791 |
dna copy | #2791 |
dyslexia | #2792 |
neurotrophic factor | #2794 |
overt | #2794 |
auditory perception | #2796 |
constellation | #2796 |
suicidality | #2799 |
explained | #2802 |
958 | #2803 |
dependence | #2804 |
references | #2806 |
clinical experience | #2808 |
recognition visual | #2808 |
397 | #2809 |
monetary | #2809 |
misdiagnosis | #2809 |
goodness | #2810 |
predefined | #2812 |
disc1 | #2815 |
midnight | #2816 |
gene polymorphism | #2816 |
primary caregivers | #2817 |
subsequent | #2819 |
circuitry | #2823 |
indexes | #2823 |
1300 | #2824 |
telephone | #2824 |
comorbidities | #2825 |
pediatric obesity | #2827 |
intervention strategies | #2828 |
and or | #2830 |
refusal | #2833 |
disorder characterized | #2835 |
tested | #2838 |
discriminant validity | #2839 |
early recognition | #2839 |
adoption | #2841 |
reelin | #2843 |
treatment study | #2843 |
prefrontal cortex | #2844 |
socioeconomic status | #2846 |
emotional intelligence | #2849 |
early identification | #2850 |
matter volume | #2852 |
parent child | #2853 |
disabled | #2856 |
restless legs syndrome | #2857 |
suicide attempted | #2858 |
depression scale | #2863 |
continental ancestry | #2863 |
parenting parents | #2865 |
screened | #2866 |
addresses | #2866 |
mothers children | #2867 |
internal external | #2867 |
cognition humans | #2868 |
discordance | #2868 |
focus | #2869 |
silico | #2870 |
psychosocial stress | #2872 |
splicing | #2875 |
diagnosis differential | #2876 |
gwa | #2878 |
sixteen | #2880 |
appeared | #2884 |
measure | #2884 |
citations | #2885 |
age differences | #2885 |
shifting | #2885 |
rare variants | #2887 |
protective effects | #2889 |
trinucleotide | #2890 |
brain size | #2900 |
asr | #2901 |
alternate | #2902 |
debate | #2903 |
duplicate | #2905 |
low birth weight | #2906 |
alcohol disorder | #2907 |
newer | #2909 |
independent component analysis | #2911 |
etiologies | #2912 |
behavior children | #2913 |
precursor | #2914 |
cognitive control | #2916 |
amph | #2916 |
institutes | #2919 |
variability | #2919 |
biological mechanisms | #2919 |
age study | #2921 |
genetic contributions | #2922 |
115 | #2924 |
attentional | #2925 |
subject | #2928 |
behavioral outcomes | #2931 |
486 | #2931 |
adherence | #2932 |
92 | #2935 |
machine learning | #2941 |
causal relationship | #2942 |
disorders sleep | #2942 |
disorders patients | #2946 |
distinct | #2946 |
motor control | #2953 |
pcb | #2956 |
smoked | #2959 |
journal | #2965 |
facilitating | #2967 |
previous | #2968 |
331 | #2970 |
markers | #2971 |
overlaps | #2971 |
models neurological | #2976 |
stratification | #2981 |
qtl | #2983 |
725 | #2983 |
weight height | #2988 |
investigators | #2989 |
imaging mri | #2991 |
attempts | #2991 |
tic | #2997 |
performance measures | #2997 |
overweight | #2998 |
variants | #2999 |
subjective | #3000 |
bold | #3002 |
referral | #3005 |
196 | #3006 |
centres | #3006 |
377 | #3007 |
19th century | #3010 |
remission | #3011 |
genetic variation | #3011 |
genetic promoter regions | #3012 |
resonance imaging | #3016 |
987 | #3017 |
chen | #3018 |
worldwide | #3020 |
response relationship | #3021 |
inferior frontal gyrus | #3022 |
disease susceptibility | #3023 |
mouse models | #3024 |
choice | #3028 |
conference | #3030 |
models psychological | #3033 |
familiarity | #3034 |
emotion dysregulation | #3036 |
symptoms patients | #3039 |
difficulties questionnaire | #3039 |
female humans life | #3040 |
thomson | #3044 |
neural correlates | #3047 |
variants genes | #3053 |
developmental | #3054 |
treatment adherence | #3054 |
protective factor | #3057 |
improvement | #3058 |
280 | #3061 |
pilot | #3061 |
fear female | #3063 |
117 | #3064 |
ultimately | #3065 |
339 | #3068 |
216 | #3072 |
stress reactivity | #3073 |
p0004 | #3074 |
frontal lobe | #3076 |
appears | #3077 |
cortical | #3078 |
driving | #3078 |
positive | #3079 |
sociodemographics | #3081 |
males | #3089 |
key findings | #3092 |
pairwise | #3093 |
allelic | #3094 |
pregnancy women | #3095 |
predictable | #3098 |
stressful life | #3098 |
modified version | #3099 |
central nervous | #3104 |
intron | #3105 |
brain health | #3107 |
076 | #3107 |
naïve | #3110 |
siemens | #3111 |
interviewed | #3114 |
symptoms study | #3116 |
amygdala hippocampus | #3123 |
articles | #3123 |
marijuana abuse | #3124 |
mass screening | #3125 |
ptsd symptoms | #3127 |
383 | #3127 |
functional laterality | #3129 |
tcc | #3132 |
psychiatrist | #3133 |
temporal cortex | #3134 |
childhood adversity | #3135 |
pharmacies | #3137 |
maternal | #3142 |
accuracies | #3144 |
nation | #3146 |
european countries | #3146 |
99 | #3150 |
exploratory | #3150 |
ancestry | #3151 |
behavior social | #3152 |
pharmacokinetic | #3157 |
oxford | #3157 |
spd | #3165 |
explanations | #3165 |
biological processes | #3166 |
functional consequences | #3166 |
aggregation | #3168 |
hippocampal | #3169 |
teenagers | #3170 |
caution | #3171 |
status humans | #3171 |
report | #3174 |
hypophyseal | #3175 |
math | #3176 |
wealth | #3178 |
contrast | #3180 |
imaging study | #3187 |
methyltransferase | #3187 |
adolescents young adults | #3187 |
receiver | #3188 |
prodrug | #3189 |
published | #3190 |
view | #3190 |
emotion processing | #3195 |
collect | #3195 |
comprehension | #3201 |
initial treatment | #3202 |
attempt | #3202 |
erythematosus sle | #3205 |
answers | #3208 |
normative | #3209 |
naming | #3212 |
snvs | #3214 |
pathophysiological | #3216 |
gene polymorphisms | #3216 |
psychotherapy | #3222 |
environment | #3223 |
angeles | #3228 |
scanner | #3229 |
situation | #3229 |
discontinuity | #3229 |
65 | #3235 |
depression study | #3236 |
htt | #3237 |
mediation analysis | #3237 |
414 | #3239 |
abstinence | #3241 |
databases genetic | #3247 |
determine | #3250 |
features | #3254 |
210 | #3255 |
211 | #3257 |
correlated | #3257 |
caudate nucleus | #3265 |
publicly | #3265 |
interactive effects | #3266 |
17p | #3266 |
humans magnetic | #3266 |
moderator | #3269 |
370 | #3270 |
symbols | #3271 |
researchers | #3272 |
prefrontal cortex pfc | #3274 |
expertise | #3276 |
memory processing | #3281 |
increased likelihood | #3282 |
longitudinal cohort | #3282 |
cognitive functioning | #3289 |
condition | #3291 |
glutamate receptor | #3296 |
replication | #3297 |
surveys | #3299 |
strict | #3304 |
contributed | #3305 |
clinical severity | #3306 |
synaptic function | #3306 |
genomics | #3309 |
restrictions | #3314 |
corrected | #3315 |
attribute | #3316 |
spearman | #3321 |
digit | #3322 |
neuroimaging data | #3323 |
differently | #3325 |
fewer | #3331 |
earlier studies | #3333 |
mrt | #3334 |
metropolitan | #3336 |
ambiguity | #3336 |
clock gene | #3336 |
417 | #3340 |
6 | #3343 |
slide | #3345 |
revealing | #3348 |
clinical | #3351 |
hoc analyses | #3352 |
healthy control | #3354 |
affect | #3357 |
national institute | #3359 |
functional studies | #3361 |
april | #3362 |
friend | #3366 |
motivational | #3367 |
retest | #3369 |
067 | #3370 |
glycolysis | #3371 |
battery | #3371 |
frontal regions | #3371 |
treatment strategies | #3373 |
cortex pfc | #3375 |
088 | #3376 |
marker | #3379 |
functional neuroimaging | #3382 |
initially | #3384 |
sex chromosomes | #3385 |
impaired performance | #3386 |
typically developing | #3386 |
stressful life events | #3387 |
monozygotic | #3389 |
clock genes | #3390 |
multimorbidity | #3390 |
health children | #3392 |
accounting | #3393 |
cnp | #3393 |
ifg | #3398 |
358 | #3402 |
baseline followup | #3404 |
depression symptoms | #3405 |
traumatic brain | #3405 |
desirability | #3406 |
oxidase | #3411 |
pool | #3413 |
performing | #3413 |
aucs | #3415 |
lack | #3419 |
health surveys | #3422 |
therapeutic response | #3423 |
longitudinal data | #3426 |
stepwise | #3431 |
03 | #3433 |
pediatric population | #3436 |
definition | #3439 |
experiencing | #3439 |
exert | #3441 |
fluency | #3446 |
showing | #3448 |
lca | #3448 |
children mothers | #3448 |
schoolaged children | #3449 |
lowered | #3450 |
supports | #3455 |
psychotropic medication | #3455 |
inception | #3457 |
schooling | #3461 |
estimating | #3463 |
differentiate | #3464 |
genomewide association study | #3466 |
hallucinations | #3466 |
cognitive behavioral | #3466 |
male sex | #3472 |
bilaterally | #3473 |
scan | #3475 |
methylation | #3477 |
remaining | #3477 |
behavioral response | #3478 |
irr | #3480 |
postmortem | #3482 |
transmission | #3482 |
slower | #3488 |
lesser | #3489 |
convergent | #3489 |
exposure pregnancy | #3489 |
epidemiological study | #3492 |
applying | #3492 |
aged polymorphism | #3497 |
083 | #3497 |
alpha2 | #3497 |
social behaviors | #3497 |
short stature | #3497 |
matched healthy | #3502 |
brain function | #3506 |
p002 | #3506 |
identifier | #3506 |
antidepressants | #3512 |
checklist | #3514 |
sans | #3518 |
specificity | #3519 |
104 | #3519 |
113 | #3520 |
antipsychotic | #3524 |
spouse | #3525 |
constitutes | #3527 |
pediatricians | #3527 |
basis | #3527 |
reflect | #3529 |
asperger syndrome | #3529 |
clinical phenotype | #3533 |
rett syndrome | #3535 |
reliable | #3536 |
preferentially | #3536 |
enrichment analysis | #3538 |
social behavior | #3539 |
school aged | #3540 |
mother child | #3541 |
cognitive behavioral therapy | #3544 |
sleep wake | #3544 |
fact | #3544 |
coming | #3545 |
rts | #3546 |
documentation | #3547 |
score | #3548 |
dmn | #3550 |
344 | #3557 |
ecgs | #3558 |
neuronal function | #3558 |
preventive interventions | #3558 |
prevalence estimates | #3563 |
suggestions | #3564 |
genetic analysis | #3567 |
psychiatrists | #3568 |
prevent | #3569 |
prospectively | #3570 |
developmental stages | #3573 |
psychosocial interventions | #3579 |
genotyping | #3580 |
reliability | #3583 |
mse | #3585 |
collaborative | #3585 |
neurite outgrowth | #3587 |
mpfc | #3587 |
crh | #3603 |
interrater reliability | #3604 |
major gene | #3606 |
cardio | #3606 |
consists | #3609 |
299 | #3613 |
screen | #3614 |
modalities | #3617 |
questions | #3618 |
methylation status | #3618 |
348 | #3620 |
races | #3621 |
pharmacogenetics | #3622 |
objectives | #3623 |
reviewed | #3624 |
article | #3625 |
214 | #3626 |
101 | #3628 |
neglect | #3630 |
185 | #3631 |
hypothalamo | #3634 |
prior | #3640 |
posttraumatic stress | #3640 |
seeking | #3641 |
wgs | #3648 |
cohesion | #3653 |
enrolment | #3654 |
facilitate | #3660 |
negative | #3661 |
downward | #3662 |
study association | #3663 |
increased prevalence | #3666 |
socioeconomic factors | #3668 |
weight | #3669 |
93 | #3670 |
administration oral | #3672 |
captured | #3675 |
360 | #3681 |
1st | #3682 |
genotype data | #3686 |
behavior problems | #3690 |
frontal lobes | #3691 |
marijuana | #3695 |
online survey | #3696 |
nacetylcysteine | #3700 |
disorders animals | #3703 |
oe | #3705 |
problem behavior | #3707 |
effort | #3711 |
brain cognition | #3719 |
manipulations | #3722 |
9 years | #3729 |
situations | #3730 |
pha | #3732 |
070 | #3733 |
ultimate | #3734 |
daily life | #3735 |
neurotransmission | #3735 |
fifty | #3736 |
depressed mood | #3737 |
hapmap | #3737 |
population | #3738 |
therapy cbt | #3744 |
international | #3744 |
relative | #3745 |
offer | #3746 |
reply | #3750 |
persisted | #3751 |
shortterm | #3753 |
epigenesis genetic | #3755 |
depression risk | #3756 |
proportional | #3757 |
333 | #3758 |
neurophysiological | #3758 |
interim analysis | #3760 |
comprehensive assessment | #3767 |
315 | #3777 |
addiction | #3780 |
transitions | #3781 |
recognition psychology | #3782 |
cocaine disorders | #3783 |
promoter polymorphism | #3787 |
peers | #3787 |
1012 | #3791 |
nonresponse | #3794 |
predictive validity | #3797 |
discriminate | #3800 |
forecast | #3802 |
monozygotic twins | #3803 |
statistical analyses | #3806 |
355 | #3809 |
ways | #3814 |
scientific | #3822 |
dimensions | #3824 |
030 | #3825 |
neurotransmitter | #3829 |
acetylcysteine | #3835 |
inclusion | #3837 |
male marijuana | #3844 |
exchanger | #3844 |
disease genes | #3850 |
children aged | #3850 |
developmental disorders | #3850 |
risk development | #3851 |
elevations | #3851 |
midlife | #3852 |
36 | #3854 |
rely | #3856 |
test | #3858 |
animal dopamine | #3859 |
superior temporal | #3862 |
strong | #3863 |
drug administration | #3866 |
prospective | #3872 |
explain | #3874 |
208 | #3876 |
influences | #3876 |
74 | #3876 |
p001 | #3879 |
ireland | #3882 |
mark | #3883 |
globus | #3886 |
child cohort | #3888 |
reevaluation | #3888 |
tesla | #3890 |
p0003 | #3895 |
plasma membrane | #3898 |
neurology | #3898 |
histories | #3901 |
obstetric | #3905 |
congruent | #3913 |
clinicians | #3915 |
ethnicities | #3922 |
monotherapy | #3923 |
variable | #3924 |
illnesses | #3925 |
robust | #3929 |
dbd | #3930 |
drug targets | #3931 |
suicidal behavior | #3932 |
antidepressant treatment | #3935 |
preexisting | #3937 |
specific factors | #3937 |
frontal gyrus | #3937 |
females males | #3944 |
2nd | #3945 |
directions | #3947 |
controversy | #3951 |
integrate | #3953 |
nicotine | #3956 |
normalization | #3959 |
support | #3960 |
systematic review metaanalysis | #3962 |
indicating | #3967 |
older children | #3969 |
trauma | #3970 |
disease control | #3971 |
untreated | #3976 |
alcohol | #3978 |
brain functional | #3980 |
forecasts | #3981 |
factorial | #4000 |
categorization | #4000 |
preliminary evidence | #4000 |
vulnerabilities | #4003 |
medial prefrontal | #4004 |
primary aim | #4005 |
initiating | #4012 |
kappa | #4013 |
cortex | #4018 |
eqtls | #4021 |
construct | #4023 |
fusiform gyrus | #4032 |
represent | #4036 |
clinical improvement | #4046 |
diabetes risk | #4047 |
common variants | #4047 |
mathematics | #4051 |
modeled | #4051 |
discussion | #4051 |
consequences | #4052 |
relevant | #4057 |
contextual factors | #4058 |
jointly | #4058 |
criminal | #4060 |
divergent | #4062 |
intellectual disability | #4063 |
causal role | #4064 |
cag | #4068 |
magnetic resonance | #4068 |
serotonin uptake | #4068 |
forecasting | #4071 |
statistics | #4072 |
118 | #4074 |
portion | #4075 |
child age | #4076 |
outcomes children | #4078 |
birth order | #4082 |
belgium | #4086 |
genetic loci | #4088 |
study efficacy | #4090 |
heroin | #4090 |
clinical characteristics | #4096 |
temporal lobe | #4098 |
lobe | #4098 |
maternal depression | #4100 |
genetic variations | #4100 |
limbic | #4102 |
age matched | #4103 |
psychologists | #4103 |
list | #4105 |
evidence base | #4107 |
062 | #4109 |
eicosapentaenoic | #4113 |
traumatic | #4115 |
vary | #4117 |
plausible | #4121 |
comprises | #4121 |
epigenesis | #4128 |
cortical areas | #4130 |
relationship | #4136 |
principal components | #4139 |
244 | #4140 |
german | #4145 |
dosing | #4145 |
span | #4146 |
neuronal migration | #4148 |
sectional | #4150 |
mj | #4156 |
regression | #4158 |
extensively | #4160 |
259 | #4161 |
124 | #4164 |
indicative | #4166 |
pathophysiology | #4167 |
fm | #4169 |
somatization | #4170 |
risk depression | #4174 |
bioinformatics | #4177 |
mapping | #4178 |
sedation | #4180 |
340 | #4182 |
dopamine d3 | #4184 |
109 | #4187 |
mri scans | #4188 |
preventive | #4190 |
military | #4191 |
lupus erythematosus | #4192 |
morphometry | #4193 |
structural connectivity | #4194 |
study differences | #4195 |
268 | #4196 |
describes | #4198 |
116 | #4199 |
transporter | #4204 |
growing | #4213 |
children age | #4215 |
helpful | #4216 |
route | #4216 |
based sample | #4218 |
suicidal thoughts | #4219 |
subgroups | #4219 |
functional magnetic | #4223 |
copy variations | #4224 |
determining | #4227 |
valproic | #4230 |
calcineurin | #4237 |
administration | #4239 |
tap | #4245 |
rat model | #4247 |
1987 | #4251 |
gpcr | #4253 |
predict | #4253 |
differential female humans | #4254 |
emerge | #4256 |
mortem | #4259 |
representative | #4263 |
trajectory | #4263 |
confers | #4264 |
posttreatment | #4268 |
antipsychotic medication | #4269 |
225 | #4270 |
follow‐up | #4273 |
early intervention | #4276 |
paediatric | #4280 |
principal component analysis | #4282 |
contributors | #4285 |
polymorphisms genes | #4292 |
select | #4293 |
deletion | #4296 |
pressor | #4302 |
outpatients | #4305 |
demographic variables | #4309 |
child development | #4314 |
adequacy | #4315 |
potential targets | #4315 |
highest risk | #4319 |
mutual | #4324 |
cardiovascular effects | #4326 |
patients diagnosed | #4327 |
buprenorphine | #4332 |
occasion | #4341 |
cingulate cortex | #4348 |
occurs | #4350 |
chart review | #4352 |
catechol | #4353 |
acute treatment | #4353 |
segregation | #4358 |
dropouts | #4361 |
searched | #4362 |
adjunct | #4363 |
166 | #4369 |
cambridge | #4370 |
aging brain | #4372 |
logistic regression analysis | #4373 |
relation | #4375 |
exists | #4375 |
intolerance | #4378 |
mediate | #4378 |
066 | #4382 |
psychological adolescent | #4383 |
clarity | #4383 |
solving | #4391 |
docosahexaenoic | #4391 |
transcriptomic | #4391 |
human | #4393 |
volumetric | #4395 |
privacy | #4396 |
low dose | #4399 |
exon | #4404 |
sexual dimorphism | #4409 |
corpus striatum | #4410 |
impulse | #4412 |
survive | #4413 |
diverse | #4413 |
membrane glycoproteins | #4416 |
polychlorinated biphenyls | #4418 |
ethnic differences | #4424 |
intranasal | #4426 |
opioids | #4429 |
terminology | #4434 |
concurrent | #4438 |
morbidities | #4444 |
197 | #4445 |
bias | #4447 |
human studies | #4449 |
striatal dopamine | #4449 |
62 | #4454 |
genotypes | #4454 |
192 | #4461 |
symposium | #4462 |
locomotor | #4464 |
serotonergic | #4465 |
outgrowth | #4467 |
dna methylation | #4470 |
219 | #4471 |
entered | #4473 |
emissioncomputed | #4476 |
smell | #4477 |
synapse | #4482 |
compilation | #4486 |
ethical | #4490 |
criterion validity | #4491 |
fourth | #4495 |
informal | #4500 |
superior temporal gyrus | #4501 |
parametric | #4508 |
313 | #4509 |
valuation | #4516 |
disorders cognitive | #4516 |
visits | #4516 |
alcohol abuse | #4517 |
investigate | #4521 |
notion | #4525 |
laterality | #4526 |
considerable | #4540 |
postnatal day | #4540 |
multiple | #4541 |
children families | #4542 |
incentive | #4546 |
transmit | #4548 |
pharmacology | #4552 |
higher level | #4553 |
employment | #4553 |
birth | #4564 |
preschool children | #4564 |
emr | #4565 |
component | #4572 |
22 | #4573 |
neuronal differentiation | #4587 |
psd | #4587 |
address | #4593 |
origin | #4595 |
initiated | #4599 |
006 | #4603 |
≤ | #4609 |
february | #4610 |
009 | #4612 |
indices | #4613 |
israel | #4617 |
attributed | #4630 |
genomic data | #4633 |
ssris | #4634 |
television | #4636 |
head injury | #4638 |
q1 | #4643 |
clinical risk | #4643 |
question | #4648 |
unmet | #4651 |
trouble | #4651 |
regression model | #4652 |
marriage | #4658 |
microsatellite | #4660 |
deliveries | #4660 |
centers | #4660 |
anterior cingulate cortex | #4661 |
243 | #4662 |
trajectories | #4662 |
children study | #4665 |
homogeneity | #4667 |
mitigate | #4668 |
fg | #4668 |
european | #4669 |
healthy individuals | #4670 |
psychometric properties | #4673 |
routes | #4676 |
disease onset | #4679 |
subsequently | #4680 |
pregnancy risk | #4682 |
264 | #4684 |
names | #4689 |
hunt | #4696 |
accurate diagnosis | #4699 |
concerns | #4705 |
5 | #4706 |
cardiorespiratory | #4707 |
imply | #4710 |
autosomal | #4711 |
vector machine | #4715 |
hazards models | #4715 |
estimate | #4716 |
smd | #4717 |
mbr | #4719 |
sed | #4719 |
appropriateness | #4720 |
positional | #4725 |
cinahl | #4729 |
fusiform | #4730 |
eqtl | #4731 |
participants included | #4732 |
biological factors | #4735 |
drug addiction | #4736 |
prototypes | #4745 |
val | #4747 |
unemployment | #4747 |
pons | #4753 |
cooperative | #4755 |
drug | #4757 |
taiwan | #4757 |
77 | #4760 |
conflict | #4760 |
tasks | #4762 |
heavily | #4763 |
portions | #4763 |
fumarate | #4773 |
231 | #4774 |
mother | #4782 |
subjects risk | #4784 |
samples | #4791 |
noncarriers | #4791 |
sharing | #4795 |
mp | #4798 |
publication administration | #4798 |
cleaning | #4804 |
coronary artery disease | #4814 |
fractional anisotropy | #4820 |
cognitive tests | #4825 |
modafinil | #4825 |
excluding | #4832 |
surge | #4835 |
visual perception | #4836 |
experts | #4837 |
223 | #4838 |
continuity | #4843 |
sparse | #4849 |
recognized | #4853 |
imaging female | #4858 |
41 | #4865 |
rg | #4873 |
specific | #4874 |
207 | #4875 |
deterioration | #4880 |
wave | #4880 |
subsamples | #4881 |
cigarettes | #4881 |
young age | #4881 |
omega3 | #4882 |
fp | #4882 |
prisma | #4885 |
facts | #4890 |
cascades | #4891 |
eliminated | #4894 |
antiepileptic drugs | #4910 |
operating | #4914 |
002 | #4915 |
preclinical studies | #4916 |
achievements | #4923 |
early adolescence | #4923 |
additive | #4924 |
bdi | #4929 |
scored | #4929 |
parietal lobe | #4930 |
outcome measures | #4932 |
034 | #4933 |
brain activity | #4937 |
inventory | #4941 |
relating | #4947 |
delays | #4949 |
hemispheric | #4949 |
pooled analysis | #4951 |
powerful | #4951 |
snap | #4957 |
rule | #4959 |
diffusion tensor imaging | #4962 |
acetylcholine receptor | #4965 |
srs | #4967 |
212 | #4969 |
altered expression | #4972 |
eye tracking | #4973 |
explosion | #4978 |
empirical data | #4979 |
continental | #4983 |
lower | #4994 |
170 | #4995 |
022 | #5001 |
treatment modalities | #5005 |
timing | #5008 |
esr1 | #5015 |
aged nerve | #5017 |
caucasians | #5021 |
selective attention | #5021 |
disagreement | #5024 |
aug | #5025 |
rarely | #5027 |
serotonin receptors | #5029 |
variation | #5030 |
adolescent health | #5031 |
specialty | #5036 |
task | #5038 |
probabilistic | #5039 |
discuss | #5039 |
distinguish | #5040 |
correct | #5040 |
anxiety depression | #5047 |
cingulate gyrus | #5047 |
auc | #5047 |
sga | #5050 |
convergent validity | #5051 |
marital | #5051 |
early | #5051 |
predictor | #5052 |
2003 | #5055 |
analgesics | #5056 |
obesity | #5064 |
gender identity | #5067 |
bidirectional | #5067 |
18 years | #5070 |
continuation | #5077 |
cadherins | #5079 |
decreasing | #5085 |
reductions | #5086 |
chinese children | #5092 |
placebo patients | #5095 |
aes | #5097 |
epilepsy | #5099 |
reached | #5101 |
09 | #5101 |
screening | #5104 |
103 | #5104 |
relative contributions | #5105 |
qtc | #5106 |
volume reduction | #5107 |
ancestral | #5112 |
time points | #5118 |
relevance | #5119 |
variables | #5127 |
substances | #5129 |
mediation | #5132 |
single nucleotide polymorphisms | #5132 |
maladaptive | #5133 |
ppv | #5134 |
individuals risk | #5136 |
mechanisms | #5142 |
readers | #5143 |
mental retardation | #5145 |
difference | #5146 |
inherent | #5146 |
involves | #5147 |
pharmacogenomics | #5147 |
carrying | #5158 |
enrichment | #5160 |
administered | #5162 |
homozygote | #5166 |
dropout | #5168 |
biological | #5170 |
diffusivity | #5177 |
picture | #5178 |
ventral | #5181 |
reuptake inhibitors | #5182 |
extent | #5183 |
dopamine d1 | #5187 |
adjustment | #5190 |
238 | #5193 |
disability | #5193 |
predictive | #5195 |
weighted | #5197 |
pleiotropy | #5205 |
characteristic | #5212 |
molecular biology | #5215 |
remains | #5215 |
term | #5218 |
conclude | #5223 |
dopaminergic neurons | #5224 |
167 | #5226 |
nonsmokers | #5231 |
dutch | #5233 |
256 | #5234 |
fail | #5237 |
smoking behavior | #5240 |
interaction | #5242 |
accurately | #5245 |
119 | #5246 |
critical period | #5248 |
tolerated | #5255 |
generated | #5260 |
boundaries | #5261 |
americans | #5263 |
exceeded | #5264 |
delineation | #5266 |
genotypic | #5269 |
daytime sleepiness | #5278 |
ws | #5278 |
cell surface receptors | #5280 |
brain injuries | #5283 |
001 | #5286 |
participated | #5287 |
variety | #5289 |
normality | #5290 |
written | #5291 |
trend | #5295 |
billion | #5295 |
eye movements | #5296 |
motor | #5298 |
oligodendrocytes | #5299 |
thalamus | #5299 |
learning | #5301 |
234 | #5302 |
emotion recognition | #5306 |
life events | #5308 |
072 | #5308 |
52 | #5309 |
healthy participants | #5310 |
environmental | #5312 |
observer | #5313 |
dense | #5316 |
hints | #5321 |
definite | #5322 |
treatment initiation | #5323 |
genomic imprinting | #5333 |
credibility | #5335 |
inferences | #5339 |
individual level | #5345 |
predictive tests | #5345 |
social interactions | #5345 |
classic | #5351 |
prenatal | #5353 |
word | #5354 |
estimated | #5359 |
cerebellum | #5363 |
nonresponders | #5368 |
nervosa | #5369 |
interplay | #5375 |
eventrelated potentials | #5376 |
higher frequency | #5380 |
penetrance | #5380 |
suicide attempts | #5382 |
lost | #5382 |
internet addiction | #5390 |
sweden | #5391 |
huntington disease | #5392 |
domains | #5396 |
potential confounders | #5402 |
37 | #5403 |
label | #5403 |
empirical | #5410 |
register | #5411 |
daily | #5413 |
0007 | #5419 |
average | #5424 |
tensor imaging | #5432 |
224 | #5436 |
pcp | #5449 |
172 | #5451 |
wiley | #5452 |
adjunctive therapy | #5454 |
modifiers | #5464 |
hour | #5467 |
risk individuals | #5468 |
york | #5468 |
× 10 | #5471 |
aim | #5474 |
settings | #5475 |
borderline | #5478 |
environmental effects | #5484 |
brains | #5486 |
copy | #5488 |
recall | #5491 |
confirms | #5494 |
locomotor activity | #5499 |
homozygotes | #5502 |
year | #5505 |
clinics | #5517 |
commission | #5518 |
termed | #5519 |
promoter regions | #5525 |
verbal fluency | #5525 |
fdr | #5534 |
320 | #5536 |
anxiety behavior | #5537 |
155 | #5547 |
modulate | #5547 |
elevated | #5549 |
closely | #5549 |
prevention | #5551 |
restraint | #5552 |
flanking | #5552 |
occur | #5553 |
154 | #5559 |
copy variation | #5562 |
health conditions | #5563 |
icd10 | #5564 |
baseline treatment | #5565 |
frontal cortex | #5565 |
15 | #5567 |
european ancestry | #5567 |
213 | #5574 |
predominance | #5578 |
significance | #5578 |
240 | #5579 |
mediators | #5579 |
spatial memory | #5581 |
subacute | #5584 |
175 | #5590 |
locus | #5592 |
epidemiological | #5593 |
scientists | #5596 |
narcolepsy | #5597 |
nrg1 | #5607 |
anhedonia | #5608 |
amygdala | #5623 |
percent | #5628 |
heavier | #5631 |
total | #5640 |
allocation | #5657 |
perinatal | #5663 |
lower risk | #5663 |
divided | #5666 |
exploring | #5670 |
probability | #5677 |
calculate | #5678 |
proportional hazards | #5684 |
1999 | #5686 |
40 years | #5686 |
gene variants | #5687 |
markov | #5688 |
vbm | #5688 |
published data | #5689 |
oculomotor | #5690 |
brain development | #5694 |
normal | #5696 |
databases | #5696 |
systems biology | #5703 |
cognitive functions | #5713 |
primary outcome measure | #5713 |
58 | #5723 |
signal detection | #5725 |
pleasure | #5727 |
focused | #5728 |
thirty | #5728 |
psychological surveys | #5735 |
020 | #5739 |
19 | #5745 |
definitions | #5746 |
cognitive tasks | #5751 |
missing data | #5755 |
divorce | #5758 |
approaches | #5761 |
nac | #5762 |
interactive | #5765 |
aged children | #5767 |
additional | #5773 |
deficient | #5778 |
oral | #5779 |
72 | #5780 |
rats inbred | #5786 |
susceptibility locus | #5788 |
extracted | #5792 |
206 | #5796 |
preferential | #5797 |
16 | #5799 |
139 | #5802 |
deaths | #5811 |
intracranial | #5814 |
nuclear | #5815 |
0002 | #5819 |
0005 | #5820 |
aaa | #5823 |
133 | #5826 |
nerve net | #5827 |
98 | #5827 |
ethnic groups | #5834 |
multidimensional | #5836 |
fell | #5841 |
dependency | #5846 |
cannabis | #5849 |
deletions | #5857 |
current understanding | #5860 |
signaling peptides | #5862 |
gene expression profiles | #5869 |
fetuses | #5872 |
membership | #5874 |
auditory | #5875 |
retrospective chart review | #5879 |
sexual behavior | #5880 |
synaptophysin | #5887 |
16 years | #5894 |
small | #5898 |
september | #5901 |
council | #5910 |
imputation | #5910 |
appendix | #5916 |
characterizing | #5917 |
broad | #5919 |
activity level | #5919 |
ethics | #5923 |
parietal | #5925 |
statement | #5928 |
region | #5928 |
linked | #5928 |
individuality | #5929 |
rights | #5930 |
prolactin | #5931 |
medical treatment | #5933 |
rapamycin | #5937 |
biphenyls | #5940 |
striatal | #5955 |
community | #5956 |
electroencephalography evoked | #5964 |
clearance | #5965 |
132 | #5966 |
cmax | #5969 |
091 | #5971 |
missed | #5974 |
explore | #5994 |
website | #6000 |
exclusively | #6001 |
threshold | #6003 |
rois | #6005 |
moderating role | #6005 |
matched | #6006 |
chromosomal | #6009 |
module | #6011 |
functional connectivity | #6013 |
newcastle | #6017 |
extreme | #6020 |
Relatório de execução | |
Prominent publications by Stephen V Faraone∗
IMPORTANCE: Attention-deficit/hyperactivity disorder (ADHD) is a heritable neurodevelopmental disorder. It has been linked to reductions in total brain volume and subcortical abnormalities. However, owing to heterogeneity within and between studies and limited sample sizes, findings on the neuroanatomical substrates of ADHD have shown considerable variability. Moreover, it remains unclear whether neuroanatomical alterations linked to ADHD are also present in the unaffected siblings of ...
Conhecido por Unaffected Siblings | Putamen Volume | Participants Adhd | Hyperactivity Disorder | Total Brain |
Motor coordination problems in children and adolescents with ADHD rated by parents and teachers: effects of age and gender
[ PUBLICATION ]
Summary.Objective. ADHD is frequently accompanied by motor coordination problems. However, the co-occurrence of poor motor performance has received less attention in research than other coexisting problems in ADHD. The underlying mechanisms of this association remain unclear. Therefore, we investigated the prevalence of motor coordination problems in a large sample of children with ADHD, and the relationship between motor coordination problems and inattentive and hyperactive/impulsive ...
Conhecido por Motor Coordination Problems | Children Adhd | Boys Girls | Hyperactivity Child Child | Parents Prevalence |
Hyperactivity and hyperconnectivity of the default network in schizophrenia and in first-degree relatives of persons with schizophrenia
[ PUBLICATION ]
We examined the status of the neural network mediating the default mode of brain function, which typically exhibits greater activation during rest than during task, in patients in the early phase of schizophrenia and in young first-degree relatives of persons with schizophrenia. During functional MRI, patients, relatives, and controls alternated between rest and performance of working memory (WM) tasks. As expected, controls exhibited task-related suppression of activation in the default ...
Conhecido por Default Network | Patients Relatives | Rest Task | Wm Performance | Mpfc Dlpfc |
Patterns of Psychopathology and Dysfunction in High-Risk Children of Parents With Panic Disorder and Major Depression
[ PUBLICATION ]
OBJECTIVE: The purpose of the study was to evaluate 1) whether an underlying familial predisposition is shared by all anxiety disorders or whether specific risks are associated with specific disorders, and 2) whether panic disorder and major depression have a familial link.
METHOD: The study compared four groups of children: 1) offspring of parents with panic disorder and comorbid major depression (N=179), 2) offspring of parents with panic disorder without comorbid major depression ...
Conhecido por Major Depression | Panic Disorder | Offspring Parents | Risk Children | Factors Social |
OBJECTIVE: Attention deficit hyperactivity disorder (ADHD), autism spectrum disorder (ASD), and obsessive-compulsive disorder (OCD) are common neurodevelopmental disorders that frequently co-occur. The authors sought to directly compare these disorders using structural brain imaging data from ENIGMA consortium data.
METHODS: Structural T1-weighted whole-brain MRI data from healthy control subjects (N=5,827) and from patients with ADHD (N=2,271), ASD (N=1,777), and OCD (N=2,323) from 151 ...
Conhecido por Adhd Asd | Cortical Thickness | Children Adolescents | Brain Volume | Disorder Ocd |
BACKGROUND: Neuroimaging studies have shown structural alterations in several brain regions in children and adults with attention deficit hyperactivity disorder (ADHD). Through the formation of the international ENIGMA ADHD Working Group, we aimed to address weaknesses of previous imaging studies and meta-analyses, namely inadequate sample size and methodological heterogeneity. We aimed to investigate whether there are structural differences in children and adults with ADHD compared with ...
Conhecido por Brain Volume | Adults Adhd | Attention Deficit | Hyperactivity Disorder | Subcortical Structures |
AIMS: To determine comorbidity patterns in treatment-seeking substance use disorder (SUD) patients with and without adult attention deficit hyperactivity disorder (ADHD), with an emphasis on subgroups defined by ADHD subtype, taking into account differences related to gender and primary substance of abuse.
DESIGN: Data were obtained from the cross-sectional International ADHD in Substance use disorder Prevalence (IASP) study.
SETTING: Forty-seven centres of SUD treatment in 10 ...
Conhecido por Disorder Patients | Psychiatric Comorbidity | Attention Deficit | Seeking Substance | Presence Adhd |
CONTEXT: Controversy exists about the appropriate criteria for a diagnosis of adult attention-deficit/hyperactivity disorder (ADHD).
OBJECTIVE: To examine the structure and symptoms most predictive of DSM-IV adult ADHD.
DESIGN: The data are from clinical interviews in enriched subsamples of the National Comorbidity Survey Replication (n = 131) and a survey of a large managed health care plan (n = 214). The physician-administered Adult ADHD Clinical Diagnostic Scale (ACDS) was used to ...
Conhecido por Adult Adhd | Hyperactivity Disorder | Illness Surveys | Clinical Diagnostic | Symptoms Childhood |
The Massachusetts General Hospital studies of gender influences on attention-deficit/hyperactivity disorder in youth and relatives
[ PUBLICATION ]
With the single exception of SUDs, no statistically significant gender-by ADHD interactions were identified in the multiple, outcomes evaluated. These results suggest that with the exception of SUDs, ADHD expresses itself similarly in boys and girls relative to comparison subjects of the same gender, indicating that ADHD-associated impairments are correlates of ADHD in both genders. Gender differences, such as the higher prevalence of symptoms of inattention and lower rates of ...
Conhecido por Girls Adhd | Hyperactivity Disorder | Gender Differences | Higher Prevalence | Symptoms Inattention |
OBJECTIVE: To complete an exploratory uncontrolled study of the effects of lisdexamfetamine dimesylate (LDX) on growth of children treated for attention-deficit/hyperactivity disorder (ADHD).
METHOD: Height, weight, and body mass index (BMI) from 281 children ages 6 to 13 years from longitudinal assessments up to 15 months were compared to norms from the Centers for Disease Control.
RESULTS: At study entry, children were taller and heavier than average. Growth delays were largest for ...
Conhecido por Lisdexamfetamine Dimesylate | Height Weight | Growth Children | Ldx Bmi | Centers Disease Control |
Psychopathology in Adolescent Offspring of Parents With Panic Disorder, Major Depression, or Both: A 10-Year Follow-Up
[ PUBLICATION ]
OBJECTIVE: The authors examined the specificity and course of psychiatric disorders from early childhood through adolescence in offspring of parents with confirmed panic disorder and major depressive disorder.
METHOD: The authors examined rates of psychiatric disorders at 10-year-follow-up (mean age, 14 years) in four groups: offspring of referred parents with panic and depression (N=137), offspring of referred parents with panic without depression (N=26), offspring of referred parents ...
Conhecido por Panic Disorder | Offspring Parents | Parental Depression | Disruptive Behavior | Year Follow |
BACKGROUND: The goal of this study was to investigate the occurrence, severity and clinical correlates of emotional lability (EL) in children with attention deficit/hyperactivity disorder (ADHD), and to examine factors contributing to EL and familiality of EL in youth with ADHD.
METHODS: One thousand, one hundred and eighty-six children with ADHD combined type and 1827 siblings (aged 6-18 years) were assessed for symptoms of EL, ADHD, associated psychopathology and comorbid psychiatric ...
Conhecido por Symptoms Adhd | Emotional Lability | Hyperactivity Disorder | Attention Deficit | Odd Disruptive Behavior |
A Controlled Study of Behavioral Inhibition in Children of Parents With Panic Disorder and Depression
[ PUBLICATION ]
OBJECTIVE: "Behavioral inhibition to the unfamiliar" has been proposed as a precursor to anxiety disorders. Children with behavioral inhibition are cautious, quiet, introverted, and shy in unfamiliar situations. Several lines of evidence suggest that behavioral inhibition is an index of anxiety proneness. The authors sought to replicate prior findings and examine the specificity of the association between behavioral inhibition and anxiety.
METHOD: Laboratory-based behavioral observations ...
Conhecido por Behavioral Inhibition | Major Depression | Children Parents | Panic Disorder | Controlled Study |
Traumatic Brain Injury and Schizophrenia in Members of Schizophrenia and Bipolar Disorder Pedigrees
[ PUBLICATION ]
OBJECTIVE: Schizophrenia following a traumatic brain injury could be a phenocopy of genetic schizophrenia or the consequence of a gene-environment interaction. Alternatively, traumatic brain injury and schizophrenia could be spuriously associated if those who are predisposed to develop schizophrenia have greater amounts of trauma for other reasons. The authors investigated the relationship between traumatic brain injury and psychiatric diagnoses in a large group of subjects from families ...
Conhecido por Traumatic Brain Injury | Bipolar Disorder | Subjects Schizophrenia | Mental Illness | Genetic Vulnerability |
Pessoas importantes para Hyperactivity Disorder
Stephen V Faraone∗:Impacto especializado
Conceitos para os quaisStephen V Faraone∗tem influência direta:Hyperactivity disorder, Bipolar disorder, Attention deficit, Deficit hyperactivity, Disorder adhd, Anxiety disorders, Disorder hyperactivity, Children adhd.
Stephen V Faraone∗:Kol Impact
Conceitos relacionados ao trabalho de outros autores para os quaisfor which Stephen V Faraone∗ tem influência:Bipolar disorder, Attention deficit, Children adhd, Executive function, Mental health, Schizophrenia patients.
Tools
Este é o seu perfil? Reivindique seu perfil Copiar URL Incorporar link para o seu perfil |